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Tropical parasitic diseases such as malaria, human African trypanosomiasis, Chagas disease, 
mycetoma, and leishmaniasis affect more than a billion people worldwide and have devastating 
consequences. There is no vaccine for any of these diseases, and the current drugs are 
problematic given their serious adverse effects and the emergence of drug-resistant parasites. 
Thus, there is an urgent need for the development of new, efficacious, safe, and cost-effective 
drugs. 
Natural products have in many instances provided new leads to combat neglected tropical 
diseases. The aim of this work was to systemically evaluate Sudanese medicinal plants for their 
antiparasitic activity along with their cytotoxicity profile; followed by phytochemical 
investigation to identify bioactive compounds. A library of 235 plant extracts was prepared 
from over 60 plants used in Sudanese traditional medicine, and it was assessed for 
antiprotozoal activity against Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Leishmania 
donovani, and Plasmodium falciparum. 
Dereplication was performed for active extracts to enable a rapid identification of known active 
compounds and prioritization for follow-up isolation. Plants that displayed interesting activities, 
namely Croton gratissimus, Cuscuta hyalina, and Haplophyllum tuberculatum, were further 
pursued. HPLC-based activity profiling led to localization of activity and identification of the 
types of compounds in these plant extracts. Compound isolation and structure elucidation were 
achieved by a combination of analytical, preparative, and semipreparative chromatographic 
techniques such as HPLC-PDA-ELSD-MS and microprobe NMR. 
HPLC-based activity profiling of Croton gratissimus allowed the identification of flavonoids, 
mainly quercetin derivatives, as responsible for the antileishmanial activity of the chloroform 
fraction of the crude ethanolic extract. Of these compounds, quercetin-3,7-dimethylether and 





Compounds that displayed moderate to higher antitrypanosomatid activity shared structural 
features, such as Δ2,3 unsaturation, presence of a hydroxyl group at C-3, a carbonyl group at C-4, 
and a catechol moiety in ring B. Phytochemical characterization of Cuscuta hyalina lead to the 
isolation of a unique flavonoid, pseudosemiglabrin, for the first time from Cuscuta species. 
The antileishmanial activity of Haplophyllum tuberculatum was tracked by HPLC-based activity 
profiling, and eight compounds were isolated from the chloroform fraction. These included the 
lignans tetrahydrofuroguaiacin B, nectandrin B, furoguaiaoxidin, and 3,3′-dimethoxy-4,4′-
dihydroxylignan-9-ol; and four cinnamoylphenethyl amides, namely dihydro-
feruloyltyramine, N-trans-feruloyltyramine, N,N′-diferuloylputrescine, and 7′-ethoxy-
feruloyltyramine. The water fraction yielded steroidal saponins. All these compounds were 
reported for the first time from Haplophyllum species and the family Rutaceae. Nectandrin B 
exhibited the highest activity against L. donovani (IC50 4.5 µM) and the highest selectivity index 
(25.5). 
Given the urgent need for better drugs and the fact that mycetoma is the most neglected of the 
neglected diseases, mycetoma has received special consideration. Different approaches were 
tackled to ultimately identify potential hits. With regard to antimycetomal natural products, 
several compounds were selected based on an educated-guess and were assessed accordingly. 
Of the tested natural compounds, magnolol possessed the highest activity (MIC of 15 µM) and 
selectivity (SI of 4.9). 
In parallel, a drug repurposing (repositioning) strategy was pursued to find more promising hits. 
A series of nitroimidazole compounds were screened in vitro against the fungus Madurella 
mycetomatis. From this screening, niclosamide showed interesting activity with a minimal 
inhibitory concentration ˂5 µM. Furthermore, additional niclosamide analogues were tested for 
proof of concept. The tested compounds showed similar activity compared to niclosamide, not 
only against M. mycetomatis but also against the bacteria Actinomadura spp. The finding that a 
drug like niclosamide, which is on the WHO's list of Essential Medicines, exhibits in vitro activity 
against both fungal and bacterial mycetoma warrants the consideration of niclosamide or its 
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1.1 Neglected Tropical Diseases 
 
Neglected tropical diseases (NTDs), as classified by the WHO, are a group of 18 chronic disabling 
infections caused either by viruses, bacteria, fungi, protozoa or helminths. The diseases affect 
more than a billion people world-wide, mainly in Africa and mostly those living in remote rural 
areas, urban slums, or conflict zones [1]. The burden of these diseases has a high impact in 
terms of human suffering as well as contributing to poverty and under-development. NTDs 
account for 48 million disability-adjusted life years (DALYs) and 152 000 deaths per year [2,3]. 
Three of these diseases are Human African Trypanosomiasis (HAT) caused by Trypanosoma 
rhodesiense spp., Leishmaniasis caused by Leishmania spp., and Chagas disease (American 
trypanosomiasis) caused by Trypanosoma cruzi [4]. The three pathogens belong to the 
trypanosomatidae, a large family of flagellated protozoa. Although malaria, caused by the 
apicomplexan parasite Plasmodium falciparum, is no longer considered an NTD since 2000, 
owing to increased funding level globally by various international bodies and philanthropic 
organizations (e.g. the Global Fund, Bill and Melinda Gates Foundation, and the Medicines for 
Malaria Venture (MMV)), the disease still remains a major challenge due to the heavy death toll 
and its negative economic impact, which translate to 1.3% annual loss in gross domestic 
product (GDP) in malaria endemic African countries [5]. In addition, the occurrence of the 
disease among the poor is disproportionate with high mortality levels among pregnant women 
and children [6]. In the context of the present work, malaria will be addressed among the NTDs. 
General information about the above mentioned NTDs is summarized in Table 1. 
Mycetoma was recently included in the WHO list of NTDs [7]. It is one of the most neglected 
diseases at all levels. Mycetoma is a chronic, progressively destructive morbid inflammatory 
disease acquired by traumatic inoculation of certain fungi (Eumycetoma) or ‎bacteria (Actino-
mycetoma) into the subcutaneous tissue [8]. The disease is geographically distributed through 
what is called as “the Mycetoma belt”, which includes India, Yemen, Somalia, Sudan, Senegal, 
Mexico, Venezuela, Colombia, and Argentina [9]. Usually the foot is the most affected part but 
any part of the body can be involved [10]. Late chronic stages of the disease result in 
destruction, deformity and loss of function and often lead to amputation. 
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Table 1: Summary of Neglected Tropical Disease under the scope of the study 
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1.1.1 NTDs and Sudan 
According to WHO reports, of the 17 neglected diseases, 9 are a recognized public health 
problem in Sudan (Figure 1). These include: leishmaniasis, schistosomiasis, lymphatic filariasis, 
onchocerciasis, trachoma, guinea worm, mycetoma, soil transmitted helminths, and leprosy. 
Large populations living in rural areas are infected by one or more of these diseases, with the 
school-age children being the most affected [12]. Sudan had made large progress in the 
eradication of dracunculiasis (guinea-worm disease). However, the country is still endemic for 
schistosomiasis and trachoma (3.6 million cases), and it has the highest incidence for cutaneous 
and visceral leishmaniasis in sub-Saharan countries with 15,000–20,000 new cases annually 
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[13]. The situation for mycetoma is not any better. Sudan is considered among the highest 
infected countries with more than 6000 cases, of which, 64% are under the age of 30. Of the 
mycetoma cases reported, 70% are eumycetoma, stressing the high need for effective 
treatment and adequate preventive and control measures to reduce the disease morbidity and 
mortality [14]. For malaria, Sudan is considered a high-burden and high-risk country. In 2012, 
more than 5000 cases were reported [15]. Malaria accounted for a higher mortality burden 
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1.2 Drug Discovery for NTDs: 
1.2.1 Challenges and Gaps 
Most of the currently available drugs for NTDs have drawbacks in terms of toxicity, limited 
availability of oral therapeutic dosage forms, development of resistance, or non-affordability, 
coupled with unavailability of vaccines for any of them. However, drug discovery and 
development of new and better medicines for NTDs is costly and of low-return. As already 
reported, of the 1602 new chemical entities (NCEs) that has been approved between 1981 and 2019, 
unfortunately, only 20 medicines out of the total were for the treatment of neglected diseases [17]. The 
creation of public-private partnerships like DNDi (Drugs for Neglected Diseases initiative) has 
helped to overcome this bottleneck. A sustainable solution for new drug development became 
feasible with the backing support of international pharmaceutical policy and collaboration [18]. 
Nevertheless, there are still major gaps and so far, with the exceptions of tafenoquine for 
malaria and fexinidazole for HAT, these initiatives have brought to market mainly new 
formulations and combinations of already existing drugs. 
While the incidence of human African trypanosomiasis is at a historic low and a new oral drug, 
fexinidazole [19], has recently received positive opinion by the European Medicines Agency, the 
prospects are gloomier and less good for Chagas' disease and leishmaniasis. In Eastern Africa, a 
high-burden region of visceral leishmaniasis [20], sodium stibogluconate is still the mainstay of 
leishmaniasis chemotherapy [21], a pentavalent antimonial that can cause hepatotoxicity and 
cardiotoxicity [22]. There is one efficient and safe antileishmanial drug, AmBisome, a liposomal 
formulation of amphotericin B that was developed as a fungicide and repurposed for 
leishmaniasis [23]. However, AmBisome is expensive and requires a cold chain to delivery. 
Hence, many reports have outlined research priorities for kinetoplastids parasites regarding the 
need of new cost-effective therapies as a key element of the fight against protozoal neglected 
tropical diseases [24,25]. 
The treatment of malaria still relies globally on artemisinin-based combination therapies (ACT). 
Alarmingly, artemisinin-resistant isolates of P. falciparum have been described from south-east 
Asia [26–28] and most recently also from Africa [29]. Thanks to an increased funding level 
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globally by various international bodies and philanthropic organizations such as Medicine for 
Malaria Venture (MMV), there is a series of new molecules in the drug discovery pipeline. 
However, none of these has reached registration yet.  
The bacterial type of the mycetoma, actinomycetoma, is readily cured by antibiotics 
combination therapy [30]. In contrast, management of the fungal type (Eumycetoma) is much 
more difficult. Treatment usually involves surgical excision combined with long term use of 
azole antifungals, which have limited efficacy, toxic adverse effects, are expensive, and have 
with high percentage of treatment failures [31]. DNDi together with the Mycetoma Research 
Center in Khartoum are currently running a phase II/III clinical trial to assess the efficacy and 
safety of fosravuconazole in comparison to the currently used itraconazole. Nevertheless, there 
is a dire need to find new therapeutic agents for eumycetoma that are efficient, affordable, 
safe, and decrease treatment period and surgical interventions [32]. 
1.2.2 Drug Development Strategies for NTDs: 
Strategies for hit discovery usually involve two opposing, yet complementary, screening 
pathways; target-based (typically a protein or an enzyme), or phenotypic screening (whole 
organism, cell-based). Despite the paradigm shift in the pharmaceutical industry to move from 
whole-cell to target-based screening, in the case of antiparasitic drugs, the phenotypic 
approach has proven to be more successful. This success could be explained by the facts that (i) 
it does not require prior knowledge of the molecular target, which is the case of most neglected 
parasites where there are very few validated molecular targets; (ii) it enables high throughput 
screening of chemical libraries and identification of chemical entities  without a known target or 
mechanism of action; (iii) target deconvolution is possible with the aid of genomic tools; (iv) 
successful drug candidates are likely to involve interaction with a number of different target 
enzymes ("unspecific" mode of action), which is the case of most of the currently used 
antiparasitics [33–35]. 
Alternative approaches include structure-based drug discovery, re-purposing of drugs from 
other disease areas, and in silico methods. Each strategy has its own advantages and 
disadvantages. 
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Of the many avenues and possibilities of drug discovery for neglected tropical diseases [36,37], 
two strategies will be highlighted and discussed in the scope of this work to fill the drug pipeline 
against these devastating and global diseases. These are; i) repurposing, and ii) natural 
products. 
1.2.2.1 Repurposing 
Since drug development is lengthy and expensive, the drug repurposing strategy (i.e. finding 
new uses for existing drugs) offers an attractive shortcut between the bench and the clinic, 
particularly where the resources for R&D are limited [38]. The concept of repurposing is actively 
pursued for NTDs, and many drugs that are currently used for the treatment of neglected 
tropical diseases have been ‘repositioned’ (Table 2). Concurrently, most of the repurposed 
compounds have arisen from phenotypic screening campaigns rather than target-based 
strategies [39], Owing to the limited number of fully validated targets in NTDs, as discussed 
earlier. Repurposing screening campaigns for NTDs have revealed potential molecules of 
different drug classes, like tricyclic antidepressants for antipalsmodial activity, tadalafil and the 
antispasmodic mebeverine for Chagas’ disease, along with other molecules that fit established 
criteria of Target Product Profiles (TPP) for NTDs [40]. Interestingly, not only drugs used in other 
diseases are repurposed for NTDs, but also the other way around: suramin, developed for 
Nagana and sleeping sickness, was repurposed for the treatment of cancers and autism [41], 
and an exciting case is the antimalarial chloroquine in clinical trials for the treatment of the 
recent virus pandemic COVID-19 [42]. In the context of this work, nitroimidazoles were tested 
for their in vitro activity against Madurella mycetomatis, the major causative agent of 
Eumycetoma. 
Table 2: Drugs repurposed for NTDs  
Drug Original use Repurpose Reference 
Eflornithine Anticancer HAT [43] 
Ivermectin Onchocerca in horses River blindness [44] 
Fosmidomycin Antibiotic Malaria [45] 
Doxycycline Antibiotic Filariasis  and Malaria [46] 
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Amphotericin B Antifungal Visceral leishmaniasis [47] 
Miltefosine Anticancer Visceral leishmaniasis [47] 
Paromomycin Antibiotic Visceral leishmaniasis [47] 
Pentamidine Equine trypanosomiasis HAT- Stage 1 [43] 
Albendazole Anthelmintic for livestock Lymphatic filariasis [48] 
Nifurtimox Chagas disease HAT [49] 
 
1.2.2.2 Natural Products 
Natural products (NPs) remain a successful source of inspiration for the discovery of new drugs. 
A recent comprehensive review by Newman and Cragg, covering approved drugs during the 
period 1981-2019, revealed that one third of the small molecules launched over the last four 
decades were derived directly or indirectly from natural resources. Moreover, of the 20 
approved antiparasitic drugs, 9 were of natural origin [17], some of them are summarized in 
Table 3. Many chemo-informatic studies showed that natural products cover a much wider and 
larger chemical space than combinatorial and synthetic compounds, due to their diversity in 
terms of chiral centers and richness in functional groups, which render them viable for a wider 
ligand affinity and better specificity to biological targets [50,51].  
Table 3: Examples of antiparasitic drugs of natural or derived from natural origin  
Drug Natural origin Source Classification Reference 
Artemisinin Artemisia annua Plant N [52] 
Ivermectin Streptomyces avermitilis Bacteria N [53] 
Quinine Cinchona succirubra Plant N [54] 
Moxidectin Milbemycin derivative from 
Streptomyces cyanogriseus spp. 
Bacteria ND [55] 
Eflornithine Difluoromethyl derivative of 
ornithine 
Amino acid ND [56] 
N: natural product; ND: natural product derivative 
Many secondary metabolites with a wide variety of scaffolds, namely alkaloids, terpenes, and 
phenolic compounds (e.g. lignans, tannins, coumarins, flavonoids) have shown potent inhibition 
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of parasites responsible for NTD [37,57–59]. However, the potent activities displayed by some 
of these NPs are hampered by their toxicity and pharmacokinetic profiles that prevent their use 
in the clinic. Nonetheless, these hits can be modified by medicinal chemistry and drug delivery 
approaches to enhance the pharmacokinetic and safety characteristics. 
1.2.2.3 Challenges and opportunities of Natural Products Drug Discovery 
Despite the success of NPs, the interest of several major pharmaceutical companies has waived, 
and they cut down the use of natural products in their drug discovery programs. A major 
concern is that NPs are incompatible with high throughput screening (HTS), laborious to handle, 
highly complex, have non-specific activities, and issues with accessibility, logistics, and 
patentability [60]. A more rational and economic search for new lead structures from nature 
must therefore be a priority in order to overcome these problems. Key factors to achieve this 
competitiveness include employment of technological advances like robotics, bioassay 
miniaturization, and developments in spectroscopy in the NPs-based lead discovery processes 
such as speed of dereplication, bioassay-guided isolation, and structure elucidation [61]. 
Innovative omics-based approaches integrated with molecular networking enabled the 
prioritization and targeted isolation of novel natural products, and provided means to bridge 
the gap between ethnopharmacological drug discovery and industrial biotechnology for 
monitoring fermentation or other production processes [61–63].  
1.2.2.4 Strategies for identification and Isolation of Bioactive Natural Products 
A variety of approaches are being used for identification of bioactive secondary metabolites 
from plant, fungal, microbial, or marine sources, such as: i) traditional medicine and ethno-
pharmacological knowledge (antimalarials, quinine and artemisinin), ii) taxonomical - 
chemotaxonomical (anticancer, taxol), iii) ecology-based (marine natural products, insecticides, 
antifeedants), and iv) pharmacophore-based or virtual screening (computer-based) [64].  
The process of “bioassay-guided fractionation” starts once an extract has shown favorable 
activity in a screening. Then, it is necessary to isolate the compound(s) responsible for the 
pharmacological properties. Since extracts are complex matrices, there is the challenge of 
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localizing activity in the extract by overlaying biological data and chemo-analytical information 
in order to identify the active principles at an early stage [65]. One of these approaches is 
dereplication. Dereplication was initially defined as “the process of quickly identifying known 
chemotypes’’ [66]. The definition has developed and extended over the years to include many 
strategies with the ultimate goal of accelerating the discovery of bioactive substances by 
improving the characterization methods of natural resources. Dereplication allows elimination 
and prioritization of extracts by comparing the chemical and biological characteristics of 
unknown compounds to that of previously identified compounds in databases. Hence, 
comprehensive databases are crucial for high performance dereplication workflows [67,68]. 
 Another approach is HPLC-based activity profiling, which has been successfully used for 
tracking bioactive compounds in crude mixtures [69]. The principle of this approach consists in 
the analytical scale HPLC separation of bioactive extracts. UV and MS data are recorded online 
in parallel to collection of fractions into microplates or deep-well plates, via a T-split of the 
column effluent. The fractions are dried, re-dissolved in a small amount of a suitable solvent 
(usually DMSO) and assayed for bioactivity. The chromatogram and the activity profile are then 
matched to identify active peaks. On-line spectroscopic information in combination with 
database searches can be used to dereplicate known compounds and facilitates prioritization of 
samples for follow-up activities [70,71]. (Figure 2) 
 




Figure 2: HPLC-based activity profiling approach 
1.3 Ethnomedicine in Sudan and Biodiversity 
Sudan is the third largest country in the African continent (after Algeria and Democratic 
Republic of the Congo). Located in east central Africa with a total surface area of 1.8 million 
km2, Sudan encompasses different terrains and climatic zones, ranging from desert and semi-
arid in the north to tropical savanna in the south. The country consists of a vast flat landscape 
bordered by mountains on the north east (the Red Sea Hills) and the west (the Marrah 
Mountains). The northern part features the Nubian Desert (part of the Sahara desert) and the 
east part reaches out to the red sea (Figure 3). This matchless geographical topography of 
Sudan, with its variable climates, makes it a unique place with different ecosystems and a 
















Figure 3: Topographical map of the Sudan, desert in the North and main mountain ranges: Red sea hills 
in northeast and Marrah mountains in the west.  
(Source: https://www.nationsonline.org/oneworld/map/sudan-topographic-map.htm) 
 
The flora of Sudan consists of 3137 species of flowering plants belonging to 170 families and 
1280 genera [72]. It is estimated that 15% of these plants are endemic to Sudan. The 
intersection of diverse African, Arabic and Islamic cultures influenced the uniqueness of 
folkloric and herbal medicine [72]. Sudanese traditional medicine is an indigenous form of 
holistic health care system involving both mind and body (i.e. psychosomatic medicine). It is a 
unique combination of natural, cultural and religious background that prevalent in the 
community. However, there is limited published data available on the biological activities of the 
Sudanese medicinal plants. 
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1.4  Objectives 
 
Sudan's biodiversity of medicinal plants coupled with deeply rooted ethno-botanical heritage 
remains a promising untapped reservoir for the discovery of diverse chemical entities. The main 
goals of this Ph.D. thesis are:  
1. Better characterization of Sudanese medicinal plants and a rationale for their use. 
2. Finding promising antiparasitic hit compound(s) that have the potential to generate 
novel leads. 
3. Exploring different approaches of drug discovery for the neglected disease Mycetoma. 
 
Chapter 2 starts with a comprehensive overview on medicinal plants that are being used 
traditionally in Sudan for tropical illnesses, with a focus on protozoal diseases and plants that 
were pharmacologically investigated. On the basis of this survey, a library consisting of 235 
extracts andfractions thereof, representing 62 plants reputed as antiparasitics that belong to 35 
different plant families, was assembled, prepared, and screened phenotypically for in vitro 
activity against the following panel of protozoal parasites: T. b. rhodesiense bloodstream form, 
T. cruzi intracellular amastigote form grown in rat L6 cells, L. donovani axenic amastigote form 
grown at low pH, and P. falciparum proliferative erythrocytic stages grown in human 
erythrocytes. For selected active extracts, HPLC-based activity profiling in combination with on-
line spectroscopy enabled a rapid identification of some of the bioactive compounds by 
dereplication. 
Chapter 3 and Chapter 4 continue with phytochemical characterization using the HPLC- activity 
profiling approach for plant extracts of promising antiprotozoal activity, followed by the 
isolation of their bioactive compounds by different preparartive and semipreaparative 
chromatographic techniques, and finally elucidation of the chemical structures. The activity of 
the isolated compounds was determined in vitro (whole-cell assays), alongside with cytotoxicity 
testing in mammalian cells. The main purpose of the cytotoxicity test was to calculate the 
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selectivity index (SI), which allows discriminating attractive compounds from poorly selective 
ones. 
Chapter 5 investigates the In vitro antimycetomal activity, together with cytotoxicity profiling of 
compounds isolated from the chloroform and the water fractions of the ethanolic extract of 
Haplophyllum tuberculatum roots (Forsskal) A. Juss. (Rutaceae). In addition, various natural 
compounds of different calsses of plant secondary metabolites obtained from different plant 
species, and that have been previously reported for their antifungal and anti-infective activities, 
were also screened for their activity and cytotoxicity against Maduralla mycetomatis. 
Chapter 6, the repurposing approach, was pursued for finding potential drug candidates that 
are active against fungal mycetoma. Selection and testing of nitroimidazoles and other redox-
active molecules was performed based on their potential antifungal mechanism of action. The 
hypothesis that redox-active molecules will also be active against Madurella mycetomatis, the 
principal causative agent of eumycetoma, was not confirmed. Nevertheless, niclosamide was 
identified as a potential drug candidate. 
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Neglected tropical diseases are major health hazards in developing countries. Annually, 
up to thirty million people are affected by either Chagas disease, African trypansomiasis 
or leishmaniasis, and more than 200 million by malaria. Most of the currently available 
drugs have drawbacks in terms of toxicity, limited oral availability, development of 
resistance, or non-affordability. Tropical plants of the arid zones are a treasure chest for 
the discovery of bioactive secondary metabolites. This study aims to compile Sudanese 
medicinal plants, validate their antiprotozoal activities, and identify active molecules. 
We have performed a survey of medicinal plants of Sudan and selected 62 that are 
being used in Sudanese traditional medicine. From these, we collected materials such as 
leaves, stem, bark, or fruit. The plant materials were extracted in 70% ethanol and 
further fractionated by liquid-liquid partitioning using solvents of increasing polarity. 
This resulted in a library of 235 fractions. The library was tested in vitro against 
Plasmodium falciparum (erythrocytic stages), Trypanosoma brucei rhodesiense 
(bloodstream forms), Trypanosoma cruzi (intracellular amastigotes), and Leishmania 
donovani (axenic amastigotes). Active fractions were also tested for cytotoxicity. Of the 
235 fractions, 125 showed growth inhibitory activity >80% at 10 μg/mL, and >50% at 2 
μg/mL against at least one of the protozoan parasites. Plasmodium falciparum was the 
most sensitive of the parasites, followed by T. b. rhodesiense and L. donovani. Only few 
hits were identified for T. cruzi, and these were not selective. Contrary to expectation 
based on phylogeny, but in agreement with previous results, a large number of extracts 
displayed mutual activity against T. brucei and P. falciparum. HPLC-based activity 
profiling for selected active extracts was performed to identify the bioactive principles. 
Active compounds identified by dereplication were guieranone A from Guiera 
senegalensis J.F.Gmel.; pseudosemiglabrin from Tephrosia apollinea (Delile) DC; ellagic 
acid and quercetin from Anogeissus leiocarpa (DC.) Guill. & Perr.; and catechin, ethyl 
gallate, and epicatechin gallate from Acacia nilotica (L.) Delile. Also the extracts of 
Croton gratissimus var. gratissimus and Cuscuta hyalina Roth ex Schult. exhibited 
promising antitrypanosomatid activity. This assessment provides a comprehensive 
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overview of Sudanese medicinal plants and supports the notion that they are a potential 
source of bioactive molecules against protozoan parasites. 
 
 
Keywords: HPLC-activity profiling, Drug discovery, Sudan, Medicinal plant, 
Trypanosoma, Leishmania, Plasmodium. 
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2.2  Introduction 
 
Infections by protozoan parasites remain to be among the most devastating causes of 
mortality in the tropics. The trypanosomatids are a large family of flagellated protozoa, 
some of which cause neglected tropical diseases of high public health relevance and 
socio-economic impact [1,2]. These are Trypanosoma cruzi (Chagas' disease), T. brucei 
gambiense and T. b. rhodesiense (human African trypanosomiasis or sleeping sickness), 
and Leishmania spp. (different kinds of leishmaniasis) [3]. The apicomplexan parasite 
Plasmodium falciparum is the causative agent of malaria tropica, the most dangerous 
form of malaria, which –  despite the successes by various international bodies and 
philanthropic organizations – still claims an annual death toll of 435,000 (World Malaria 
Report, WHO 2018). These diseases disproportionally affect the poor and vulnerable 
populations [4], calling for action to improve global well-being. A key element of the 
fight against protozoan neglected tropical diseases and malaria is the discovery of novel 
chemotherapeutic agents. 
While the incidence of human African trypanosomiasis is at a historic low and a new 
drug, fexinidazole [5], has recently received positive opinion by the European Medicines 
Agency, the prospects are slightly gloomy for other protozoal diseases. Chagas' disease 
has reached global dimensions [6], and leishmaniasis as well [7]. Sudan has the highest 
incidence of leishmaniasis in sub-Saharan countries, with 15,000–20,000 new cases per 
annum [8]. The successful treatment of malaria is threatened by artemisinin-resistant 
mutants of P. falciparum, first reported from Southeast Asia [9–11] and, more recently, 
also from Africa [12]. 
Plants are still considered as important sources for the discovery of novel bioactive 
molecules. Plants secondary metabolism represents a huge and unique reservoir of 
chemical diversity, which may serve as a source of new drugs, either directly or after 
optimization by medicinal chemistry. Independent chemoinformatic analyses have 
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consistently shown that natural products often exhibit unique features, a high degree of 
structural diversity, and drug- or lead-like structural properties [13–15]. 
A retrospective analysis showed that approx. 50% of drugs approved within the last 30 
years are derived, directly or indirectly, from natural products, whereby plant derived 
compounds played an important role [16]. 
Sudan's biodiversity coupled with a deeply rooted ethno-botanical heritage is an 
untapped reservoir for the discovery of new bioactive natural products. Here we 
performed a survey of plants from Sudan that are used in traditional medicine, with a 
focus on malaria and neglected tropical diseases caused by protozoa. On the basis of 
this survey a library of plant extracts was assembled and screened against 
trypanosomatid parasites and P. falciparum. Active compounds in the most promising 
extracts were tracked with the aid of an activity-driven approach. 
 





2.3.1 Review of medicinal plants from Sudan 
Ethnopharmacological literature review based on scholarly databases (Pubmed, 
Medline, SciFinder) and other supporting documents revealed that 34 of the 62 plants 
had been recorded for use against leishmaniasis, trypanosomiasis or malaria, including 
the symptoms related to any of these diseases (Table 1). Several of the plants had also 
been investigated pharmacologically and had exhibited anti-infective activity (Table 2). 
 
Table 1: Plants investigated in the present study that have a reported use as anti-infective in 
traditional medicine. 
 





Traditional medicinal use 








Acacia nilotica (L.) Delile Fabaceae Sunt Leaves 
Malaria [18], respiratory 
infections, diarrhoea, 
haemorrhage [19] 
Ambrosia maritima L. Asteraceae Damsissa Leaves 
Malaria, kidney stones, 
renal colic, hypertension 
[20] 




flatulence and dyspepsia, 
joint swelling, sedative for 
babies, lactogenic [21] 
Annona muricata L. Annonaceae  Leaves Antitumor, antiparasitic [22] 
Anogeissus Leiocarpa (DC.) Guill. & Perr. Combretaceae Sahab Bark 
Cough, dysentry, giardiasis 
[23] 
Argemone mexicana L. Papaveraceae  Leaves 
Malaria, early-stage 
trypansomiasis [24] 
Aristolochia bracteolata Lam. Aristolochiaceae 
Irg el Agrrab, 
Um Galagil 
Root Malaria, scorpion stings [25] 
Azadirachta indica A.Juss. Meliaceae Neem Oil Malaria, antihelminthic [26] 
Boswellia papyrifera (Caill. ex Delile) Hochst Burseraceae Luban Gum 
Cough, respiratory 
infections [27] 
Cardiospermum halicacabum L. Sapindaceae  Leaves Malaria, antiparasitic [28] 
Combretum glutinosum Perr. ex DC. Combretaceae Habeil Seeds Fever, rheumatism [29] 
Combretum hartmannianum Schweinf. Combretaceae  Wood 
Jaundice, diabetes, rheuma, 
wound healing, 
anthelminthic [30] 
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Traditional medicinal use 
Croton gratissimus var. gratissimus Euphorbiaceae Um-Geleigla Fruit 
Malaria, hypertension, 
menstrual pain [31] 
Cymbopogon citratus (DC.) Stapf Poaceae Lemon grass Leaves 
Kidney stones and 
infections, malaria [32] 
Cyperus rotundus L. Cyperaceae  Rhizome 
Fever, stomach disorders, 
bowel irritation [33] 
Grewia tenax  (Forssk.) Fiori Tiliaceae Godeim Fruits Malaria, iron deficiency [34] 
Guiera senegalensis J.F.Gmel. Combretaceae Gubeish Leaves 
Jaundice, malaria, 
hyperglycemia [25] 
Haplophyllum tuberculatum (Forssk) A.Juss. Rutaceae Haza Leaves 
Malaria, asthma, kidney 
diseases, gynecological and 
bowel disorders [30,35] 
Jatropha curcas L. Euphorbiaceae 
Habat El 
Muluk 
Leaves Malaria [36] 
Lupinus albus subsp. graecus (Boiss. & 
Spruner) Franco & P.Silva (syn. Lupinus 
termis Forssk.) 
Leguminosae Tormos Seeds 
Paste for eczema and 
herpes zoster [37] 








Nauclea latifolia Sm. Rubiaceae Karmadoda 
Fruit, 
root bark 
Malaria, abdominal disease, 
antimicrobial [40,41] 
Piper cubeba L. f. Piperaceae  Fruits 




Prosopis chilensis (Molina) Stuntz Leguminosae Miskeet Leaves 
Antiinflammatory, analgesic 
[43] 





Malaria, jaundice [25] 
Striga hermonthica (Delile) Benth. 
Orobanchaceae 
 










Terminalia laxiflora Engl. Combretaceae Darout Bark 
Fever and respiratory 
infections [46] 
Typha angustifolia L. Typhaceae Si'da Stem 
Leprosy wound bleeding, 
diarrhoea, anthelminthic, 
diuretic [47] 
Xanthium Strumarium subsp. brasilicum 
(Vell.) O.Bolòs & Vigo (syn. Xanthium 
brasilicum Vell.) 
Compositae  Leaves Malaria  [48] 
Tinospora bakis (A.Rich.) Miers Menispermaceae Irg alhagar Root 
Fever, diarrhoea, abdominal 
pain [35] 
Ziziphus spina-christi (L.) Desf. Rhamnaceae Sidir Leaves 
Fever, spasmolytic and anti- 
diarrhea [30] 




Table 2. Plants investigated in the present study for which anti-infective properties have been 
examined experimentally. 
Plant species Part Tested activities IC 50 value Active metabolite(s) 
Ref 
Acacia nilotica (L.) 
Delile 
Seed Antiplasmodial 1.5 µg/mL Terpenoids and tannins. [18] 
Anethum graveolens L. Leaves Antiplasmodial - Volatile oils [24] 
Annona muricata L. Leaves Antileishmanial 25 µg/mL Acetogenins [49] 
Anogeissus Leiocarpa 
(DC.) Guill. & Perr. 
Bark Antiplasmodial 19 µg/mL 
Ellagic acid, gallic acid, and 
gentisic acid 
[50] 
Argemone mexicana L. Leaves Antiplasmodial 1.7 μg/mL 





Root Antiplasmodial ˂ 5 μg/mL - [18] 
Azadirachta indica 
A.Juss. 
Leaves Antiplasmodial 2.5 μg/mL Gedunin [52,53] 
Cardiospermum 
halicacabum L. 
Leaves Antiplasmodial 42 µg/mL - [54] 
Combretum glutinosum 
Perr. ex DC. 




Bark Antiplasmodial 0.2 μg/mL - [38] 
Commiphora myrrha 
(Nees) Engl. 
Gum resin Trypanocidal 8.1 μg/mL - [56] 
Croton gratissimus var. 
gratissimus 




Curcuma longa L. Rhizome Antiplasmodial 3- 4.2  μg/mL 
Curcumin, demethoxycurcumin, 




Leaves Antiplasmodial - Essential oils [59] 
Cyperus rotundus L. Whole plant Antiplasmodial - 

















(2) 0.2 μg/mL 
(1) R-(+)-limonene 
 
(2) Justicidin B 
[63–65] 
Jatropha curcas L. Seeds Trypanocidal 
1.9 µg/mL (T. 
brucei) and 
7.4 µg/mL , 
(T. cruzi) 
Phorbol esters [66] 
Mangifera indica L. Stem bark Antiplasmodial ˃ 50 µg/mL - [67] 
Moringa oleifera Lam. Leaves Antileishmanial 5.25 µM Niazinin [68] 











2.3.2 Testing for antiparasitic activity 
The original extracts and all fractions obtained by partitioning were tested at two 
concentrations, 2 μg/mL and 10 μg/mL, against the following panel of protozoan 
parasites: T. b. rhodesiense bloodstream form, T. cruzi intracellular amastigote form 
grown in rat L6 cells, L. donovani axenic amastigote form grown at low pH, and P. 
falciparum erythrocytic stage grown in human erythrocytes. Percent inhibition was 
calculated in comparison to untreated controls. All tests were carried out in 
independent duplicates. The results are compiled in Supplementary Table S1. 
Extracts that exhibited >80% growth inhibition at 10 μg/mL, or >50% growth inhibition 
at 2 μg/mL against at least one of the tested parasites was considered active. Of the 235 
extracts in our library, 125 (53%) fulfilled these activity criteria. A total of 34 (27%) of the 
active extracts exhibited activity against T. b. rhodesiense, L. donovani and P. falciparum 
collectively. Regarding parasite species-selective inhibition, P. falciparum appeared to 
be the most susceptible parasite, followed by T. b. rhodesiense and L. donovani. Among 
Plant species Part Tested activities IC 50 value Active metabolite(s) 
Ref 
Piper cubeba L. f. Fruits 
Antitrypanosomal 
against T. cruzi 
amastigotes 
87.9 µg/mL Essential oil [70] 
Senna occidentalis (L.) 
Link (syn.Cassia 
occidentalis L. 
Leaves Antiplasmodial <3 µg/mL 





Whole plant Antiplasmodial 274.8 µg/mL - [44] 
Tinospora bakis 
(A.Rich.) Miers 
Roots Antiplasmodial 28.6 µg/mL Alkaloids [71] 
Xanthium Strumarium 
subsp. brasilicum (Vell.) 








2.95 µg/mL  











Leaves Antileishmanial >30 µg/mL - [38] 
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Figure 1. Susceptibility of parasites against a library of Sudanese medicinal plants. Activity 
criteria: >80% growth inhibition at 10 μg/mL or >50% growth inhibition at 2 μg/mL against one 
or more of the four included parasites. Venn diagram drawn with 
(https://bioinfogp.cnb.csic.es/tools/venny/). 
 
2.3.3 Two-way clustering of the bioactivity data 
We used the screening results obtained with 2 µg/mL for two-way clustering, i.e. 
clustering the plants according to their bioactivity, and clustering the parasites 
according to their susceptibility (Figure 2). Per plant only one fraction from the 
partitioning was included, i.e. the one which had displayed the highest activity against 
any of the four parasites. This approach clearly confirmed the notion that T. b. 
rhodesiense and P. falciparum, despite their large phylogenetic distance, have a similar 
susceptibility profile. It also highlighted T. cruzi as the least susceptible of the four 
tested parasites (Figure 2). There was no clear separation between the medicinal plants 
with reported anti-infective use (printed in red in Figure 2) and the rest. Regarding 
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antiplasmodial activity, the plants that had a reported use against malaria (n=17; 
Table 1) were slightly more active against P. falciparum in vitro, both at 2 µg/mL (mean 
inhibition of 43% vs. 39%) and at 10 µg/mL (mean inhibition of 89% vs. 75%). However, 























Figure 2. Heat map showing two-way clustering of bioactivity of extracts, and of parasites. 
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2.3.4 Testing for cytotoxicity 
Extracts with antiparasitic activity were also tested for cytotoxicity. This was done 
against rat L6 skeletal myoblast cells, the same cell line that had been used as host cells 
for testing against amastigote T. cruzi. Concentration-response curves allowed the 
calculation of both 50% and 90% inhibitory concentrations (IC50 and IC90; Table 3). The 
cytotoxicity data of the tested fractions cannot directly be compared to their 
antiparasitic activity because the antiparasitic and cytotoxic activity of a given fraction 
can be due to different molecules. Nevertheless, the aim was to identify non-toxic 
fractions for the following HPLC-based activity profiling and identification of active 
compounds. 
 
Table 3. Cytotoxicity of antiprotozoal extracts as determined against rat L6 skeletal myoblast 
cells in vitro. 
Plant Part Fraction 
Cytotoxicity [µg/mL] 
IC50 IC90 
Acacia nilotica (L.) Delile Leaves Ethyl acetate 21.5 83.0 
Ambrosia maritima (L.) Leaves Ethyl acetate 38.1 85.8 
Annona  muricata L. Leaves Chloroform 20.3 71.3 
Argemone  mexicana L. Leaves Ethyl acetate 58.5 91.9 
Boswellia papyrifera (Caill. ex Delile) Hochst Gum Petroleum ether 31.6 83.5 
Commiphora myrrha (Nees) Engl. Gum Methanol 5.5 9.9 
Croton gratissimus var. gratissimus Fruits Chloroform 32.5 81.8 
Cuscuta hyalina Roth ex Schult. Stem Chloroform 19.6 30.2 
Cymbopogon citratus (DC.) Stapf Leaves Ethyl acetate 53.8 N/A
a
 
Cyperus rotundus L. Rhizome Ethyl acetate 64.3 N/A
a
 
Guiera senegalensis J.F.Gmel. Leaves Ethyl acetate 16.0 67.8 
Haplophyllum tuberculatum (Forssk.) A.Juss. Root Chloroform 6.3 10.3 
Moringa oleifera Lam. Leaves Ethyl acetate 89.6 N/A
a
 
Prosopis chilensis (Molina) Stuntz Leaves Chloroform 5.9 9.8 
Struthanthus concinnus Mart. Branches Ethyl acetate 44.6 86.1 
Tephrosia apollinea (Delile) DC Leaves Chloroform 15.5 51.8 
Xanthium Strumarium subsp. brasilicum (Vell.) 
O.Bolòs & Vigo (syn. Xanthium brasilicum Vell.) 
Leaves Petroleum ether 13.3 28.8 
a
N/A = Not Achievable 




2.3.5 Extracts with selective anti-trypanosomal activity 
The most potent and selective activity against T. b. rhodesiense was exhibited by the 
chloroform fraction of the leaves of Terminalia catappa L. (Combretaceae), which 
showed 98% inhibition at 10 µg/mL and 80% inhibition at 2 µg/mL. Five of the ethyl 
acetate fractions showed growth inhibition > 85% at 10 µg/mL: fruits of Croton 
gratissimus var. gratissimus (Euphorbiaceae), processed fruits of Nauclea latifolia Sm. 
(Rubiaceae), leaves of Lippia lacunosa Mart. & Schauer (Verbenaceae) and 
Xanthium strumarium subsp. brasilicum (Vell.) O.Bolòs & Vigo (syn. Xanthium brasilicum 
Vell.) (Compositae), and the mango Mangifera indica L. fruit peels (Anacardiaceae). In 
addition, the water fraction of processed fruits of Nauclea latifolia showed significant 
inhibition of T. b. rhodesiense at the two tested concentrations. 
Only five percent of the library extracts were preferentially active against L. donovani. 
These were mostly lipophilic, e.g. the chloroform fraction of Ambrosia maritima L. 
(Asteraceae) leaves and the petroleum ether fractions of Piper cubeba L. f. (Piperaceae)  
fruits, Portulaca oleracea L. (Portulacaceae) aerial parts, and Typha angustifolia L. 
(Typhaceae) stem. 
Trypanosoma cruzi was the least sensitive among the tested parasites. Only the crude 
extract of Annona muricata L. (Annonaceae) leaves and the methanolic fraction of 
Commiphora myrrha (Nees) Engl. (Burseraceae) oil and resin inhibited the growth of 
intracellular T. cruzi more than 50% at 2 µg/mL. However, these activities were not 
specific for T. cruzi (Figure 1, Table S1). 
2.3.6 Extracts of selective antiplasmodial activity 
Thirteen fractions showed >80% growth inhibition of P. falciparum at 10 µg/mL, but 
none showed >50% growth inhibition at 2 µg/mL. Among the most active ones were the 
chloroform fraction of Cuscuta hyalina Roth ex Schult. (Convolvulaceae) stem and the 
ethyl acetate fractions of the leaves of Abutilon pannosum var. figarianum (Webb) 
Verdc. (syn. Abutilon figarianum Webb (Malvaceae), Annona muricata, Tephrosia 
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apollinea (Delile) DC (Leguminosae), and Cardiospermum halicacabum L. Moreover, 
both the chloroform and the ethyl acetate fractions of the leaves of Cymbopogon 
citratus (DC.) Stapf (Poaceae) exhibited selective antiplasmodial activity above 80% 
inhibition at 10 µg/mL. However, the ethyl acetate fraction, in particular, exhibited 
cytotoxicity on L6 cells with an IC50 of 53.8 µg/mL (Table 3). 
2.3.7 HPLC-based activity profiling 
The ethyl acetate fraction of Ziziphus spina-christi (L.) Desf. (Rhamnaceae) leaves had 
shown >80% growth inhibition at 10 µg/mL, and >50% inhibition at 2 µg/mL across all 
parasites (Table S1). HPLC-based activity profiling revealed that the time-windows of 
antiparasitic activity against L. donovani on the one side, and against T. b. rhodesiense 
and P. falciparum on the other side, were different. The antitrypanosomal and 
antiplasmodial activity was associated with more polar, earlier eluting compounds, 
while the antileishmanial activity was located in the more lipophilic and later eluting 














Figure 3. HPLC-based activity profiling of an ethyl acetate fraction from leaves of Ziziphus spina-
christi (L.) Desf. The ELSD chromatogram of the fraction separation on an analytical RP-HPLC 
column is shown. Activity of the one minute micro-fractions is indicated for trypanocidal A) and 
antileishmanial activity (B), expressed as % of growth inhibition. 
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In the chloroform fraction of Guiera senegalensis J.F.Gmel. (Combretaceae) leaves the 
two time windows of activity against T. b. rhodesiense and P. falciparum were identical 
(Figure 4), likely indicating molecules of dual activity. However, the chloroform fraction 














Figure 4. HPLC-ESIMS (base peak chromatogram) and activity profile of a chloroform fraction 
from leaves of Guiera senegalensis J.F.Gmel. Similar time window for trypanocidal (A) and 
antiplasmodial activity (B) were found. Peak 1 refers to guieranone A. 
 
2.3.8 Dereplication of active principles 
HPLC-based activity profiling, in combination with on-line spectroscopic data (MS and 
UV) and comparison with natural products databases was used to dereplicate known 
active compounds. The antiplasmodial activity of Guiera senegalensis J.F.Gmel.was in 
accordance with previous reports. In the window of activity a HPLC peak was detected 
which exhibited a [M+H]+ ion at m/z 316 in the MS, and λmax 241 and 276 nm in the UV 
spectrum. This peak was assigned to guieranone A (MW 316.35 g/mol), a compound 
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previously reported from this species [73]. The chloroform fraction of Tephrosia 
apollinea (Delile) DC. leaves was active against three parasites (Table S1), as well as 
cytotoxic in L6 cells (Table 3). In the window of activity a HPLC peak exhibiting a [M+H]+ 
ion at m/z 393 in the ESIMS, and λmax 256 and 310 nm in the UV spectrum corresponded 
to pseudosemiglabrin, a major secondary metabolite in this plant [74], of known 
antioxidant and anti-inflammatory activity. 
The ethyl acetate fraction of the leaves, roots and seeds of Anogeissus leiocarpa (DC.) 
Guill. & Perr. (Combretaceae) exhibited promising inhibitory activity against T. b. 
rhodesiense and P. falciparum (Figure 5). In the active time window HPLC peaks with MS 
and UV data indicative for ellagic acid and quercetin were seen, and their identity was 
confirmed by co-injection of authentic samples. The two compounds have been 
previously reported from A. Leiocarpa [50,75]. Ellagic acid has been previously shown to 
possess antiplasmodial activity [76,92] which has been attributed to the inhibition of 
beta-haematin formation in the parasite [77]. The antiplasmodial activity of quercetin 
[78] has been associated with the inhibition of a parasite protein kinase [79].  
  
Figure 5. HPLC-PDA antiplasmodial activity profiling of the ethyl acetate fraction of the leaves of 
Anogeissus Leiocarpa (DC.) Guill. & Perr. recorded at 254 nm. Peaks 3 and 4 refer to ellagic acid 
and quercetin, respectively. 
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The leaf extract of Acacia nilotica (L.) Delile inhibited T. b. rhodesiense and P. falciparum 
at 2 µg/mL, and moderate cytotoxicity (IC50 of 21.5 µg/mL against L6; Table 3).  In the 
HPLC activity profile (Figure 6) peaks with [M+H]+ ions at m/z 291.0 and m/z 442.9 in the 
ESIMS, and with λmax 277 nm and 280 nm in the UV spectra were detected in the active 
time window. These peaks corresponded to catechin [80] and epicatechin gallate [81], 
respectively. The occurrence of these compounds in A. nilotica has been reported 
[82,83]. Catechins were found to possess antiplasmodial activity by inhibiting both the 
ATPase and chaperone functions of the P. falciparum heat shock proteins (PfHsps) 
through direct binding to PfHsp70-1 and PfHsp70-z [84]. In addition, a peak 
corresponding to ethyl gallate was detected in the active time window. Gallate esters 
are known inhibitors of trypanosome alternative oxidase, and they can increase 
intracellular glycerol to toxic levels resulting in trypanocidal activity [85]. However, we 
cannot exclude that ethyl gallate was formed from gallic acid during ethanol extraction. 



























Figure 6. HPLC-UV trace of the ethyl acetate fraction of Acacia nilotica (L.) Delile leaves detected 
at 254 nm, and the % of inhibition of the one minute micro-fractions against Trypanosoma 
brucei rhodesiense (A), Leishmania donovani (B), and Plasmodium falciparum (C). Peaks 5-7 refer 
to catechin, ethyl gallate, and epicatechin gallate, respectively. 
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2.4 Discussion  
 
A total of 62 Sudanese plants were selected on the basis of their traditional use as 
medicinal plants, with an emphasis on plants that had been used to treat protozoal 
diseases. Of these plants a library of 235 extracts was prepared and tested against four 
protozoan parasites: Plasmodium falciparum (erythrocytic stages), Trypanosoma brucei 
rhodesiense (bloodstream forms), Trypanosoma cruzi (intracellular amastigotes), and 
Leishmania donovani (axenic amastigotes). The methods used were standard in vitro 
tests for drug discovery, where the measured signals correlated with the number of 
parasites.  Screening of the library resulted in 125 potential hits that fulfilled the chosen 
activity criteria, i.e. >80% growth inhibition at 10 μg/mL or >50% growth inhibition at 2 
μg/mL against one or more of the four parasites. A total of 11 extracts were solely active 
against T. b. rhodesiense, 13 against P. falciparum, and 5 against L. donovani. A total of 
27 extracts exhibited activity against three parasites. The percentage of extracts that 
displayed activity against both T. brucei and P. falciparum (21%) was considerably higher 
than that with activity against T. brucei and L. donovani (5%), despite the fact that 
trypanosomes and leishmania are taxonomically related trypanosomatid parasites. This 
somehow surprising result is in agreement with previous screening campaigns reports 
[86–88]. The lack of overlap between activity against T. cruzi and L. donovani is not 
unusual and has been documented previously [89,90]. They are different parasites living 
in different compartments, i.e. cytoplasma for T. cruzi but acidic environment for 
Leishmania. 
 Interestingly, a major part of these extracts were from plants of the family 
Combretaceae (Guiera senegalensis J.F.Gmel., Anogeissus Leiocarpa (DC.) Guill. & Perr., 
Combretum glutinosum Perr. ex DC., Combretum indicum (L.) DeFilipps (syn. Quisqualis 
indica L.) and Terminalia laxiflora Engl.). Plants of this family are known to be rich in 
phenolic compounds. The lowest number of hits was found for T. cruzi. This may be due, 
in part, to the fact that T. cruzi amastigotes (which are the clinically relevant stages for 
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chemotherapy) cannot be grown axenically. Hence, activity can only be identified if the 
antiparasitic activity against T. cruzi is significantly higher than cytotoxicity in L6 cells 
used for culturing the parasite. 
 
 
Figure 7. Chemical structures of compounds identified by dereplication. Guieranone A (1), 
pseudosemiglabrin (2),  ellagic acid (3),  quercetin (4), catechin (5), ethyl gallate (6), and 
epicatechin gallate (7). 
 
Our findings corroborate previously reported activities of some plants, e.g. for Z. spina-
christi [91], A. Leiocarpa [33,60], G. senegalensis [61], Terminalia spp. and X. strumarium 
[72,93]. Antiprotozoal activities of some other plants are reported here for the first 
time, e.g. the antitrypanosomal activity of Cuscuta hyalina , Combretum indicum , and 
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Croton gratissimus . HPLC activity profiling, in combination with on-line spectroscopy, 
enabled a rapid identification of some of the active compounds by dereplication 
(Figure 7), i.e. guieranone A (1) from G. senegalensis, pseudosemiglabrin (2) from T. 
apollinea,  ellagic acid (3) and quercetin (4) from A. Leiocarpa, and catechin (5), ethyl 
gallate (6), and epicatechin gallate (7) from A. nilotica. HPLC-based activity profiling will 
also be of use for the identification of antiprotozoal compounds from promising 
Sudanese plants such as Croton gratissimus var. gratissimus and Cuscuta hyalina Roth ex 
Schult., which exhibited interesting antitrypanosomatid activity. In summary, we have 
compiled a comprehensive library of Sudanese medicinal plants and demonstrate that 
they are a promising source of bioactive molecules against protozoan parasites. 
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2.5 Material and Methods 
 
Preparation of a library of plant extracts 
A total of 62 plants reputed as antiparasitic in traditional medicine in Sudan were 
sollicited from the repository of the Faculty of Pharmacy, University of Science & 
Technology. The plants belonged to 35 different families, of which the Combretaceae, 
Leguminosae, Verbenaceae, Lamiaceae and Compositae were the most frequent. Where 
available, different parts of a given plant species were included in the study.  
The taxonomic identity was confirmed by the Medicinal and Aromatic Plants Research 
Institute, Sudan. Voucher specimens (USTH 01-USTH 62) have been deposited at the 
Herbarium of the faculty of Pharmacy, University of Science and Technology, 
Omdurman, Sudan. 
Dried plant material was milled to coarse powder in a hammer mill. 100-500 g of 
powdered material was extracted for 24 h with 500 mL of 70% ethanol in a magnetic rod 
stirrer. Extracts were filtered through Whatman no. 1 filter paper and concentrated by 
solvent removal in a rotary vacuum evaporator. Crude extracts were suspended in water 
and partitioned consecutively with petroleum ether, chloroform, ethyl acetate, and n-
butanol. Crude extracts and their respective fractions were allowed to dry at room 
temperature, weighed, and reconstituted in DMSO (10 mg/mL) to serve as stock 
solutions for antiparasitic testing. This resulted in a library of 235 samples. 
 
HPLC analyses and microfractionation 
HPLC analyses were performed on a Shimadzu HPLC system equipped with photo diode 
array detector (PDA) (SPD-M20A, Shimadzu), evaporative light scattering detector 
(ELSD) (3300, Alltech), and an electrospray ionisation mass spectrometer (ESIMS) (LCMS-
8030, Shimadzu). LabSolutions software was used for data acquisition and processing. 
The separation was performed on a C18 SunFire column (3.0 × 150 mm; 3.5 μm; Waters).  
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Microfractionation of the active samples was carried out by analytical RP-HPLC on an LC-
MS 8030 system (Shimadzu) connected with an FC204 fraction collector (Gilson). For 
each fraction, a solution of 10 mg/mL was prepared in DMSO. A total of three injections 
were performed: 2 × 35 μL with only UV detection (254 nm) for collection (0.7 mg of 
fraction in total) and 1 × 35 μL with UV-ELSD-ESIMS detection without collection. 
The mobile phase consisted of water with 0.1% formic acid (A) and acetonitrile with 
0.1% formic acid (B). The gradient was 5% to 100% B in 30 min, followed by washing 
with 100% B for 10 min. The flow rate was 0.4 mL/min. Fractions of 1 min each were 
collected from minute 1 to minute 40, resulting in 40 microfractions in total. 
Microfractions of two successive injections of a given sample were collected into the 
corresponding wells of a 96-deepwell plate. Plates were then dried in a Genevac EZ-2 
evaporator [94,95]. 
 
Activity testing against Trypanosoma brucei rhodesiense 
In vitro activity was tested against bloodstream-form T. b. rhodesiense STIB 900, which 
had been obtained in 1982 from a Tanzanian patient and adapted to axenic culture [96]. 
The culture medium was MEM supplemented with 25 mM HEPES, 1 g/L additional 
glucose, 1% MEM nonessential amino acids, 0.2 mM 2-mercaptoethanol, 1 mM Na-
pyruvate, and 15% heat inactivated horse serum. In the two-concentration assay, 50 µL 
medium containing the corresponding samples concentration (10 µg /mL or 2  µg /mL) 
was added to the wells of a 96 well plate. For the IC50 determination, 50 µL medium was 
added to each well and a serial sample dilution of eleven 3-fold dilution steps covering a 
range from 100 to 0.002 μg/mL were prepared. Then 104 T. b. rhodesiense in 50 µL 
medium was added to the wells and the plate was incubated for 72 h at 37 °C in a 
humidified atmosphere of 5% CO2. 10 µL resazurin solution (12.5 mg resazurin dissolved 
in 100 mL distilled water) was added to each well and incubated for a further 2 to 4 h 
[97]. Plate reading was performed in a Spectramax Gemini XS microplate fluorometer 
(Molecular Devices Corporation) using an excitation wavelength of 536 nm and emission 
wavelength of 588 nm. Melarsoprol was used as reference drug. Final in-test DMSO 
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concentration did not exceed 1%.  All assays were performed in two independent 
replicates at least. 
 
Activity testing against Leishmania donovani 
L. donovani amastigotes strain MHOM/ET/67/L82 were grown in axenic culture in SM 
medium at pH 5.4 with 10% heat-inactivated fetal bovine serum, at 37 °C in a humidified 
atmosphere of 5% CO2. In the two-concentration assay, 50 uL medium containing the 
corresponding samples concentration (10 µg/mL or 2 µg/mL) was added to the wells of 
a 96 well plate. For the IC50 determination, 50 µL medium was added to each well and a 
serial sample dilution of eleven 3-fold dilution steps covering a range from 100 to 
0.002 μg/mL were prepared. Then 105 L. donovani amastigotes in 50 µL medium was 
added to the wells and the plate was incubated for 72 h at 37 °C in a humidified 
atmosphere of 5% CO2. After 72 h of incubation, 10 μL of resazurin solution were added 
to each well and the plates incubated for another 2 h [98]. Plate reading was performed 
as described for T. brucei. Miltefosine was used as reference drug. Final in-test DMSO 
concentration did not exceed 1%. All assays were performed in two independent 
replicates at least. 
 
Activity testing against Trypanosoma cruzi 
All tests were performed with the T. cruzi Tulahuen strain C2C4, which expresses the β-
galactosidase (LacZ) gene [99]. L6 rat skeletal myoblasts served as host cells. Cultures 
were maintained in RPMI 1640 medium supplemented with 10% FBS and 1.7 µM L-
glutamine at 37°C in a humidified atmosphere of 5% CO2. Host cells were seeded in 96-
well microtitre plates, 2 × 103 per well in 100 µl medium. After 24 h, 50 µl of a 
suspension of 1 × 105/mL trypomastigote T. cruzi were added. The medium was 
replaced at day 4, test samples were added, and the plates incubated for further 4 d. 
Finally, 50 µl of 2.5x CPRG/Nonidet solution was added to all wells. A colour reaction 
was visible within 2-6 h, which was quantified in an absorbance reader at 540 nm 
(Spectramax). Benznidazole was used as reference drug. Final in-test DMSO 
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concentration did not exceed 1%. All assays were performed in two independent 
replicates at least. 
 
Activity testing against Plasmodium falciparum 
In vitro antimalarial activity was tested against the erythrocytic stages of P. falciparum 
NF54, originally isolated from a patient at Schiphol airport. The parasites were grown in 
human erythrocytes in RPMI 1640 supplemented with 0.5% ALBUMAX® II, 25 mM 
Hepes, 25 mM NaHCO3 (pH 7.3), 0.36 mM hypoxanthine, and 100 U/mL neomycin and 
kept in an atmosphere of 3% O2, 4% CO2, and 93% N2 in humidified modular chambers 
at 37 °C. In the two-concentration assay, 100 µL medium containing the corresponding 
samples concentration (final sample concentration of 10 µg /mL or 2  µg /mL) was added 
to the wells of a 96 well plate. For the IC50 determination, 50 µL medium was added to 
each well and a serial sample dilution of eleven 3-fold dilution steps covering a final 
range from 100 to 0.002 μg/mL were prepared. Then 100 µL parasite (erythrocytes at 
1.25% final hematocrit and 0.3% final parasitemia) was added. After 48 h of incubation 
with test compounds, 0.25 μCi of [3H]hypoxanthine was added per well and the plates 
were incubated for an additional 24 h. Cells were harvested onto glass-fiber filters and 
radioactivity was counted using a Betaplate liquid scintillation counter. Artemisinin was 
used as reference drug. Final in-test DMSO concentration did not exceed 1%. All assays 
were performed in two independent replicates at least. 
 
Clustering according to antiprotozoal activity 
Two-way clustering was performed on the bioactivity data measured at 2 µg/mL (Table 
S1). Percent inhibition was converted to decimals and the maximum was set to 1. For 
sake of clarity, we included only one fraction per plant, i.e. the one which had exhibited 
the highest activity against any of the four protozoan parasites. Hierarchical clustering 
was performed with the Eisen lab programs Cluster and Treeview [100] using Euclidean 
distance and average linkage. 
 




L6 rat skeletal myoblast cells were seeded in 96-well microtiter plates at 2 × 104 cells/mL 
in RPMI 1640 medium supplemented with 10% FBS and 1.7 µM L-glutamine. The cells 
were allowed to attach overnight, then test compounds were added. After 72 h of 
incubation, 10 µL of resazurin solution (see above) was added and the plates were 
incubated for an additional 2 h. Plates were read in a fluorescence scanner at 536 nm 
excitation and 588 nm emission wavelength. Podophyllotoxin was used as reference. All 
assays were performed in two independent replicates at least. 
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2.7 Supporting Information:  
Table S1. Screening results of protozoan activity of plant extracts at two concentrations, 10 µg/ml and 2 µg/ml. 
Plant species Family Part Fraction 
T. b. 
rhodesiense 
L. donovani T. cruzi P. falciparum 

































Abutilon pannosum var. 
figarianum (Webb) Verdc. 
Malvaceae Leaves 
Crude 50.5 23.4 0.0 0.0 22.3 19.1 48.3 9.5 
Petroleum ether 75.7 42.1 106.0 37.1 19.8 9.6 88.1 9.5 
Chloroform 83.9 42.7 42.1 22.4 4.5 1.2 77.2 13.6 
Ethyl acetate 62.4 39.9 52.1 27.1 0.9 10.5 89.2 48.7 
Water residue 28.0 26.6 16.0 25.1 5.4 4.5 19.3 7.6 
Acacia nilotica (L.) Delile Fabaceae 
Flowers 
Crude 102.4 83.9 20.9 29.8 11.8 2.0 99.6 76.1 
Petroleum ether 89.5 27.8 48.2 31.6 0.0 0.8 95.3 10.6 
Chloroform 103.1 79.3 30.2 21.4 2.2 2.1 97.7 42.6 
Ethyl acetate 44.1 42.3 10.3 19.6 11.2 8.7 44.4 32.7 
Water residue 72.2 72.7 7.9 7.3 2.5 4.2 72.4 67.0 
Leaves 
Crude 99.3 83.2 3.1 5.4 20.0 6.8 99.0 68.2 
Petroleum ether 96.7 67.5 91.0 0.0 45.4 17.2 81.5 7.6 
Chloroform 102.9 104.6 83.8 43.1 66.7 13.6 103.8 97.3 
Ethyl acetate 101.5 80.6 24.9 26.4 3.8 12.8 103.2 65.1 
Water residue 74.9 11.9 33.3 31.7 0.1 9.8 24.8 5.4 
Ambrosia maritima L. Asteraceae Leaves 
Crude 29.6 9.7 35.2 14.8 9.9 5.8 21.4 5.9 
Petroleum ether 60.7 21.4 107.0 36.6 13.1 0.0 84.5 5.4 
Chloroform 58.9 18.5 91.8 36.9 6.2 8.7 54.0 5.7 
Ethyl acetate 101.1 32.5 91.4 37.1 13.2 11.2 36.5 11.6 
Water residue 7.6 4.2 27.6 29.1 10.2 7.9 15.8 3.2 
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Rhamnaceae Leaves Ethyl acetate 62.6 21.7 105.5 85.1 15.5 12.6 99.7 13.4 
Butanol 55.5 23.9 38.5 18.1 0.9 4.4 48.0 3.3 
Anethum graveolens L. Apiaceae Leaves 
Crude 8.9 36.2 21.5 13.3 2.2 0.0 0.0 0.0 
Hexane 4.9 0.0 19.9 26.4 5.2 5.9 2.1 0.0 
Chloroform 1.4 1.7 11.7 12.7 9.0 3.3 3.1 0.0 
Ethyl acetate 38.9 22.1 44.3 34.1 2.1 0.0 10.5 13.8 
Annona  muricata L. Annonaceae Leaves 
Crude 90.8 28.2 77.9 1.1 81.7 72.7 94.9 62.9 
Petroleum ether 93.8 28.3 99.6 44.2 82.7 30.9 102.4 31.4 
Chloroform 76.8 25.6 98.6 34.7 81.1 55.2 98.1 69.1 
Ethyl acetate 55.4 27.1 71.6 39.9 63.9 40.5 89.3 44.6 
Water residue 13.8 12.3 41.4 32.4 3.8 7.1 43.3 5.0 
Anogeissus Leiocarpa (DC.) 
Guill. & Perr. 
Combretaceae 
Bark Ethyl acetate 99.8 69.3 14.3 0.0 0.9 3.1 101.8 45.8 
Leaves 
Chloroform 100.0 68.5 94.2 12.1 11.6 0.0 102.1 27.9 
Ethyl acetate 100.2 75.0 68.2 8.8 17.5 2.2 102.9 103.4 
Root Ethyl acetate 100.8 64.9 29.2 3.8 12.3 4.2 103.2 67.3 
Seeds 
Chloroform 99.7 50.2 94.1 46.0 15.3 6.0 99.5 34.8 
Ethyl acetate 98.6 73.3 90.4 40.5 18.1 4.3 102.5 106.4 
Wood Ethyl acetate 97.0 76.8 81.2 0.0 18.0 12.3 102.3 98.2 
Argemone mexicana L. Papaveraceae 
Leaves 
Crude 33.4 11.1 76.2 33.8 0.0 6.9 97.6 7.1 
Petroleum ether 65.1 9.7 107.0 32.1 7.0 7.6 98.3 6.8 
Chloroform 75.2 28.0 108.0 37.1 11.3 8.7 98.2 82.6 
Ethyl acetate 56.5 14.5 106.6 40.4 2.8 9.5 98.4 7.9 
Water residue 2.1 3.1 24.4 22.6 6.7 9.9 62.2 4.4 
Bark Crude 26.5 9.4 27.6 23.9 9.1 1.9 89.7 15.1 
Aristolochia bracteolata Lam. Aristolochiaceae Root Ethyl acetate 103.1 44.4 88.2 36.7 40.0 12.7 76.0 20.4 
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Azadirachta indica A.Juss. Meliaceae Leaves Oil 7.3 2.4 13.8 17.9 39.3 6.0 71.2 6.1 
Bathysa australis (A.St.-Hil.) 
K.Schum. 
Rubiaceae Leaves 
Hexane 91.3 58.4 83.8 1.0 36.7 15.4 82.6 10.6 
Methylene 
chloride 
100.2 77.1 96.5 46.2 33.7 5.4 101.1 17.0 
Ethyl acetate 44.6 16.8 36.5 32.2 10.8 14.2 64.5 4.6 
Butanol 41.3 10.5 39.2 32.1 4.2 5.1 34.0 5.0 
Bertholletia excelsa Bonpl. Lecythidaceae 
Fruit 
(endocarp) 
Hexane 83.7 21.3 69.3 34.4 5.1 9.4 98.6 14.4 
Bark (trunk) Crude 104.6 36.2 88.2 37.8 13.2 6.5 97.8 100.3 
Seeds 
(tugument) 
Crude 81.3 19.9 40.5 42.5 2.4 9.0 46.3 5.3 
Boswellia papyrifera (Caill. ex 
Delile) Hochst 
Burseraceae Gum resin 
Crude 23.7 4.4 104.8 47.0 4.8 3.5 91.8 15.4 
Petroleum ether 71.6 8.2 116.8 76.9 9.8 0.8 100.0 41.5 
Chloroform 29.0 9.7 117.1 49.9 6.2 2.5 94.1 9.5 
Ethyl acetate 10.3 7.0 46.4 40.5 7.0 5.2 0.2 3.9 
Water residue 19.8 11.4 73.0 35.8 8.7 5.1 83.6 0.0 




Crude 58.4 18.4 56.1 36.2 7.8 9.3 32.8 5.0 
Petroleum ether 42.0 7.2 79.7 35.4 4.9 6.1 35.0 5.7 
Chloroform 51.9 18.5 64.6 29.3 11.7 12.3 51.7 7.4 
Ethyl acetate 28.1 14.9 30.6 15.2 24.2 10.9 83.2 13.8 
Water residue 0.5 2.2 0.0 0.0 7.7 14.9 10.7 0.1 




Chloroform 51.6 41.7 12.0 24.4 9.6 7.1 18.3 9.0 
Ethyl acetate 102.6 85.7 96.5 35.2 13.6 2.9 103.5 103.5 
Wood 
Chloroform 103.9 60.5 106.3 53.6 7.7 6.0 104.1 85.3 
Ethyl acetate 103.2 82.6 93.3 53.6 9.7 9.6 102.4 99.6 
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Chloroform 101.4 84.0 64.7 10.7 18.7 4.6 102.3 68.1 
Ethyl acetate 101.0 85.9 94.8 63.0 20.1 2.1 102.9 97.4 
Wood 
Chloroform 94.6 49.1 101.1 42.1 52.8 22.8 102.4 32.6 
Ethyl acetate 95.1 57.0 83.4 22.3 33.2 5.3 102.5 61.2 
Combretum indicum (L.) 
DeFilipps (syn. Quisqualis 
indica L.)  
Combretaceae 
Leaves 
Chloroform 84.3 53.2 80.8 36.9 3.2 16.4 72.3 15.5 
Ethyl acetate 80.8 21.4 52.8 29.7 12.0 11.4 92.7 27.0 
Flowers 
Chloroform 34.2 12.7 17.2 4.0 26.9 1.0 10.3 0.7 
Ethyl acetate 98.6 80.3 100.5 4.0 37.1 1.0 98.5 91.3 
Commiphora myrrha (Nees) 
Engl. 
Burseraceae Gum resin 
Methanol 85.0 99.1 103.2 104.4 104.2 95.0 98.3 94.8 
Oil 83.3 97.9 101.5 103.8 101.0 76.3 97.6 97.2 




Crude 49.6 45.6 92.7 40.2 2.9 3.6 88.8 9.3 
Petroleum ether 99.8 74.8 100.8 103.0 88.5 14.6 103.0 103.9 
Chloroform 63.9 12.5 107.1 55.9 38.4 11.0 97.8 24.9 
Ethyl acetate 100.1 32.9 25.3 17.8 9.4 0.1 76.8 32.5 
Water residue 21.0 2.2 20.9 15.9 6.9 10.3 18.1 0.2 
Leaves 
Petroleum ether 75.1 9.7 8.6 0.0 47.8 6.9 57.4 0.0 
Chloroform 85.1 16.0 96.1 9.3 41.9 16.1 43.7 13.0 
Ethyl acetate 34.9 6.5 55.2 20.9 10.9 7.5 57.9 4.9 
Curcuma longa L. Zingiberaceae Rhizome 
Crude 29.3 14.3 54.1 38.3 3.8 0.0 1.6 0.0 
Petroleum ether 11.3 6.9 46.2 35.8 6.3 0.0 1.7 3.3 
Chloroform 54.2 26.7 88.0 43.5 6.3 4.6 92.7 7.7 
Ethyl acetate 33.0 13.7 39.0 27.1 4.4 5.2 1.2 1.9 
Water residue 16.3 11.3 46.3 35.4 0.0 0.0 6.4 7.5 
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Crude 66.9 4.7 2.5 0.0 59.1 42.5 58.8 7.7 
Petroleum ether 55.5 21.8 85.2 33.7 27.1 6.5 85.5 6.3 
Chloroform 17.1 15.7 65.7 31.2 67.8 7.8 103.7 4.8 
Ethyl acetate 95.3 24.9 58.5 36.9 50.7 32.6 100.6 7.2 
Water residue 3.4 10.8 39.3 27.6 9.6 12.3 29.9 3.5 
Cymbopogon citratus (DC.) 
Stapf 
Poaceae Leaves 
Crude 24.1 15.4 43.5 32.4 0.3 0.0 12.6 5.4 
Chloroform 37.2 25.6 51.0 35.6 0.5 1.4 96.2 19.9 
Ethyl acetate 39.9 16.0 73.2 38.0 2.4 0.0 85.0 25.7 
Water residue 16.8 3.6 56.5 37.7 3.5 0.0 0.0 2.0 
Oil 12.5 5.5 62.4 28.7 1.9 0.0 0.6 5.4 
Cyperus rotundus L. Cyperaceae Rhizome 
Crude 19.0 10.2 63.6 35.5 7.9 11.9 44.9 4.5 
Petroleum ether 72.6 17.8 106.0 82.0 73.4 17.4 103.5 50.7 
Chloroform 55.8 18.8 106.6 45.4 15.1 12.2 100.7 40.5 
Ethyl acetate 29.4 4.5 29.6 33.1 7.3 14.5 34.1 3.3 
Water residue 0.3 0.9 27.8 25.3 4.2 14.1 17.8 5.4 
Eucalyptus camaldulensis 
Dehnh. 
Myrtaceae Leaves Oil 8.9 4.5 57.5 32.2 0.0 1.7 5.3 3.5 
Grewia tenax (Forssk.) Fiori  Malvaceae  
Bark Methanol 79.1 45.7 68.7 45.8 6.6 9.4 44.7 14.7 
Leaves 
Petroleum ether 84.5 42.0 93.6 35.0 9.8 4.7 94.0 11.1 
Chloroform 84.7 29.7 41.3 34.2 5.3 8.4 81.5 9.3 
Ethyl acetate 65.9 22.5 50.1 36.6 14.7 6.3 67.2 33.8 
Root Methanol 33.8 18.8 15.7 0.0 17.4 6.9 17.3 6.5 
Stem Methanol 55.1 23.9 42.1 39.0 7.8 5.1 27.9 12.3 
Guiera sengalensis J.F.Gmel. Combretaceae Leaves 
Crude 101.2 46.2 58.8 16.7 8.6 14.5 84.0 5.1 
Petroleum ether 95.8 66.7 96.8 49.4 57.3 16.4 100.1 39.1 
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Chloroform 104.3 91.2 109.1 54.3 66.9 11.4 103.0 84.9 
Ethyl acetate 103.1 79.5 108.5 34.3 46.2 15.1 100.9 67.9 




Crude 23.8 16.1 39.5 28.5 12.9 9.8 35.9 7.2 
Petroleum ether 71.1 26.0 105.0 61.2 26.8 8.3 99.2 36.8 
Chloroform 62.1 23.7 106.4 40.0 67.4 15.7 102.1 25.3 
Ethyl acetate 35.1 16.7 40.8 30.3 8.2 11.6 39.2 2.7 
Water residue 16.5 3.7 38.7 29.2 7.1 5.9 20.6 4.4 
Hyptis monticola Mart. ex 
Benth. 
Lamiaceae 
Leaves Crude 0.0 0.0 23.1 22.1 10.2 14.3 22.3 2.7 
Flowers Crude 74.6 20.9 103.0 60.4 35.6 14.4 100.3 20.7 
Jatropha curcas L. Euphorbiaceae Leaves 
Crude 32.9 17.1 61.9 43.2 2.8 2.6 0.0 0.0 
Petroleum ether 21.3 4.5 45.8 21.2 6.2 4.7 21.7 0.0 
Chloroform 32.2 18.7 47.4 30.0 3.9 0.0 22.7 11.0 
Ethyl acetate 19.5 8.5 47.2 37.2 4.2 0.0 4.3 3.0 
Water residue 16.9 7.1 49.8 35.1 0.0 0.0 1.6 0.0 
Lantana fucata Lindl. Verbenaceae Aerial parts Crude 97.8 66.2 106.9 103.6 90.9 26.2 101.9 70.1 
Lantana trifolia L. Verbenaceae Branches Butanol 71.5 11.8 11.6 15.1 5.3 8.2 23.0 0.0 
Lippia lacunosa Mart. & 
Schauer 
Verbenaceae Leaves 
Crude 81.4 20.9 62.2 2.5 3.1 9.2 46.5 5.5 
Ethyl acetate 96.3 66.2 15.5 3.6 27.4 13.3 30.7 5.6 
Butanol 71.0 11.2 6.1 0.0 2.2 13.0 31.1 2.6 
Lippia origanoides Kunth Verbenaceae Leaves Crude 99.5 67.1 105.2 79.9 35.8 7.1 103.2 26.2 
Lupinus albus subsp. graecus 
(Boiss. & Spruner) Franco & 
P.Silva (syn. Lupinus termis 
Forssk.) 
Leguminosae Seeds 
Crude 17.8 4.0 2.0 1.0 4.7 3.4 28.5 3.5 
Petroleum ether 35.0 14.4 7.4 3.2 6.3 8.2 24.7 5.0 
Chloroform 35.3 24.3 31.5 27.7 2.8 5.9 24.9 0.0 
Ethyl acetate 57.9 22.6 0.0 0.0 23.8 18.9 41.2 20.4 
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Water residue 44.2 21.9 22.2 20.2 9.6 5.0 32.4 39.6 
Mangifera indica L. Anacardiaceae Peels 
Crude 18.0 8.8 48.2 33.9 3.9 0.0 5.3 0.8 
Petroleum ether 11.7 6.4 52.8 37.2 6.3 0.0 0.0 0.0 
Chloroform 43.4 15.2 52.9 35.0 6.5 0.0 3.4 0.0 
Ethyl acetate 101.9 19.9 44.6 28.8 6.0 1.1 67.1 1.5 
Water residue 8.4 2.3 32.8 22.3 11.8 0.2 0.0 0.0 
Matricaria chamomilla L. Compositae Flower 
Crude 41.4 32.0 37.7 27.8 17.0 1.9 29.1 6.1 
Petroleum ether 75.8 24.6 106.6 22.1 10.2 3.7 91.1 5.0 
Chloroform 82.5 36.5 83.3 26.5 6.7 1.6 94.6 28.5 
Ethyl acetate 79.1 29.5 69.8 30.3 12.6 0.0 53.4 9.0 
Water residue 24.4 20.4 31.0 17.1 14.3 0.0 11.8 4.7 
Moringa oleifera Lam. Moringaceae Leaves 
Crude 36.2 17.0 43.9 31.4 1.7 0.0 48.6 7.3 
Hexane 12.2 5.3 45.5 35.0 0.9 0.0 1.5 7.6 
Chloroform 22.1 11.8 48.0 35.8 0.0 0.0 7.2 11.1 
Ethyl acetate 33.1 20.9 57.5 43.3 0.0 0.0 2.2 9.7 
Water residue 23.7 8.6 54.3 38.2 4.1 0.0 1.4 3.2 
Nauclea latifolia Sm. Rubiaceae 
Unprocesse
d  Fruit 
Crude 61.9 21.0 26.2 20.2 10.7 1.2 17.5 5.1 
Petroleum ether 68.8 21.0 34.0 3.4 8.3 0.0 30.5 5.6 
Chloroform 103.1 57.0 91.7 31.2 56.0 3.2 83.5 30.9 
Ethyl acetate 70.9 6.0 0.0 0.0 18.6 6.9 43.4 6.9 
Water residue 26.1 12.5 31.3 26.6 3.4 4.3 33.4 39.7 
Root Bark 
Crude 53.1 19.1 41.1 34.2 15.5 6.3 38.9 5.0 
Petroleum ether 64.1 15.6 76.3 33.9 33.7 6.4 66.0 8.3 
Chloroform 86.0 35.5 95.9 41.6 18.2 5.5 93.6 19.3 
Ethyl acetate 87.5 47.1 43.9 25.1 11.8 5.2 61.9 18.5 
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Water residue 24.9 7.0 37.5 25.9 8.8 2.7 21.2 3.4 
Processed  
Fruit 
Crude 47.6 15.4 43.0 29.3 8.9 8.2 35.3 12.7 
Petroleum ether 26.0 7.3 36.9 23.6 12.5 2.0 23.6 1.5 
Chloroform 51.8 14.2 40.3 19.7 7.6 0.0 35.1 7.2 
Ethyl acetate 45.5 4.2 25.4 14.9 4.0 0.1 21.9 8.0 
Water residue 81.1 66.0 0.0 0.0 16.9 9.1 18.2 9.8 
Nigella sativa L. Ranunculaceae Seeds Oil 6.5 13.9 36.6 21.0 3.9 0.0 9.9 20.7 
Operculina macrocarpa (L.) 
Urb. 
Convolvulaceae Roots Crude 43.9 20.5 61.1 28.4 43.3 7.6 102.8 43.6 
Opopanax hispidus (Friv.) 
Griseb. 
Apiaceae Fruits Oil 59.7 6.5 57.8 30.1 5.5 5.1 0.0 0.0 
Piper cubeba L. f. Piperaceae Fruits 
Crude 79.6 16.2 33.0 35.3 12.9 3.1 53.7 9.9 
Petroleum ether 71.1 16.2 103.4 29.5 5.2 3.3 45.0 10.9 
Chloroform 86.0 29.2 64.0 28.0 9.6 5.3 101.2 21.3 
Ethyl acetate 101.9 74.2 47.4 26.1 13.8 5.0 103.2 81.1 
Water residue 33.0 3.0 36.5 24.1 10.9 13.6 31.5 7.6 
Portulaca oleracea L. Portulacaceae Aerial part 
Crude 29.1 9.1 36.5 23.6 8.8 2.2 29.1 12.8 
Petroleum ether 69.0 8.5 103.2 26.4 15.2 19.9 58.9 11.1 
Chloroform 81.2 13.9 56.2 22.2 7.6 1.1 73.7 7.7 
Ethyl acetate 77.4 7.6 23.9 19.6 8.1 0.9 28.1 3.3 
Water residue 8.2 0.4 0.0 0.0 26.1 11.0 24.2 7.5 
Prosopis chilensis (Molina) 
Stuntz 
Leguminosae Leaves 
Crude 102.5 103.5 36.7 29.8 29.8 2.3 99.6 103.5 
Hexane 102.9 0.8 77.5 36.1 17.2 5.5 95.8 98.0 
Chloroform 104.5 102.8 49.2 36.3 25.6 4.6 103.4 98.2 
Ethyl acetate 8.4 7.9 51.9 30.7 11.7 3.5 32.0 6.3 
Prosopis juliflora (Sw.) DC. Leguminosae Leaves Crude 103.0 102.3 40.1 21.9 14.9 28.2 101.1 105.0 
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Rollinia sylvatica (A. St.-Hil.) 
Martius 
Annonaceae Leaves Crude 85.3 20.3 66.2 26.4 50.9 9.8 90.5 47.5 
Saussurea costus (Falc.) 
Lipsch. 
Compositae Leaves Methanol 99.4 19.6 105.2 36.5 26.1 7.4 45.3 5.0 
Senna occidentalis (L.) Link 
(syn. Cassia occidentalis L.) 
Leguminosae Aerial  part 
Crude 25.8 15.5 30.4 31.1 4.9 8.9 27.4 5.1 
Petroleum ether 54.4 17.3 105.6 35.9 19.0 6.7 91.6 3.0 
Chloroform 40.4 46.0 58.2 34.4 12.1 9.5 53.7 6.1 
Ethyl acetate 21.9 15.1 51.9 37.1 8.5 7.4 25.5 5.1 
Water residue 8.3 8.0 45.7 32.6 4.4 8.7 16.0 2.0 
Solanum aethiopicum L. Solanaceae Fruits Butanol 15.2 11.7 36.2 24.8 17.6 7.6 26.8 4.2 
Striga hermonthica (Delile) 
Benth. 
Orobanchaceae  Stem 
Crude 20.1 1.5 42.6 20.8 7.4 8.3 36.5 9.2 
Petroleum ether 78.9 12.3 102.4 24.8 12.8 0.6 99.5 36.2 
Chloroform 66.9 7.8 77.6 0.0 16.1 12.1 51.8 9.2 
Ethyl acetate 85.9 22.4 88.3 30.7 16.3 6.5 36.9 5.2 
Water residue 13.8 4.9 42.8 34.2 7.7 1.9 20.1 2.4 
Struthanthus concinnus Mart. Loranthaceae Branches 
Ethyl acetate 89.6 38.7 80.4 32.4 10.6 5.2 102.0 18.8 
Butanol 11.6 1.9 41.9 25.1 3.1 5.4 23.7 8.3 
Struthanthus marginatus 
(Desr.) G.Don 
Loranthaceae Branches Ethyl acetate 17.4 10.3 51.9 31.5 7.9 5.9 31.8 2.3 
Tephrosia apollinea (Delile) 
DC. 
Leguminosae Leaves 
Crude 44.5 17.1 41.4 23.4 18.2 3.8 46.7 10.7 
Petroleum ether 80.8 28.8 78.6 24.9 79.6 19.4 91.2 14.9 
Chloroform 96.8 31.4 99.8 23.2 69.9 6.5 100.0 30.1 
Ethyl acetate 43.8 15.6 38.6 20.3 9.7 5.9 87.9 10.4 
Water residue 94.8 41.3 91.6 0.0 83.2 12.0 66.1 38.7 
Terminalia brownii Fresen Combretaceae Seeds Ethyl acetate 103.0 52.4 88.0 12.3 5.5 1.1 97.5 92.9 
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Chloroform 98.4 80.1 61.9 27.5 12.5 4.8 78.1 17.4 
Ethyl acetate 102.1 80.5 55.2 32.2 9.1 5.9 101.6 58.2 
Terminalia laxiflora Engl. Combretaceae 
Seeds 
Chloroform 72.3 33.8 39.8 40.3 9.3 7.7 44.7 12.7 
Ethyl acetate 102.1 77.5 96.6 45.2 17.9 11.2 99.8 93.4 
Bark 
Chloroform 86.4 57.8 100.3 49.9 16.0 3.6 100.3 19.3 
Ethyl acetate 102.5 82.6 73.6 29.6 11.3 5.9 99.8 68.6 
Tinospora bakis (A.Rich.) 
Miers 
Menispermaceae Root 
Chloroform 17.7 4.2 26.3 20.0 7.0 7.4 17.3 4.6 
Methanol: 
Acetone (7:3) 
28.5 18.8 44.9 20.9 1.2 0.0 89.1 13.4 
Typha angustifolia L. Typhaceae Stem 
Crude 57.0 16.6 98.9 26.5 8.4 3.7 64.2 6.7 
Petroleum ether 27.2 7.0 104.5 43.4 51.7 6.7 23.4 5.0 
Chloroform 78.2 19.0 86.0 33.1 23.0 9.0 93.3 24.8 
Ethyl acetate 41.3 11.7 48.7 28.7 7.8 4.1 61.2 17.2 
Water residue 30.1 4.5 41.7 25.0 13.8 5.5 46.8 6.5 
Vitex cooperi Standl. Lamiaceae Barks Methanol 1.0 1.9 38.6 23.3 16.4 10.2 29.5 6.2 
Vitex polygama Cham. Lamiaceae Leaves Water residue 16.8 5.3 37.1 23.4 2.3 9.0 37.2 8.9 
Xanthium Strumarium subsp. 
brasilicum (Vell.) O.Bolòs & 
Vigo (syn. Xanthium 
brasilicum Vell.) 
Compositae Leaves 
Crude 70.5 5.4 36.6 18.4 14.9 11.5 41.3 9.3 
Petroleum ether 102.8 16.2 98.8 23.1 45.9 6.2 100.3 41.1 
Chloroform 101.1 20.0 52.1 15.1 8.4 4.0 85.8 10.2 
Ethyl acetate 94.7 14.3 58.5 0.0 35.8 5.7 62.5 8.8 
Water residue 9.4 5.6 25.5 21.5 11.7 4.5 30.3 0.0 




Chloroform 96.4 83.1 99.2 6.4 48.1 8.3 100.9 12.4 
Ethyl acetate 101.5 102.8 99.0 72.8 65.5 13.5 101.5 102.6 
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In a screening of Sudanese medicinal plants for antiprotozoal activity, the chloroform fraction 
obtained by liquid-liquid partitioning from ethanolic extracts of fruits of Croton gratissimus var. 
gratissimus and stems of Cuscuta hyalina Roth ex Schult. exhibited in vitro activity against 
axenically grown Leishmania donovani amastigotes. This antileishmanial activity was localized 
by HPLC-based activity profiling. Targeted preparative isolation afforded flavonoids 1-6, 3-
methoxy-4-hydroxybenzoic acid (7), and benzyltetrahydroisoquinoline alkaloids laudanine (8) 
and laudanosine (9) from C. gratissimus, and pinoresinol (10), isorhamnetin (11), (-)-
pseudosemiglabrin (12), and kaempferol (13) from C. hyalina.  
The antiprotozoal activity of 1-13 against Leishmania donovani (axenic and intracellular 
amastigotes), Trypanosoma brucei rhodesiense (bloodstream forms), and Plasmodium 
falciparum (erythrocytic stages), and cytotoxicity in L6 murine myoblast cells were determined 
in vitro. Quercetin-3,7-dimethylether (6) showed the highest activity against axenic L. donovani 
(IC50 4.5 µM, selectivity index (SI) 12.3), P. falciparum (IC50 7.3 µM, SI 7.6) and T. b. rhodesiense 
(IC50 2.4 µM, SI 23.2). The congener ayanin (2) exhibited moderate antileishmanial (IC50 8.2 µM, 
SI 12.2), antiplasmodial (IC50 7.8 µM, SI 12.9) and antitrypanosomal activity (IC50 11.2 µM, SI 
8.9). None of the compounds showed notable activity against the intramacrophage form of 
L. donovani.  
 
Keywords: Croton gratissimus, Cuscuta hyalina, antiprotozoal activity, HPLC-activity profiling, 
Flavonoids  
  





Parasitic protozoa are the causative agents of devastating, yet often neglected diseases. The 
kinetoplastids, a group of flagellated protozoa, cause neglected tropical diseases that put more 
than one billion people around the globe at risk [1,2]. These diseases are human African 
trypanosomiasis (HAT) caused by Trypanosoma brucei spp., Chagas' disease caused by 
Trypanosoma cruzi, and Leishmaniasis caused by Leishmania spp. [3]. The apicomplexan 
parasite Plasmodium falciparum is the causative agent of malaria tropica which claims more 
than 400,000 lives every year [4]. 
These infections are of high public health relevance and socio-economic impact. Most of the 
currently available drugs have drawbacks in terms of toxicity, limited availability of oral 
therapeutic dosage forms, development of resistance, or non-affordability. 
Natural products have in many instances provided new leads to combat neglected tropical 
diseases [5]. As part of an ongoing screening project of Sudanese medicinal plants for 
antiprotozoal activity [6,7], the chloroform extract of Croton gratissimus var. gratissimus 
(Euphorbiaceae), and Cuscuta hyalina Roth ex Schult. (Convolvulaceae) showed promising 
activity against P. falciparum and Leishmania donovani. 
The genus Croton comprises over 1300 species that are widely distributed throughout tropical 
and subtropical regions of the world. Croton species have been used traditionally in Africa, 
South Asia and Latin America for the treatment of infections and digestive disorders [8,9]. In 
Sudan, C. gratissimus, locally known as Um-Geleigla, has been used traditionally for the 
treatment of hypertension and malaria [10]. The main secondary metabolites include 
flavonoids, terpenoids and essential oil [11–13]. Previous studies have demonstrated that the 
roots of C. gratissimus possessed antiplasmodial activity in vivo [14]. Cembranolide diterpenes 
isolated from the leaves were found to be active when tested against P. falciparum [15]. 
The genus Cuscuta comprises over 200 species distributed worldwide. They are stem obligate 
holoparasitic plants possessing neither roots nor fully expanded leaves. The interaction 
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between parasite and host is established through haustoria [16]. Different Cuscuta species have 
been used in traditional Indian and Chinese medicine. Cytotoxic, antioxidant, and antimicrobial 
activities have been reported [17]. Previous phytochemical investigations of the genus Cuscuta 
identified flavonoids, lignans, alkaloids, fatty acids, and essential oil [17,18]. The 
phytochemistry and antiparasitic activity of C. hyalina has not been studied. 
In an earlier screening of Sudanese medicinal plants for antiprotozoal activity, the ethanolic 
extracts of Croton gratissimus fruits and Cuscuta hyalina stems had been found to exhibit in 
vitro antiprotozoal activity against axenic L. donovani (MHOM/ET/67/L82). Subsequent liquid 
liquid partitioning against petroleum ether, chloroform and ethyl acetate located the activity in 
the chloroform portion [6]. We here report on the targeted isolation and structure elucidation 
of compounds responsible for the activity, and on their in vitro activity against T. b. rhodesiense 
(STIB 900), axenic and intramacrophage amastigotes of L. donovani (MHOM/ET/67/L82), and P. 
falciparum (NF54).  
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3.3 Results and Discussion 
3.3.1 Extraction and HPLC-based Activity Profiling 
The methanolic extracts of Croton gratissimus var. gratissimus fruits and Cuscuta hyalina Roth 
ex Schult. stems had been previously found to exhibit antiprotozoal activity [6]. The 
antileishmanial activity displayed by the chloroform fractions of the two plants was tracked by 
HPLC-based activity profiling, a procedure combining analytical separation with on-line 
spectroscopy and time-based microfractionation for bioactivity testing [19,20]. One-minute 
microfractions were collected and tested for L. donovani growth inhibition. The HPLC‑ESIMS 
(positive base peak chromatograms) trace and the corresponding antileishmanial activity 
profiles for C. gratissimus and C. hyalina are shown in Figures 1 and 2. Major antileishmanial 
activity and a series of distinct peaks in the HPLC-ESIMS trace were observed in the time 









Figure 1. HPLC-based activity profiling of the chloroform fraction of Croton gratissimus var. gratissimus 
against axenic amastigotes of L. donovani.  The ESIMS (positive base peak chromatogram) of a 
separation of 300 μg of fraction on an analytical RP-HPLC column is shown. Activities of one-minute 
microfractions are shown with grey columns, and are expressed as percent growth inhibition compared 

















Figure 2. HPLC-based activity profiling of the chloroform fraction of Cuscuta hyalina Roth ex Schult. 
against axenic amastigotes of L. donovani. The ESIMS (positive base peak chromatogram) and activity 
profile (gray bars) are shown.  Bold numbers in the chromatogram refer to compounds 10-13. 
 
3.3.2 Compound Isolation and Structure Elucidation 
Separation of the chloroform fraction of C. gratissimus on a Sephadex LH-20 column yielded 19 
subfractions (A-S). Based on the HPLC‑PDA-ESIMS analysis, subfractions M, O, K, and C were 
found to contain peaks associated with the active time window. Further purification by 
semipreparative RP-HPLC afforded compounds 1-3 from subfraction M, 4-6 from subfraction O, 
7 from subfraction K, and 8 and 9 from subfraction C. 
By means of 1D and 2D NMR data (Tables S1-S4; Supporting Information), six flavonoids were 
identified as quercetin-3,3’,4’-trimethylether (1) [21], ayanin (2) [22], retusin (3) [22], 
naringenin (4) [23], quercetin-3,4’-dimethyl ether (5) [24], quercetin-3,7-dimethylether (6) [25], 
along with 3-methoxy-4-hydroxybenzoic acid (7) [26], and the two benzyltetrahydroisoquinoline 
alkaloids laudanine (8) [27] and laudanosine (9) [27]. For naringenin (4), an optical rotation 
close to 0 and the absence of a Cotton effect (CE) in the ECD indicated a 1:1 mixture of R- and S-
stereoisomers. The absolute configuration of 8 and 9 was determined as R based on the optical 
rotation ([α]25D -6.6 (c 0.04, MeOH) for 8 [28] and [α]
25
D -62.5 (c 0.04, MeOH) for 9 [29]. 
Moreover, the ECD spectra of both compounds showed two negative cotton effects (CEs) at 
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210-215 and 240-242 nm which were in good agreement with calculated spectra of the R-
stereoisomers (Figure S1 and S2, Supporting Information). 
Compounds 1-9 are reported here for the first time from C. gratissimus, but some have been 
previously identified in other Croton species, such as ayanin (2) and quercetin-3,7-
dimethylether (6) from C. schiedeanus [30], quercetin-3,4’-dimethylether (5) from C. arboreus 
[31], 3-methoxy-4-hydroxybenzoic acid (7) from C. tonkinensis [32], and R-laudanine (8) and R-
laudanosine (9) from leaves and stems of C. celtidifolius [33]. 
Preparative chromatography on silica gel of the chloroform fraction of C. hyalina yielded 16 
subfractions (A-P). Peaks associated with the active time window were detected in subfraction 
B. Further separation by semipreparative RP-HPLC afforded compounds 10-12. 
Based on the NMR data (Tables S5 and S6, Supporting Information), compounds were identified 
as the lignan pinoresinol (10) [34] and as flavonoids isorhamnetin (11) [35] and (-)-
pseudosemiglabrin (12) [36]. In addition, kaempferol (13) was identified by dereplication with a 
reference compound. The absolute configuration of 10 and 12 was established based on their 
optical activity and ECD spectra. For compound 10, the optical rotation [α]25D + 69.0 (c 0.10, 
MeOH) and the positive cotton effect at 207 nm (Δε +21.78) in the ECD spectrum indicated a 
(+)-(7S,7’S,8R,8’R) configuration of pinoresinol (Figure S3, Supporting Information).The optical 
rotation [α]25D -410.0 (c 0.05, MeOH) of 12 indicated (-)-pseudosemiglabrin. The ECD spectrum 
showed four negative CEs at 206 (Δε -12.84), 226 (Δε -10.40), 257 (Δε -11.01), 275 (Δε -7.99) 
nm, and a positive CE at 215 nm (Δε +3.69). This was in agreement with calculated spectra for 
the  3’’S,4”R,5’’S stereoisomer (Figure S4, Supporting Information), and opposite to the ECD 
data published for (+)-pseudosemiglabrin [37]. However, the assignment of C-5’’ as S by Pirrung 
and Lee was incorrect. The absolute configuration of (-)-pseudosemiglabrin (12) was thus 
assigned as 3’’S,4”R,5’’S. 
Kaempferol (13) and isorhamnetin (11) have been previously reported from different Cuscuta 
species [17], while pinoresinol has been identified in C. chinensis [38]. To the best of our 
knowledge, this is the first report on isolation of pseudosemiglabrin (12) from Cuscuta species. 
 





















Figure 3. Chemical structures of compounds 1-13 
 
3.3.3 Activity against Leishmania donovani Axenic and Intracellular Amastigotes  
All compounds were tested for their activity against L. donovani (MHOM/ET/67/L82) axenic 
amastigotes (Table 1). Quercetin-3,7-dimethylether (6) has shown the highest activity (IC50 
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4.5 µM), followed by ayanin (2) (IC50 8.2 µM). Both compounds exhibited similar selectivity 
indices (SI 12.3), which were the highest among the tested compounds. 
Compounds 1 and 5 from C. gratissimus, and 11-13 from C. hyalina exhibited IC50 values in the 
range of 15-22 µM against axenic amastigotes. These compounds showed varying degrees of 
cytotoxicity in L6 rat skeletal cells. Moderate selectivity (selectivity indices (SI) of 4 – 6) towards 
L. donovani axenic amastigotes was observed for compounds 11-13, while quercetin-3,4’-
dimethylether (5) showed the highest toxicity (SI 1.3).   
The benzyltetrahydroisoquinoline alkaloids laudanine (8) and laudanosine (9), and the 
furofurano lignan pinoresinol (10) showed only marginal activity against L. donovani axenic 
amastigotes (IC50 ˃ 150 µM). The weak activity of the alkaloids was in agreement with previous 
reports [39]. 
After a first testing against axenic amastigotes, compounds were tested against L. donovani 
amastigotes in mouse macrophages. However, in this more elaborate and more physiological 
model none of the compounds showed activity (Table 1).  In general, IC50 values for the 
intramacrophage form are higher than those for the axenic amastigotes [40]. This loss of 
activity in the intracellular model could be due to poor cellular permeability of the compounds, 
binding to cytosolic proteins in the host cell, or metabolism in the host cell phagolysosome [40–
42]. 
3.3.4 Activity against Trypanosoma brucei rhodesiense 
All compounds were also tested for their in vitro activity against the blood stream form of T. 
brucei rhodesiense (STIB 900) (Table 1). As for L. donovani, quercetin-3,7-dimethylether (6) was 
the most active (IC50 2.4 µM) and most selective (SI 23.2). Quercetin-3,4’-dimethyl ether (5) was 
also active (IC50 6.6 µM) but had a low selectivity (SI 2.9). Ayanin (2) had an IC50 of 11.2 µM with 
moderate cytotoxicity (SI 8.9), and isorhamnetin (11) an IC50 of 25.9 µM and a SI of 5.0. 
Kaempferol (13), pseudosemiglabrin (12) and 3-methoxy-4-hydroxybenzoic acid (7) showed 
marginal activity (IC50 36-39 µM), and IC50 ˃ 80 µM were determined for retusin (3), naringenin 
(4), laudanine (8), laudanosine (9) and pinoresinol (10).  
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3.3.5 Activity against Plasmodium falciparum 
 In vitro activity against the erythrocytic stages of the P. falciparum drug sensitive strain NF54 
was determined for all compounds (Table 1). Ayanin (2) and quercetin-3,7-dimethylether (6) 
showed IC50 values of 7 to 8 µM, but 2 exhibited a higher selectivity index (SI 12.9) than 6 (SI 
7.6). Quercetin-3,4’-dimethylether (5) was also rather active (IC50 ˂20 µM) but equally showed 
cytotoxic in L6 cells. Isorhamnetin (11) and pseudosemiglabrin (12) showed IC50’s around 20 µM 
against P. falciparum and a moderate degree of selectivity towards the parasite (SI ~ 5). 3-
Methoxy-4-hydroxybenzoic acid (7), and pinoresinol (10) were the least active among the 
tested compounds.  
3.3.6 Correlation between Chemical Structure of Isolated Flavonoids and Antiprotozoal 
Activity 
Of the isolated compounds, only flavones showed notable activity (Table 1). From a comparison 
of flavones 1-3, 5, 6, 10 and 13 the following conclusions can be drawn: Compounds with a 
hydroxyl group at C-3’ (2, 5, and 6) were the most active against the three parasites, whereby a 
catechol moiety as in 6 further increased the activity. Free hydroxyl groups at C-3 or C-7 (as in 5, 
11 and 13) had not resulted in significant in vitro activity. Compounds 2 and 6 exhibited the 
highest selectivity, while 5 showed significant cytotoxicity in L6 cells leading to a low SI.   
Naringenin (4) displayed the weakest antiparasitic activity among the tested flavonoids. The 
presence of a double bond between C-2 and C-3 has been previously found to be essential for 
antiparasitic activity [41]. Overall, our results were in agreement with previous structure-
activity studies of flavonoids [43]. 
The influence of a balance between antioxidant and prooxidant properties of flavonoids on 
antiparasitic activity, and a correlation with their chemical structure has been investigated with 
the aid of QSAR models [44]. Compounds that displayed moderate to higher antitrypanosomal 
activity shared structural features, such as Δ2,3 unsaturation, presence of a hydroxyl group at C-
3, a carbonyl group at C-4, and a catechol moiety in ring B. Our results were in line with these 
findings. To the best of our knowledge, the antitrypanosomal activities of quercetin-3,7-
dimethylether (6) and ayanin (2) are here reported for the first time. 
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Table 1: In vitro activity of compounds 1−13 against T. b. rhodesiense (STIB 900), L. donovani (MHOM-
ET-67/L82) axenic and intracellular amastigotes, P. falciparum (NF54), and cytotoxicity in L6 cells. 
a 
The IC50s are mean values from at least two independent replicates (the variation is a maximum of 20%). 
b 










  IC50 
a  (µM)    






  Axenic 
Intramacro
phage 
   
1 Quercetin-3,3’,4’-trimethylether 18.8 (9.8) b ˃79.9 55.1 (3.4) b 42.1 (4.4) b 186.3 
2 Ayanin 8.2 (12.3) b ˃95.9 11.2 (8.9) b 7.8 (12.9) b 100.9 
3 Retusin 34.1 (6.3) b ˃185.8 83.8 (2.6) b 23.4 (9.2) b 215.1 
4 Naringenin 41.8 (5.6) b ˃121.3 184.2 (1.3) b 73.2 (3.2) b 233.3 
5 Quercetin-3,4’-dimethylether 15.2 (1.3) b ˃33.3 6.6 (2.9) b 18.2 (1.1) b 19.2 
6 Quercetin-3,7-dimethylether 4.5 (12.3) b ˃66.7 2.4 (23.2) b 7.3 (7.6) b 55.4 
7 3-Methoxy-4-hydroxybenzoic acid 153.3 (3.9) b ˃595.2 38.6 (15.4) b 138.4 (4.3) b 595.2 
8 Laudanine 193.3 (1.5) b ˃291.5 143.1 (2.0) b 78.6 (3.7) b 291.5 
9 Laudanosine 185.4 (1.5) b ˃186.3 101.5 (2.8) b 76.1 (3.7) b 280.1 
10 Pinoresinol 151.4 (1.6) b ˃279.3 116.8 (2.1) b ˃139.7 241.9 
11 Isorhamnetin 21.7 (6.0) b ˃210.4 25.9 (5.0) b 21.6 (6.0) b 130.2 
12 Pseudosemiglabrin 18.9 (4.1) b ˃84.2 37.5 (2.1) b 16.3 (4.8) b 78.1 
13 Kaempferol 20.8 (5.3) b ˃115.4 36.4 (3.1) b 53.1 (2.1) b 111.4 
 Positive control 0.5 c 6.6 c 0.01 d 0.01 e 0.03 f 
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3.4 Materials and Methods 
 
General experimental procedures 
HPLC-grade methanol and acetonitrile from Macron Fine Chemicals (Avantor Performance 
Materials), and water from a Milli-Q water purification systems (Merck Millipore) were used for 
HPLC separations. For fractionation and preparative separation, technical grade solvents from 
Scharlau (Scharlab S. L.) were used after distillation. Silica gel 60 F254 coated aluminum TLC 
plates were obtained from Merck. Silica gel (230-400 µm, Merck) and Sephadex LH-20 (25-100 
µm, Sigma-Aldrich) were used for open column chromatography. Optical rotation was 
measured in methanol using a JASCO P-2000 digital polarimeter equipped with a sodium lamp 
(589 nm) and a temperature-controlled microcell (10 cm). UV and ECD spectra were recorded in 
methanol on a Chirascan CD spectrometer (Applied Photophysics) using 110 QS 1 mm path 
precision cells (Hellma Analytics). NMR spectra were recorded on a Bruker Avance III NMR 
spectrometer operating at 500.13 MHz for 1H and 125.77 MHz for 13C. 1H NMR, COSY, HSQC, 
HMBC, and NOESY spectra were measured at 23 °C in a 1 mm TXI probe with a z-gradient, using 
standard Bruker pulse sequences. Spectra were analyzed by Bruker TopSpin 3.5 pl 7 and 
ACDLabs Spectrus Processor. NMR spectra were recorded in DMSO-d6 (99.9 atom % D; Armar 
Chemicals). 
 
HPLC-PDA-ELSD-ESIMS data were recorded in positive- and negative-ion mode (scan range of 
m/z 200−1500) on a Shimadzu LC-MS/MS 8030 triple quadrupole MS system, connected via a T-
splitter (1:10) to a Shimadzu HPLC system consisting of degasser, binary mixing pump, 
autosampler, column oven, and a diode array detector and to an Alltech 3300 ELSD detector. 
Separation was achieved on  a SunFire C18 (3.5 μm, 150 × 3.0 mm i.d.) column equipped with a 
guard column (10 mm × 3.0 mm i.d.) (Waters). Data acquisition and processing were performed 
with LabSolution software.  
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Microfractionation was carried out with the same HPLC instrument connected via a T split to an 
FC204 fraction collector (Gilson) with only UV detection, using a SunFire C18 (3.5 μm, 150 × 3.0 
mm i.d.) column equipped with a guard column (10 mm × 3.0 mm i.d.) (Waters). 
 
Semipreparative HPLC separations were carried out with an Agilent HP 1100 Series system 
consisting of a quaternary pump, autosampler, column oven, and a diode array detector. 
SunFire C18 (5 μm, 10 × 150 mm i.d.) columns (Waters) were used for separations. Chemstation 
software was used for data acquisition and processing. Preparative separations were carried 
out on a Puriflash 4100 system (Interchim) or a Reveleris PREP purification system (Büchi). 
Sephadex LH-20 (110 × 3 cm; 25-100 µm) and silica gel (40 × 5 cm, 230−400 mesh) columns 
were used. 
All handling of infectious agents (L. donovani, T. b. rhodesiense, P. falciparum) was performed 
under strict biosafety level 2 conditions under notification A000275 to the Swiss Federal Office 
of Public Health. 
 
Plant Material 
Croton gratissimus var. gratissimus fruits and Cuscuta hyalina Roth ex Schult. stems were 
obtained from the Herbarium of the Faculty of Pharmacy, University of Science and Technology, 
Omdurman, Sudan. The taxonomic identity was confirmed by the Medicinal and Aromatic 
Plants Research Institute, Sudan and voucher specimens (CZFCHL02 and ChSCHL 02) were 
deposited. Plant materials were dried at room temperature and milled before extraction. 
 
Extraction 
Powdered materials of C. gratissimus fruits and C. hyalina stems (500 g each), respectively, 
were extracted with 1 Litre of 70% ethanol and kept in a magnet rod shaker for 24 h. The 
extraction procedure was repeated three times for each herbal drug. Extracts were filtered and 
dried under reduced pressure. For each plant, the ethanolic extract was suspended in water 
and partitioned successively with petroleum ether, chloroform, and ethyl acetate. Three 
repetitive partitioning procedures, each with 500 mL of either solvent were performed.  This 
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HPLC-based microfractionation of the chloroform extracts of C. gratissimus fruits and C. hyalina 
stems was performed [H2O + 0.1% formic acid (A), MeCN + 0.1% formic acid (B); 0→100% B (0-
30 min), 100% B (30-40 min); flow rate 0.4 mL/min; sample concentration 10 mg/mL in DMSO; 
injection volume twice 35 μL] by collecting one-minute fractions from minute 1 to minute 40 
into a 96-deepwell plate. After drying of plates in a Genevac EZ-2 evaporator, microfractions 




The chloroform fraction (3.5 g) of C. gratissimus fruits was fractionated by column 
chromatography (CC) on Sephadex LH-20 (110 × 3 cm; 25-100 µm) using methanol as eluent at 
a flow rate of 1mL/min. A total of 19 fractions (A-S) were combined based on TLC patterns 
(silica gel; CH2CL2−MeOH, 90:10, 75:25, and 50:50, respectively; detection with 1% ethanolic 
vanillin and 10% sulfuric acid, followed by heating at 105 oC). Fractions were submitted to 
HPLC-PDA-ELSD-MS analysis to track peaks previously detected in the active time windows of 
the activity profile. 
Fraction M (36 mg) was submitted to semipreparative RP-HPLC [H2O (A), CH3CN (B); 43% B 
(0−22 min), 43→100% B (22−27 min), 100% B (27−30 min), flow rate 4 mL/min; sample 
concentration 50 mg/mL in DMSO; injection volume 50 μL], yielding quercetin-3,3’,4’-
trimethylether (1, 0.3 mg, tR 10.2 min), ayanin (2, 21.9 mg, tR 16.7 min), and retusin (3, 0.4 mg, 
tR 28.8 min). 
Fraction O (15 mg) was submitted to semipreparative RP-HPLC [H2O (A), CH3CN (B); 35% B 
(0−34 min), 35→100% B (34−40 min), 100% B (40−45 min) , flow rate 4 mL/min; sample 
concentration 50 mg/mL in DMSO; injection volume 50 μL], to afford naringenin (4, 0.51 mg, tR 
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9.6 min), quercetin-3,4’-dimethylether (5, 1.9 mg, tR 12.1 min), and quercetin-3,7-dimethylether 
(6, 7.1 mg, tR 20.5 min). 
Fraction K (26.6 mg) was purified by semipreparative RP-HPLC [H2O (A), CH3CN (B), both 
containing 0.1% formic acid; 10→32% B (0−30 min), 32→100% B (30−35 min), 100% B (35−40 
min), flow rate 4 mL/min; sample concentration 50 mg/mL in DMSO; injection volume 50 μL], to 
afford 3-methoxy-4-hydroxybenzoic acid (7, 0.63 mg, tR 10.9 min). 
Fraction C (100.6 mg) was purified by semipreparative RP-HPLC [H2O (A), CH3CN (B), both 
containing 0.1% formic acid; 10→17% B (0−20 min), 17→100% B (20−25 min), 100% B (25−30 
min), flow rate 4 mL/min; sample concentration 50 mg/mL in DMSO; injection volume 50 μL], to 
afford laudanine (8, 0.41 mg, tR 9.1 min), and laudanosine (9, 0.63 mg, tR 14.5 min). 
 
The chloroform fraction (1.9 g) of C. hyalina stems was fractionated by CC on silica gel (40 × 5 
cm, 230−400 mesh), using a gradient of CH2CL2−MeOH (99:1 to 0:100) as mobile phase. A total 
of 16 fractions (A-P) were combined based on TLC patterns (silica gel; CH2CL2−MeOH, 99:1, 
90:10, and 80:20, respectively; detection with 1% ethanolic vanillin and 10% sulfuric acid, 
followed by heating). Fractions were submitted to HPLC-PDA-ELSD-MS analyses to track peaks 
previously detected in the active time windows of the activity profile.  
Fraction B (52.7 mg) was purified by semipreparative RP-HPLC [H2O (A), CH3CN (B); 25→70% B 
(0−30 min), 70→100% B (30−33 min), 100% B (33−40 min) , flow rate 4 mL/min; sample 
concentration 50 mg/mL in DMSO; injection volume 50 μL], to afford pinoresinol (10, 7.8 mg, tR 
10.2 min), isorhamnetin (11, 3.5 mg, tR 13.6 min), pseudosemiglabrin (12, 2.2 mg, tR 23.5 min). 
Kaempferol (13) was identified by co-injection of a reference standard (Sigma-Aldrich). 
 
Quercetin-3,3’,4’-trimethylether (1): amorphous solid; 1H and 13C NMR, see Table S1, 
Supporting Information; ESIMS m/z 345 [M + H]+. 
Ayanin (2): amorphous solid; 1H and 13C NMR, see Table S1, Supporting Information; ESIMS m/z 
345 [M + H]+. 
Retusin (3): amorphous solid; 1H and 13C NMR, see Table S1, Supporting Information; ESIMS m/z 
359 [M + H]+. 
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Naringenin (4): amorphous solid; 1H and 13C NMR, see Table S2, Supporting Information; ESIMS 
m/z 273 [M + H]+. 
Quercetin-3,4’-dimethylether (5): amorphous solid; 1H and 13C NMR, see Table S2, Supporting 
Information; ESIMS m/z 331 [M + H]+. 
Quercetin-3,7-dimethylether (6): amorphous solid; 1H and 13C NMR, see Table S2, Supporting 
Information; ESIMS m/z 331 [M + H]+. 
3-Methoxy-4-hydroxybenzoic acid (7): amorphous solid; 1H and 13C NMR, see Table S3, 
Supporting Information; ESIMS m/z 169 [M + H]+. 
R-Laudanine (8): amorphous solid; [α]25D -6.6 (c 0.04, MeOH); UV λmax (MeOH) (log ε) 226 (0.07), 
291 (0.01) nm; ECD (MeOH, c 3.5 x 10-4 M, 1 mm path length) λmax(Δε) 214 (-0.56), 241 (-0.47), 
290 (-0.39); 1H and 13C NMR, see Table S4, Supporting Information; ESIMS m/z 344 [M + H]+. 
R-Laudanosine (9): amorphous solid; [α]25D -62.5 (c 0.04, MeOH); UV λmax (MeOH) (log ε) 201 
(0.75), 226 (0.18), 279 (0.06) nm; ECD (MeOH, c 1.4 x 10-4 M, 1 mm path length) λmax(Δε) 211 (-
19.43), 241 (-6.67), 290 (-3.38); 1H and 13C NMR, see Table S4, Supporting Information; ESIMS 
m/z 358 [M + H]+. 
(+)-(7S,7’S,8R,8’R)-Pinoresinol (10): amorphous solid; [α]25D 69.0 (c 0.10, MeOH); UV λmax 
(MeOH) (log ε) 202 (0.70), 232 (0.10) nm; ECD (MeOH, c 7.0 x 10-5 M, 1 mm path length) 
λmax(Δε) 207 (+21.78) nm; 
1H and 13C NMR, see Table S5, Supporting Information; ESIMS m/z 
359 [M + H]+. 
Isorhamnetin (11): amorphous solid; 1H and 13C NMR, see Table S5, Supporting Information; 
ESIMS m/z 317 [M + H]+. 
(-)-(3’’S,4”R,5’’S)-Pseudosemiglabrin (12): amorphous solid; [α]25D  -410.0 (c 0.05, MeOH); UV 
λmax (MeOH) (log ε) 212 (0.73), 255 (0.49), 309 (0.43) nm; ECD (MeOH, c 2.6 x 10
-4 M, 1 mm 
path length) λmax(Δε) 206 (-12.84), 215 (+3.69), 226 (-10.40), 257 (-11.01), 275 (-7.99) nm; 
1H 
and 13C NMR, see Table S6, Supporting Information; ESIMS m/z 393 [M + H]+. 
Kaempferol (13): identified by co-injection of a reference standard (Sigma-Aldrich). 
Sample preparation 
Compounds were dissolved in DMSO (10 mg/mL) and warmed up to 40°C and/or sonicated if 
necessary. These DMSO stocks were kept at -
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in medium was prepared. This was used to prepare the serial dilutions directly in the 96-well 
assay plates. Since DMSO is cytotoxic, the maximum DMSO concentration in the test was 1%. 
Activity against Leishmania donovani axenic amastigotes 
Amastigotes of L. donovani strain MHOM/ET/67/L82 were grown under an atmosphere of 5% 
CO2 in air in axenic culture at 37 °C in SM medium [45] at pH 5.4 supplemented with 10% heat-
inactivated fetal bovine serum. 50 µL of culture medium was added in the wells of a 96-well 
plate and serial drug dilutions of eleven 3-fold dilution steps covering a final range from 100 to 
0.002 μg/mL were prepared. 50 µL culture medium with 2x105 amastigotes from axenic culture 
were added to each well. After 70 h of incubation the plates were inspected under an inverted 
microscope to assure growth of the controls and sterile conditions. 10 μL of resazurin (12.5 mg 
resazurin dissolved in 100 mL distilled water) were added to each well and the plates incubated 
for another 2 h. Then the plates were read with a Spectramax Gemini XS microplate 
fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA) using an excitation 
wavelength of 536 nm and an emission wavelength of 588 nm. Data were analyzed using the 
software Softmax Pro (Molecular Devices Cooperation, Sunnyvale, CA, USA). Decrease of 
fluorescence (= inhibition) was expressed as percentage of the fluorescence of untreated 
control cultures and plotted against the drug concentrations. From the sigmoidal inhibition 
curves the IC50 values were calculated. Miltefosine was used as positive control drug. Assays 
were performed in two independent replicates at least. 
Activity against Leishmania donovani intramacrophage amastigotes  
Mouse peritoneal macrophages (4 x 104 in 100 µL RPMI 1640 medium with 10% heat-
inactivated FBS) were seeded into wells of a 96-well plate. After 24 h, 2 x 105 amastigote 
Leishmania donovani in 100 µL were added. The amastigotes were taken from an axenic 
amastigote culture grown at pH 5.4. The medium containing free amastigote forms was 
removed after 24 h and replaced by fresh medium. The washing step was repeated and 
afterwards the serial drug dilution was prepared with at least 6 dilution steps. Compounds were 
dissolved in DMSO at 10 mg/mL and further diluted in medium. After 96 hours of incubation at 
37 °C under a 5 % CO2 atmosphere, the medium was removed and cells were fixed by adding 
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50µL 4% formaldehyde solution followed by a staining with a 5 µM DRAQ5 solution. Plates were 
imaged in ImageXpress XLS (MD) microscope using a 20x air objective (635 nm excitation: 
690/50 emission). 9 images were collected per well. Automated image analysis was performed 
with a script developed on Meta Xpress Software (MD). Three outputs were provided for each 
well: i) number of host cell nuclei; ii) numbers of infected and non-infected host cells; iii) 
number of parasite nuclei per infected host cell. The IC50 values were calculated based on the 
infection rate and the numbers of intracellular amastigotes. The cytotoxicity to macrophages 
was determined in parallel, and IC50 values were calculated based on the numbers of surviving, 
uninfected macrophages. Miltefosine was used as control. Assays were performed in two 
independent replicates at least. 
Activity against Trypanosoma brucei rhodesiense STIB900  
The stock was originally isolated from a Tanzanian patient and adapted to axenic culture 
conditions after several mouse passages and cloned. Minimum Essential Medium (50 µL) 
supplemented with 25 mM HEPES, 1g/L additional glucose, 1% MEM non-essential amino acids 
(100x), 0.2 mM 2-mercaptoethanol, 1mM Na-pyruvate [46] and 15% heat inactivated horse 
serum was added to each well of a 96-well microtiter plate. Serial drug dilutions of eleven 3-
fold dilution steps covering a range from 100 to 0.002 μg/mL were prepared. Then 4x103 
bloodstream forms of T. b. rhodesiense STIB 900 in 50 µL were added to each well and the plate 
incubated for 70 h at 37 °C and under a 5% CO2 atmosphere. 10 µL resazurin solution 
(resazurin, 12.5 mg in 100 mL double-distilled water) was then added to each well and 
incubation continued for a further 2–4 h [47]. Plates were read with a Spectramax Gemini XS 
microplate fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA) using an 
excitation wave length of 536 nm and an emission wave length of 588 nm. Softmax Pro 
programme (Molecular Devices Cooperation, Sunnyvale, CA, USA) was used for data analyses 
and IC50 values were calculated by linear regression [48], and 4-parameter logistic regression 
from the sigmoidal dose inhibition curves. Melarsoprol (Arsobal Sanofi-Aventis, received from 
WHO) was used as control. Assays were performed in two independent replicates at least. 
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Activity against Plasmodium falciparum 
In vitro activity against the erythrocytic stages of P. falciparum was determined using a 3H-
hypoxanthine incorporation assay [49], using the drug sensitive NF54 strain [50]. Compounds 
were dissolved in DMSO at 10 mg/mL and further diluted in medium before addition to parasite 
cultures incubated in RPMI 1640 medium without hypoxanthine, supplemented with HEPES 
(5.94 g/L), NaHCO3 (2.1 g/L), neomycin (100 U/mL), Albumax
R (5 g/L) and washed human red 
cells A+ at 2.5% haematocrit (0.3% parasitaemia). Serial drug dilutions of eleven 3-fold dilution 
steps covering a range from 100 to 0.002 μg/mL were prepared. The 96-well plates were 
incubated in a humidified atmosphere at 37 °C; 4% CO2, 3% O2, 93% N2. After 48 h 50 μL of 
3H-
hypoxanthine (=0.5 μCi) was added to each well of the plate. The plates were incubated for a 
further 24 h under the same conditions. The plates were then harvested with a Betaplate™ cell 
harvester (Wallac, Zurich, Switzerland), and the red blood cells transferred onto a glass fibre 
filter, and lysed with distilled water. The dried filters were inserted into a plastic foil with 10 mL 
of scintillation fluid and counted in a Betaplate™ liquid scintillation counter (Wallac, Zurich, 
Switzerland). IC50 values were calculated from sigmoidal inhibition curves by linear regression 
using Microsoft Excel. Chloroquine (Sigma C6628) was used as control. Assays were performed 
in two independent replicates at least. 
In vitro cytotoxicity with L-6 cells 
Assays were performed in 96-well microtiter plates, each well containing 100 L of RPMI 1640 
medium supplemented with 1% L-glutamine (200mM) and 10% fetal bovine serum, and 4000 L-
6 cells (a primary cell line derived from rat skeletal myoblasts) [51]. Serial drug dilutions of 
eleven 3-fold dilution steps covering a range from 100 to 0.002 μg/mL were prepared 24 h post 
seeding L-6 cells. The plates were incubated for 70 h and inspected under an inverted 
microscope to assure growth of the controls and sterile conditions. 10 L of resazurin was then 
added to each well and the plates incubated for another 2 hours. Then the plates were read 
with a Spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation, 
Sunnyvale, CA, USA) using an excitation wavelength of 536 nm and an emission wavelength of 
588 nm. The IC50 values were calculated by linear regression and 4-parameter logistic 
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regression from the sigmoidal dose inhibition curves using SoftmaxPro software (Molecular 
Devices Cooperation, Sunnyvale, CA, USA). Podophyllotoxin (Sigma P4405) was used as positive 
control. All assays were performed in two independent replicates at least. 
Activities of all compounds were expressed in µM using the formula: 
 Activity (µM) = Activity (µg/mL)*1000 / Molecular weight. 
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Table S 1. 1H and 13C NMR Spectroscopic Data for Compounds 1-3 (DMSO-d6; 500.13 Hz for 1H and 125.77 for 13C NMR; δ in ppm)  
  1  2  3 
Position  δC
a
 δH (mult J in Hz)  δC
a
 δH (mult J in Hz)  δC
a
 δH (mult J in Hz) 
2  C
b
   155.2, C   155.4, C  
3  137.4, C   137.9, C   138.3, C  
4  C
b
   177.8, C   C
b
  
5  160.9, C   160.8, C   161.0, C  
6  101.4, CH 5.73, d (1.5)  97.2, CH 6.20, br s  97.8, CH 6.36, br s 
7  C
b
   164.8, C   165.2, C  
8  95.3, CH 5.91, d (1.2)  91.7, CH 6.47, br s  92.4, CH 6.74, br s 
9  157.2, C   155.9, C   156.3, C  
10  100.4, C   105.0, C   105.3, C  
1'  123.1, C   122.2, C   C
b
  
2'  111.4, CH 7.57
 c
  115.0, CH 7.57, br s  111.6, CH 7.66, br s 
3'  148.4, C   146.2, C   148.6, C  
4'  150.6, C   150.1, C   151.4, C  
5'  111.8, CH 7.11, d (8.2)  111.5, CH 7.01, d (8.2)  111.8, CH 7.16, d (8.5) 




C NMR data extracted from HSQC and HMBC spectra, 
b 
Signal not visible in HMBC, 
c
 Overlapping signals.  
6'  121.3, CH 7.58
 c
  120.1, CH 7.49, br d (8.2)  122.1, CH 7.71, d (8.5) 
3-OMe  59.7, CH3 3.77, s  59.3, CH3 3.81, s  59.8, CH3 3.83, s 
7-OMe     55.5, CH3 3.80, s  55.8, CH3 3.87, s
 c
 
3'-OMe  55.7, CH3 3.83, s     55.8, CH3 3.86, s 
4'-OMe  55.6, CH3 3.84, s  55.4, CH3 3.88, s  55.9, CH3 3.87, s
 c
 
Chapter 3: HPLC-Based Activity Profiling for Antiprotozoal Compounds in Croton gratissimus and Cuscuta hyalina  
98 
 
Table S 2. 1H and 13C NMR Spectroscopic Data for Compounds 4, 5 and 6 (DMSO-d6; 500.13 Hz for 1H and 125.77 for 13C NMR; δ in 
ppm)  
  4 5 6 
Position  δC
a
 δH (mult J in Hz)  δC
a
 δH (mult J in Hz)  δC
a
 δH (mult J in Hz) 
2  77.8, CH 5.29, dd (12.2, 3.1)  154.5, C   155.9, C  
3  42.0, CH2 
3.03, dd (16.9, 12.4) 
2.56, dd (17.1, 3.1) 
 137.7, C   137.9, C  
4  192.8, C   177.4, C   178.0, C  
5  162.4, C   161.0, C   161.0, C  
6  96.8, CH 5.59, d (1.5)  99.0, CH 6.14, d (1.8)  97.5, CH 6.22, s 
7  174.1, C   166.4, C   165.0, C  
8  97.4, CH 5.57, d (1.5)  93.7, CH 6.34, d (1.5)  92.0, CH 6.50, br s 
9  163.7, C   156.3, C   156.1, C  
10  99.3, C   103.2, C   105.1, C  
1'  129.5, C   122.3, C   C
b
  
2'  128.0, CH 7.27, d (8.5)  114.8, CH 7.52, d (2.1)  115.6, CH 7.58, br s 
3'  115.1, CH 6.78, d (8.5)  146.2, C   145.3, C  




C NMR data extracted from HSQC and HMBC spectra, 
b 
Signal not visible in HMBC.
 
4'  157.6, C   149.9, C   148.8, C  
5'  115.1, CH 6.78, d (8.5)  111.8, CH 7.05, d (8.5)  115.7, CH 6.92, br s 
6'  128.0, CH 7.27, d (8.5)  119.9, CH 7.51, dd (8.2, 2.1)  120.6, CH 7.43, br d (7.9) 
3-OMe     59.4, CH3 3.78, s  59.5, CH3 3.79, m 
7-OMe        55.8, CH3 3.79, s 
4'-OMe     55.4, CH3 3.85, s    
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 broad signal due to concentrated sample.
 
  
                            7   
Position   δC
a
 δH (mult J in Hz)    
2   113.1, CH 7.46 b    
3   147.0, C     
5   114.7, CH 6.84, br s    
6   123.1, CH 7.43 b    
3-OMe   55.5, CH3 3.79, s    
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Table S 4. 1H and 13C NMR Spectroscopic Data for Compound 8 and 9 (DMSO-d6; 500.13 Hz for 1H and 125.77 for 13C NMR; δ in ppm)  
   8  9 
Position   δC
a
 δH (mult J in Hz)  δC
a
 δH (mult J in Hz) 
1   63.8, CH 3.61, dd (5.8, 5.8)  63.9, CH 3.66
 b
 
1a   39.6, CH2 




 39.8, CH2 
2.98, dd (13.9, 6.0) 
2.78, dd (13.9, 6.3) 
3   46.5, CH2 
3.04, ddd (12.7, 8.0, 5.2) 
2.56, m 
 46.8, CH2 
3.05, ddd (12.4, 7.8, 4.9) 
2.59 ddd (12.2, 4.6, 4.6) 





 25.0, CH2 
2.68, m 
2.46, m 
4a   126.1, C   126.4, C  
5   111.7, CH 6.59, s  112.0, CH 6.60, s 
6   146.8, C   147.1, C  
7   146.1, C   146.5, C  
8   111.5, CH 6.32, s  111.7, CH 6.35, s 
8a   129.5, C   129.4, C  
1'   132.9, C   132.6, C  





















C NMR data extracted from HSQC and HMBC spectra, 
b 
Overlapping signals.
2'   114.0, CH 6.62
 b
  114.0, CH 6.69, br s 
3'   144.5, C   148.4, C  
4'   146.8, C   147.1, C  
5'   114.7, CH 6.63
 b
  111.9, CH 6.79, d (8.2) 
6'   121.8, CH 6.51, dd (8.2, 1.2)  121.8, CH 6.64, d (7.6) 
2-NMe   42.1, CH3 2.37, s  42.4, CH3 2.38, s 
6-OMe   55.3, CH3 3.68, s  55.6, CH3 3.69, s 
7-OMe   55.1, CH3 3.53, s  55.4, CH3 3.54
 b
 
3'-OMe      55.5, CH3 3.65, s
 b
 
4'-OMe   55.4, CH3 3.65, s  55.7, CH3 3.70, s 
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Table S 5. 1H and 13C NMR Spectroscopic Data for Compound 10 and 11 (DMSO-d6; 500.13 Hz for 1H and 125.77 for 13C NMR; δ in 
ppm)  
  10  11 
Position  δC
a
 δH (mult J in Hz)  δC
a
 δH (mult J in Hz) 
1  132.3, C     
2  110.6, CH 6.92, br s  146.1, C  
3  147.6, C     
4  146.0, C   175.5, C  
5  115.3, CH 6.77
 b
  160.4, C  
6  118.6, CH 6.77
 b
  98.0, CH 6.20, d (1.2) 
7  85.2, CH 4.64, d (4.3)  164.0, C  
8  53.6, CH 3.05, m  93.2, CH 6.46, d (1.2) 
9  70.9, CH2 
4.15, dd (8.90, 6.7) 
3.76, dd (9.00, 3.5) 
 155.8, C  
10     102.5, C  
1'  132.3, C   121.7, C  
2'  110.6, CH 6.92, br s  111.7, CH 7.77, br s 
3'  147.6, C   147.1, C  









4'  146.0, C   148.5, C  
5'  115.3, CH 6.77
 b
  115.2, CH 6.95, d (8.5) 
6'  118.6, CH 6.77
 b
  121.3, CH 7.69, br d (7.6) 
7'  85.2, CH 4.64, d (4.3)    
8'  53.6, CH 3.05, m    
9'  70.9, CH2 
4.15, dd (8.90, 6.7) 
3.76, dd (9.00, 3.5) 
   
3-OMe  55.7, CH3 3.78, s    
3'-OMe  55.7, CH3 3.78, s  55.5, CH3 3.85, s 
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Table S 6. 1H and 13C NMR Spectroscopic Data for Compound 12 (DMSO-d6; 500.13 Hz for 1H and 125.77 for 13C NMR; δ in ppm)  
   12 
Position   δC
a
 δH (mult J in Hz) 
2   162.2, C  
3   107.2, CH 6.92, s 
4   176.6, C  
5   128.0, CH 7.97, d (8.5) 
6   108.9, CH 7.00, d (8.5) 
7   153.7, C  
8   112.6, C  
9   164.3, C  
10   118.2, C  
1'   131.3, C  
2'   126.6, CH 7.99
 b
 
3'   129.4, CH 7.55, m 
4'   132.2, CH 7.59, m 



























5'   129.4, CH 7.55, m 
6'   126.6, CH 7.99
 b
 
2''   85.0, C  
3''   76.7, CH 5.56, d (8.9) 
4''   47.8, CH 4.85, dd (8.7, 6.6) 
5''   112.5, CH 6.53, d (6.4) 
7''   27.5, CH3 1.33, s 
8''   23.3, CH3 1.05, s 
9''   169.4, C  




Figure S 1. Comparison of experimental and calculated UV (A) and ECD (B) spectra for 
compound 8 in MeOH (0.12 mg/mL). 




Figure S 2. Comparison of experimental and calculated UV (A) and ECD (B) spectra for 
compound 9 in MeOH (0.05mg/mL). 




 Figure S 3. Experimental UV (A) and ECD (B) spectra for compound 10 in MeOH (0.025 mg/mL).  




 Figure S 4. Comparison of experimental and calculated UV (A) and ECD (B) spectra for 
compound 12 in MeOH ( 0.1mg/mL). 
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Computational Methods for ECD calculation.  
Conformational analysis of compounds 8, 9 and 12 was performed with MacroModel 9.8 
software (Schrödinger LLC) employing the OPLS 2005 (Optimized Potential for Liquid 
Simulations) force field in H2O. The five conformers with the lowest energy were submitted to 
geometrical optimization and energy calculation using Density Function Theory (DFT) with 
Becke’s nonlocal three-parameter exchange and correlation functional and the Lee-Yang-Parr 
correlation functional level (B3LYP) using the B3LYP/6-31+G(d,p) basis set in MeOH with the 
Gaussian 09 program package [1]. Vibrational evaluation was done at the same level to confirm 
minima. Excitation energy (denoted by wavelength in nm), rotator strength (Rstr), dipole 
velocity (Rvel), and dipole length (Rlen) were calculated in MeOH by TD-DFT/B3LYP/6- 31G(d,p). 
ECD curves were obtained on the basis of rotator strengths with a half-band of 0.3 eV using 
SpecDis v1.71 [2]. ECD spectra were calculated from the spectra of individual conformers 
according to their contribution calculated by Boltzmann weighting. 
References: 
1. Frisch MJ, Trucks GW, Schlegel HB, Becke AD. Gaussian 09, Revision A. 02, Gaussian, Inc., WalҮ 
lingford CT, 2009. J Chem Phys 1993; 98: 5648 
2. Bruhn T, Hemberger Y, Schaumlöffel A, Bringmann G. SpecDis, Version 1.53; University of Wuerzburg: 
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A screening of Sudanese medicinal plants for antiprotozoal activities, revealed that, the 
chloroform and water fractions from an ethanolic extract from roots of Haplophyllum 
tuberculatum were tested active against Leishmania donovani. The antileishmanial activity 
was tracked by HPLC-based activity profiling, and eight compounds were isolated from the 
chloroform fraction. These included lignans tetrahydrofuroguaiacin B (1), nectandrin B (2), 
furoguaiaoxidin (7), and 3,3′-dimethoxy-4,4′-dihydroxylignan-9-ol (10), and four 
cinnamoylphenethyl amides, namely dihydro-feruloyltyramine (5), N-trans-feruloyltyramine 
(6), N,N′-diferuloylputrescine (8), and 7′-ethoxy-feruloyltyramine (9). The water fraction 
yielded steroid saponins 11-13. Compounds 1, 2, and 5-13 are reported for the first time 
from Haplophyllum species and the family Rutaceae. The antiprotozoal activity of the 
compounds plus two stereoisomeric tetrahydrofuran lignans fragransin B2 (3) and fragransin 
B1 (4) was determined against Leishmania donovani amastigotes, Plasmodium falciparum, 
and Trypanosoma brucei rhodesiense bloodstream forms, along with their cytotoxicity to rat 
myoblast L6 cells. Nectandrin B (2) exhibited the highest activity against L. donovani (IC50 4.5 
µM) and the highest selectivity index (25.5).   




Neglected tropical diseases (NTDs) are a group of infectious diseases that are prevalent in 
tropical and sub-tropical developing countries. NTDs are strongly associated with poverty 
and of high socio-economic impact. NTDs account for 48 million disability-adjusted life years 
(DALYs) and 152,000 deaths per year [1,2]. The NTD leishmaniasis, caused by Leishmania 
spp., imposes a global burden of 3.3 million DALYS and 51,600 annual deaths [1,2]. There is 
no vaccine, and current drugs are problematic given their serious adverse effects and the 
emergence of drug-resistant parasites [3]. There is one efficient and safe drug, AmBisome, a 
liposomal formulation of amphotericin B [4]. However, the high price of the drug and the 
need of an uninterrupted cold chain for delivery severely limit its use. In Eastern Africa, a 
high-burden region of visceral leishmaniasis [5], sodium stibogluconate is still the mainstay 
of leishmaniasis chemotherapy [3]. This pentavalent antimonial can cause hepatotoxicity and 
cardiotoxicity [6]. Thus, there is an urgent need for the development of new, efficacious, 
safe, and cost-effective drugs for the treatment of leihmaniasis and other diseases caused by 
kinetoplastid parasites [7,8]. 
A library of Sudanese medicinal plants traditionally used as anti-infectives was screened for 
antiprotozoal activity against Leishmania donovani, Trypanosoma brucei rhodesiense, 
Trypanosoma cruzi, and Plasmodium falciparum. One of the most promising hits was 
Haplophyllum tuberculatum (Forssk.) A. Juss. (Rutaceae). Chloroform and aqueous fractions 
obtained by partitioning of an ethanolic extract from roots of the plant were active against L. 
donovani and P. falciparum (˃ 85% growth inhibition at 10 µg/mL) [9]. 
Haplophyllum tuberculatum is a perennial herb distributed throughout North Africa and the 
Middle East. In Sudan, the plant is locally known as Haza, and the aerial parts have been 
used traditionally to treat malaria, asthma, kidney diseases, gynecological and bowel 
disorders [10, 11]. Anti-inflammatory, antioxidant, antibacterial, and antifungal activities 
have been reported [12–14], and alkaloids, flavonoids, coumarins and lignans have been 
identified [15–17]. The methanolic extract of aerial part and roots of H. tuberculatum 
possessed activity against P. falciparum [18], and Justicidin A was found active [19]. The 
essential oil from the leaves had antileishmanial activity [20]. Justicidin B, a lignan isolated 
from the leaves, showed trypanocidal activity [21].  
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4.3 Results and Discussion 
 
4.3.1 Extraction and HPLC-based Activity Profiling 
The chloroform and the water fractions from roots of H. tuberculatum had been previously 
found to be active against L. donovani when tested at 10 µg/mL [9]. The antileishmanial 
activity was tracked by HPLC-based activity profiling, a procedure combining time-based 
microfractionation with bioactivity testing [22]. One-minute microfractions were collected 
and tested for growth inhibition of L. donovani axenic amastigotes. The HPLC-ESIMS traces 
(base peak chromatograms in positive ion mode) overlaid with the antileishmanial activity of 
microfractions are shown for the chloroform (Figure 1) and the water fraction (Figure 2). 
Pronounced antileishmanial activity was found in the chloroform fraction in the time window 
of 16-21 min, and moderate activity in the window of 12-15 min. For the water fraction, the 











Figure 1. HPLC-based activity profiling of the chloroform fraction against axenic amastigotes of 
L. donovani. The ESIMS (base peak chromatogram in positive ion mode) from a separation of 300 μg 
of fraction is shown. For each microfraction the activity is expressed as percent growth inhibition in 
comparison to untreated cultures (grey bars). Bold numbers in the chromatogram refer to 
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Figure 2. HPLC-based activity profiling of the water fraction against axenic amastigotes of L. 
donovani. The ESIMS (base peak chromatogram in positive ion mode) from a separation of 300 μg of 
fraction is shown. For each microfraction the activity is expressed as percent growth inhibition in 
comparison to untreated cultures (grey bars). Bold numbers in the chromatogram refer to 
compounds 11-13. 
 
4.3.2 Compound Isolation and Structure Elucidation 
Preparative separation by MPLC of the chloroform fraction on C18 cartridge yielded 13 
subfractions (A-M). HPLC‑PDA‑MS analysis showed that subfractions B and C contained 
peaks from the active time window. Further purification by semipreparative RP-HPLC 
afforded compounds 1 and 2 from subfraction B. Based on NMR data (Table S1, Supporting 
Information), the two compounds were identified as the known lignans 
tetrahydrofuroguaiacin B (1) and nectandrin B (2) (Figure 3) [23–25]. Semipreparative RP-
HPLC of subfraction C afforded compounds 5-10. By means of 1D and 2D NMR data (Tables 
S2 and S3, Supporting Information), these were identified as four cinnamoylphenethyl 
amides, namely dihydro-feruloyltyramine (5) [26], (E)-N-feruloyltyramine (6) [27], N,N′-
diferuloylputrescine (8) [28], and 7′-ethoxy-feruloyltyramine (9) [29], and two lignans, 
furoguaiaoxidin (7) [25] and 3,3′-dimethoxy-4,4′-dihydroxylignan-9-ol (10) [30] (Figure 3). 
Compounds 9 and 10 showed optical rotation close to zero, and no cotton effects in the ECD 
spectra. From a comparison with published data for the two compounds, we conclude that 
they most likely were racemic mixtures.  




Figure 3. Structures of compounds 1-10.  
 
Preparative RP chromatography by MPLC of the water fraction on a C18 cartridge yielded 15 
subfractions (A-O), whereby subfractions J and K contained the peaks from the active time 
window of the activity profile (Figure 2). Semipreparative HPLC on a Hilic column afforded 
inseparable mixtures of 11 and 12 from subfraction J, and 11 and 13 from subfraction K. The 
HRESIMS spectrum of 11 exhibited a sodium adduct ion (m/z 1039.5083 [M + Na]+, calcd for 
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C50H80O21Na
+ 1039.5085) indicative of  a molecular formula of C50H80O21. The NMR data 
(Table S4) pointed to a steroidal saponin bearing four sugars. A comparison of 13C chemical 
shifts with literature data identified the aglycon as yamogenin [31]. This was corroborated by 
a detailed analysis of the 2D NMR spectra, in particular by cross peaks in the ROESY 
spectrum between H-1β (δH 1.78), H3-19 (δH 0.94), H-8 (δH 1.54), H3-18 (δH 0.72), and H-20 
(δH 1.75), between H-1α (δH 0.96) and H-3 (δH 3.46), and between H3-21 (δH 0.92), H-17 (δH 
1.65), H-16 (δH 4.27) and H-14 (δH 1.07).  After hydrolysis and derivatization the sugars were 
identified as ᴅ -glucose, ʟ -rhamnose, and ᴅ -xylose [32]. The interglycosidic linkages and the 
attachment position of the sugar chain at the aglycon were established by HMBC 
correlations from δH 4.43 (1H, d, J = 7.5 Hz, H-1-Glc1) to δc 76.9 (C-3), from δH 5.04 (1H, br s, 
H-1-Rha1) to δc 76.4 (C-2-Glc1), from δH 4.34 (1H, d, J = 7.5 Hz, H-1-Glc2) to δc 81.1 (C-4-
Glc1), and from δH 4.38 (1H, d, J = 7.1 Hz, H-1-Xyl) to δc 86.4 (C-3-Glc2). saponin 11 was 
identified as (3S,20S,22R,25S)-spirost-5-en-3-yl-(β-ᴅ-xylopyranosyl-(1 → 3)-β-ᴅ-
glucopyranosyl-(1→4)[α-ʟ-rhamnopyranosyl-(1→2)]-β-ᴅ-glucopyranoside [33]. 
Compound 12 had a molecular formula of C51H82O21 (HRESIMS data m/z 1053.5233 
[M + Na]+, calcd for C51H82O21Na
+ 1053.5241). As for compound 11, NMR data (Table S4, 
Supporting Information) indicated yamogenin bearing four sugars. The only difference was in 
the presence of a rhamnopyranose instead of a xylopyranose. Thus, saponin 12 was 
identified as (3S,20S,22R,25S)-spirost-5-en-3-yl-(β-ᴅ-rhamnopyranosyl-(1 → 3)-β-ᴅ-
glucopyranosyl-(1 → 4)[α-ʟ-rhamnopyranosyl-(1 → 2)]-β-ᴅ-glucopyranoside [34]. 
Compound 13 had a molecular formula of C50H80O21 (m/z 1039.5072 [M + Na]
+, calcd for 
C50H80O21Na
+ 1039.5085). Based on the NMR data and especially the carbon chemical shifts 
(Table S4, Supporting Information), the aglycone was identified as diosgenin [31]. The sugar 
moiety was identical to that in saponin 11. Compound 13 was therefore identified as 
(3S,20S,22R,25R)-spirost-5-en-3-yl-(β-ᴅ-xylopyranosyl-(1→3)-β-ᴅ-glucopyranosyl-(1→4)[α-ʟ-
rhamnopyranosyl-(1→2)]-β-ᴅ-glucopyranoside [33] (Figure 4). It is interesting to note that 11 
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Figure 4. Structures of saponins 11-13. 
 
4.3.3 Comparison to previously reported compounds 
The two tetrahydrofuran-type lignans 1 and 2 were previously reported from different 
Myristicaceae, Elaeagnaceae, Poaceae, and Piperaceae species [24,35]. 
Arylnaphthalen-type lignans had been identified in aerial part and roots of H. tuberculatum 
[36,37], but tetrahydrofuran-type lignans are reported here for the first time from 
Haplophyllum species.  
Cinnamoylphenethyl amides such as 5, 6, 8 and 9 have been reported from over 30 families 
of flowering plants [38]. Amides 5 and 6 have been previously reported from different 
species of Annonaceae [26,39,40] and Lauraceae [41,42]. Compound 6 was also found in 
Papaveraceae [43], Cannabaceae [44], Solanaceae [27,45], and Portulacaceae [46,47], while 
9 was identified in Portulacaceae [46,47] and Cactaceae [29]. Amide 7 has been previously 
reported from Guaiacum officinale [25], while compound 8 has been found in Tribulus 
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terrestris [48], Peltophorum pterocarpum [49], and Zea mays [50]. Amide 10 has been 
previously identified in Schisandra bicolor var. tuberculata [30]. 
Molluscicidal saponins 11-13 have been previously isolated, among a series of similar 
compounds (balanitins), from the Sudanese medicinal plant Balanites aegyptiaca 
(Zygophyllaceae) [33,34]. It can be assumed that these saponins contributed to the 
molluscicidal activity [51] that has been described for H. tuberculatum [52]. To the best of 
our knowledge, compounds 1, 2, and 5-13 have been isolated here for the first time not only 
from Haplophyllum species but also from plants of the Rutaceae family. 
 
4.3.4 Biological testing 
Compounds 1-10 were tested for their in vitro activities against the following protozoan 
parasites: Leishmania donovani (MHOM/ET/67/L82) axenic amastigotes, Plasmodium 
falciparum (NF54) proliferative erythrocytic stages, and Trypanosoma brucei rhodesiense 
(STIB 900) bloodstream forms (Table 1). In parallel, cytotoxicity of these compounds in rat 
skeletal myoblasts (L-6 cells) was determined in order to obtain an initial assessment of their 
selectivity. The results are reported in Table 1. Subfractions J and K from the aqueous 
fraction containing steroid saponins 11and 12 in J, and 11 and 13 in K, exhibited IC50 ˂ 8 
µg/mL across all parasites and a selectivity index ˂ 2, indicative of general cytotoxicity. 
 
Table 1: In vitro Activity of Compounds 1−10 against L. donovani (MHOM-ET-67/L82) axenic 
amastigotes, P. falciparum (NF54), T. b. rhodesiense (STIB 900), and Cytotoxicity in L6 Cells. 
a 
The IC50s are mean values from at least two independent replicates ± absolute deviation. 
b 









n.d: Not determined 














1 22.6 ± 6.5 4.2 53.1 ± 2.0 1.8 59.4 ± 2.5 1.6 95.2 ± 9.3 
2 4.5 ± 1.0 25.5 9.5 ± 0.1 12.1 48.3 ± 1.3 2.4 115.0 ± 2.6 
3 36.0 ± 7.3 4.7 36.1 ± 1.0 4.7 47.5 ± 4.5 3.6 170.5 ± 40.1 
4 29.2 ± 6.0 4.8 17.4 ± 2.1 8.0 40.7 ± 0.4 3.4 138.9 ± 3.8 
5 141.3 ± 1.9 n.d 158.7 n.d 206.0 ± 66.7 n.d ˃317.5 
6 99.4 ± 9.3 2.5 68.4 ± 3.8 3.6 120.9 ± 36.9 2.0 246.8 ± 3.7 
7 136.5 ± 1.5 n.d 48.1 ± 10.9 n.d 114.0 ± 0.0 n.d ˃280.9 
8 97.0 ± 0.9 1.5 30.6 ± 8.3 4.8 18.9 ± 8.4 7.8 146.5 ± 18.8 
9 69.6 ± 4.6 3.0 30.4 ± 8.0 6.8 72.7 ± 30.4 2.9 207.8 ± 21.6 
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4.3.5 Activity against Leishmania donovani axenic amastigotes 
Nectandrin B (2) was the most active (IC50 of 5 µM) and the most selective (SI 26) of all 
compounds tested. This finding contrasts with a previous report on nectandrin B being 
inactive against L. donovani [53]. The discrepancy may come from the fact that, in the 
aforementioned study, Nectandrin B was tested against the promastigote form of the 
parasite (i.e. the proliferative form in the gut of the sandfly vector) while we tested against 
the amastigote form (i.e. the proliferative form in the mammalian host). The antileishmanial 
activity cannot be ascribed to any particular mode of action at this point. In general, some 
tetrahydrofuran lignans have been reported to inhibit trypanothione reductase [54], an 
enzyme of a thiol-redox system that is unique to trypanosomatid protozoa and essential for 
their survival [55,56]. Compared to 2, tetrahydrofuroguaiacin B (1) was less active and more 
toxic. The two compounds only differ in their stereochemistry at the tetrahydrofuran ring 
which appears to play a crucial role in the antileishmanial activity of such lignans. To better 
understand the role of the stereochemistry at the central ring and the contribution of 
substituents at the aromatic rings, structurally related lignans 3 and 4 that had been 
previously reported from Myristica fragrans [23,24] were also included in the testing. 
However, both compounds were significantly less active than nectrandrin B (2). 
Unfortunately, the activity of nectandrin B (2) against L. donovani was lost in the intracellular 
amastigote assay tested up to a concentration of 30 μM. 
4.3.6 Activity against Plasmodium falciparum 
Lignans 2 and 10 were the most active and least toxic compounds (IC50 9-9.5 µM, SI 12-14). 
Compound 10 was selectively active against P. falciparum. Compared to 2, fragransin B1 (4) 
(IC50 17 µM, SI 8), was less active against P. falciparum, but was slightly more active and less 
cytotoxic than its stereoisomer fragransin B2 (3). Amides 8 and 9 showed comparable activity 
(IC50 30 µM, SI 8), while the congener 5 was the least active among all tested compounds. 
A wide spectrum of biological activities of cinnamoylphenethyl amides has been described, 
including antiproliferative [57], antibacterial [58], antifungal [59] and antioxidant activities 
[60]. To the best of our knowledge, this is the first report of antileishmanial and 
antiplasmodial activities of such compounds. 
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4.3.7 Activity against Trypanosoma brucei rhodesiense 
Of all compounds tested, diferuloylputrescine (8) exhibited the highest activity against T. b. 
rhodesiense and the highest selectivity (IC50 19 µM, SI 8). The lignan 10 showed a lower 
activity and selectivity index (IC50 28 µM and SI 5), while 5 and 6 were the least active among 
all tested compounds. None of the tetrahydrofuran lignans 1-4 exhibited significant activity 
against T. b. rhodesiense.  
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4.4 Materials and Methods 
 
General experimental procedures 
HPLC grade solvents from Sigma-Aldrich (St. Louis, MO, USA), and Macron Fine Chemicals 
(Avantor Performance Materials, Phillipsburg, NJ, USA), and ultrapure water from a Milli-Q 
water purification system (Merck Millipore, Darmstadt, Germany) were used for HPLC 
separations. For extraction and preparative separation, technical grade solvents (Scharlab S. 
L., Barcelona, Spain) were used after distillation. Silica gel 60 F254 coated aluminum TLC 
plates were obtained from Merck (Darmstadt, Germany). 
Optical rotation was measured in methanol on a JASCO P-2000 digital polarimeter (Tokyo, 
Japan) equipped with a sodium lamp (589 nm) and a temperature-controlled microcell (10 
cm). UV and ECD spectra were recorded in methanol on a Chirascan CD spectrometer 
(Applied Photophysics, Leatherhead, UK) using 110 QS 1 mm path precision cells (Hellma 
Analytics, Müllheim, Germany). NMR spectra of compounds 1, 2, and 5-10 were recorded on 
a Bruker AVANCE III 500 MHz spectrometer (Billerica, CA, USA) operating at 500.13 MHz for 
1H and 125.77 MHz for 13C. 1H, COSY, HSQC, HMBC, and NOESY spectra were measured at 
23°C in a 1-mm TXI probe with a z-gradient. The sample volume was 10 µL. NMR spectra of 
11-13 were recorded on a Bruker AVANCE NEO 600 MHz spectrometer operating at 600.18 
MHz for 1H and 150.92 MHz for 13C with an inverse 1.7-mm TCI micro-cryoprobe (30 µL 
sample volume) at 23°C. This cryogenically cooled probe delivered a 4-fold gain of mass 
sensitivity over the 1 mm TXI room-temperature probe and enabled the NMR analysis of 
small sample amounts (µg range), usually obtained for natural products. Spectra were 
analyzed by Bruker TopSpin 3.5 pl 7 and ACDLabs Spectrus Processor. NMR spectra were 
recorded in DMSO-d6 99.9 atom%D (Armar Chemicals, Dӧttingen, Switzerland). 
HRESIMS data were measured in the positive ion mode on an Orbitrap LQT XL mass 
spectrometer (Thermo Scientific, Waltham, MA, USA). HPLC-PDA-ELSD-ESIMS data were 
recorded in positive- and negative-ion mode (scan range of m/z 200−1500) on a Shimadzu 
LC-MS/MS 8030 triple quadrupole MS system (Kyoto, Japan) connected via a T-splitter (1:10) 
to a photo diode array detector (PDA) (SPD-M20A, Shimadzu, Kyoto, Japan), and evaporative 
light scattering detector (ELSD) (3300, Alltech, Büchi, Flawil, Switzerland). For data 
acquisition and processing, LabSolutions software (Kyoto, Japan) was used. 
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Separations were performed on a C18 SunFire column (3.0 × 150 mm i. d., 3.5 μm) equipped 
with a precolumn (10mm× 3.0mm i. d.) (Waters).   
Microfractionation was carried out with the same HPLC instrument connected via a T split to 
an FC204 fraction collector (Gilson, Mettmenstetten, Switzerland) with only UV detection, 
using a SunFire C18 (3.5 μm, 150 × 3.0 mm i.d.) column equipped with a guard column 
(10 mm × 3.0 mm i.d.) (Waters). Semipreparative HPLC were performed on an Agilent 1100 
system (Santa Clara, CA, USA) with PDA detector. A SunFire C18 column (5 μm, 10 × 150mm i. 
d.) fitted with a guard column (10 × 10mm i.d.) (Waters) and a Nucleodur Hilic column (5 μm 
, 10 × 150mm i. d.) (Macherey-Nagel), were used for separations. ChemStation software 
(Agilent Technologies) was used for data acquisition and processing. Preparative HPLC was 
carried out on a PuriFlash 4100 system (Interchim, Montluçon, France). Separations were 
performed on RediSep Rf Gold ®-C18 MPLC cartridge 100g (Teledyne Isco). 
 
Plant Material 
Roots of Haplophyllum tuberculatum were collected in February 2018 in Khartoum, Sudan. 
The taxonomic identity was confirmed by the Medicinal and Aromatic Plants Research 
Institute, Sudan. A voucher specimen (HTR 02) is deposited at the Herbarium of the Faculty 
of Pharmacy, University of Science and Technology, Omdurman, Sudan. The plant material 
was dried at room temperature and milled with a hammer mill before extraction. 
 
Extraction  
The powdered roots of H. tuberculatum (300 g) were extracted with 1 Litre of 70% ethanol 
under stirring for 24 h. The extract was filtered through Whatman no. 1 filter paper and 
concentrated in a rotary evaporator to obtain 35.7 g of extract. The extract amount was 
suspended in water and partitioned consecutively with petroleum ether, chloroform, and 
ethyl acetate. Three repetitive partitioning procedures, each with 500 mL of either solvent, 
were performed.  In total, 0.4 g of petroleum ether fraction, 4.0 g of chloroform fraction, 2.0 
g of ethyl acetate fraction, and 16.4 g of the water fraction wer obtained after evaporation.  
 
Microfractionation for activity profiling 
HPLC-based microfractionation of the chloroform and the water fractions was performed 
[H2O + 0.1% formic acid (A), CH3CN + 0.1% formic acid (B); 0→100% B (0-30 min), 100% B 
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(30-40 min); flow rate 0.4 mL/min; sample concentration 10 mg/mL in DMSO; injection 
volume 2 x 35 μL] by collecting one-minute fractions from minute 1 to 40 into a 96-deep-well 
plate. Plates were then dried in a Genevac EZ-2 evaporator (Ipswich, UK) and prepared for 
antiprotozoal activity testing based on previously established protocols [22,61]. 
 
Preparative Isolation 
The chloroform fraction was reconstituted in DMSO and separated on a RediSep Rf Gold ® 
RP-C18, 100 gm cartridge [H2O (A), CH3CN (B); 5→100% B (0-120 min), flow rate 20 mL/min]. 
A total of 13 subfractions (A-M) were combined based on TLC patterns. The subfractions 
were analyzed by HPLC-PDA-MS to track peaks previously detected in the active time 
windows of the activity profile. 
Subfraction B (247 mg) was submitted to semipreparative HPLC on a C18 column [H2O (A), 
CH3CN (B); 56% B (0−35 min), 56→100% B (35−40 min), 100% B (40−45 min), flow rate 4 
mL/min; sample concentration 50 mg/mL in DMSO; injection volume 50 μL; detection at 208 
nm] to afford tetrahydrofuroguaiacin B (1, 2.2 mg, tR 22.3 min) and nectandrin B (2, 1.9 mg, 
tR 29.5 min). 
A portion (200 mg) of subfraction C was separated by semipreparative HPLC on a C18 column 
[H2O (A), MeOH (B); 39→48% B (0-30 min), 48→100% B (30-40 min), 100% B (40−45 min), 
flow rate 4 mL/min; sample concentration 50 mg/mL in DMSO; injection volume 50 μL; 
detection at 254 nm], and dihydro-feruloyltyramine (5, 2.5 mg, tR 9.4 min), (E)-N-
feruloyltyramine (6, 10.6 mg, tR 16.2 min), furoguaiaoxidin (7, 1.4 mg, tR 16.2 min), N,N′-
diferuloylputrescine (8, 1.4 mg, tR 23.4 min), 7′-ethoxy-trans-feruloyltyramine (9, 1.1 mg, tR 
27.3 min), and 3,3′-dimethoxy-4,4′-dihydroxylignan-9-ol (10, 2.5 mg, tR 36.5 min) were 
obtained. 
For the water fraction, an aliquot (8 g) was re-dissolved in water and separated by 
preparative HPLC on a RediSep Rf Gold ® RP-C18, 100 gm cartridge [H2O (A), CH3CN (B); 
20→65% B (0-120 min), 65→100% B (120−135 min), flow flow rate 20 mL/min]. Fractions 
with similar TLC patterns were combined to yield 15 subfractions (A-O). HPLC-PDA-MS 
analysis located the peaks detected in the active time window in subfractions J and K. 
Subfraction J (17 mg) was submitted to semipreparative HPLC on a C18 column [H2O (A), 
CH3CN (B); 41% B (0−40 min), 41→100% B (40−45 min), 100% B (45−50 min), flow rate 4 
Chapter 4: Lignans, Amides, and Saponins from Haplophyllum tuberculatum and their Antiprotozoal Activity 
128 
mL/min; sample concentration 50 mg/mL in DMSO; injection volume 50 μL; detection at 193 
nm] to afford compounds 11 and 12 as a mixture (2 mg, tR 22.3 min).  
Subfraction K (53 mg) was submitted to semipreparative HPLC on a C18 column [H2O (A), 
CH3CN (B); 40% B (0−40 min), 40→100% B (40−45 min), 100% B (45−50 min) , flow rate 4 
mL/min; sample concentration 50 mg/mL in DMSO; injection volume 50 μL; detection at 193 
nm], yielding subfraction K3. Subfraction K3 (16 mg) was further purified by semipreparative 
HPLC on a Nucleodur Hilic column [H2O (A), CH3CN (B); 92% B (0−35 min), 92→20% B (35−45 
min), flow rate 4 mL/min; sample concentration 50 mg/mL in DMSO; injection volume 50 μL; 
detection at 193 nm], to afford compounds 11 and 13 as a mixture (4.2 mg, tR 25.2 min).  
 
Tetrahydrofuroguaiacin (1): amorphous solid; [α]25D -1.9 (c 0.2, MeOH); 
1H and 13C NMR, see 
Table S1, Supporting Information; ESI-MS m/z 345 [M+H]+.  
Nectandrin B (2): amorphous solid; [α]25D -1.2 (c 0.2, MeOH); 
1H and 13C NMR, see Table S1, 
Supporting Information; ESI-MS m/z 345 [M+H]+.  
Fragransin B2 (3): amorphous solid; ESIMS m/z 405 [M + H]
+. 
Fragransin B1 (4): amorphous solid; ESIMS m/z 405 [M + H]
+. 
Dihydro-feruloyltyramine (5): amorphous solid; 1H and 13C NMR, see Table S2, Supporting 
Information; ESIMS m/z 316 [M + H]+. 
(E)-N-Feruloyltyramine (6): amorphous solid; 1H and 13C NMR, see Table S2, 
Supporting Information; ESIMS m/z 314 [M + H]+. 
Furoguaiaoxidin (7): amorphous solid; 1H and 13C NMR, see Table S2, 
Supporting Information; ESIMS m/z 357 [M + H]+. 
N,N′-Diferuloylputrescine (8): amorphous solid; 1H and 13C NMR, see Table S2, 
Supporting Information; ESIMS m/z 441 [M + H]+. 
7′-Ethoxy-trans-feruloyltyramine (9): amorphous solid; [α]25D -2.6 (c 0.11, MeOH); UV λmax 
(MeOH) (log ε) 228 (0.23), 288 (0.12), 320 (0.11) nm; ECD (MeOH, c 2.0 x 10-4 M, 1 mm path 
length) λmax(Δε) 207 (+4.04), 224 (+2.40), 235 (+1.72) nm; 
1H and 13C NMR, see Table S3, 
Supporting Information; ESIMS m/z 358 [M + H]+. 
3,3′-Dimethoxy-4,4′-dihydroxylignan-9-ol (10): amorphous solid; [α]25D -4.9 (c 0.25, MeOH); 
UV λmax (MeOH) (log ε) 230 (0.18), 280 (0.08) nm; ECD (MeOH, c 1.4 x 10
-4 M, 1 mm path 
length) λmax(Δε) 205 (+3.07), 215 (+1.39), 235 ( +0.89) nm ;
1H and 13C NMR, see Table S3, 
Supporting Information; ESIMS m/z 693 [2M + H]+. 
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(3S,20S,22R,25S)-Spirost-5-en-3-yl (β-ᴅ-xylopyranosyl-(1→3)- β-ᴅ-glucopyranosyl-(1→4)[α-ʟ-
rhamnopyranosyl-(1→2)]-β-ᴅ-glucopyranoside (11): amorphous solid; 1H and 13C NMR, see 




(1→4)[α-ʟ-rhamnopyranosyl-(1→2)]-β-ᴅ-glucopyranoside (12): amorphous solid; 1H and 13C 
NMR, see Table S4, Supporting Information; HRESIMS m/z 1053.5233 [M + Na]+ (calcd for 
C51H82O21Na
+ 1053.5241).  
(3S,20S,22R,25R)-Spirost-5-en-3-yl (β-ᴅ-xylopyranosyl-(1→3)- β-ᴅ-glucopyranosyl-(1→4)[α-ʟ-
rhamnopyranosyl-(1→2)]-β-ᴅ-glucopyranoside (13): amorphous solid; 1H and 13C NMR, see 




Activity against Leishmania donovani axenic amastigotes 
Amastigotes of L. donovani strain MHOM/ET/67/L82 were grown under an atmosphere of 
5% CO2 in air in axenic culture at 37 °C in SM medium [62] at pH 5.4 supplemented with 10% 
heat-inactivated fetal bovine serum. 50 µL of culture medium was added in the wells of a 96-
well plate and serial drug dilutions of eleven 3-fold dilution steps covering a final range from 
100 to 0.002 μg/mL were prepared. 50 µL culture medium with 2x105 amastigotes from 
axenic culture were added to each well. The plates were incubated for 70 h and then 
inspected under an inverted microscope to assure growth of the controls and sterile 
conditions. 10 μL of resazurin (12.5 mg resazurin dissolved in 100 mL distilled water) were 
added to each well of the plates and allowed for additional 2 h incubation. Afterwards, 
plates were read with a Spectramax Gemini XS microplate fluorometer (Molecular Devices 
Cooperation, Sunnyvale, CA, USA) using an excitation wavelength of 536 nm and an emission 
wavelength of 588 nm. Data were analyzed using the software Softmax Pro (Molecular 
Devices Cooperation, Sunnyvale, CA, USA). Decrease of fluorescence (= inhibition) was 
expressed as percentage of the fluorescence of untreated control cultures and plotted 
against the drug concentrations. From the sigmoidal inhibition curves the IC50 values were 
calculated by linear regression using Microsoft Excel. Miltefosine was used as positive 
control drug. Assays were performed in two independent replicates at least. 
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Activity against Leishmania donovani intramacrophage amastigotes 
Mouse peritoneal macrophages (4 x 104 in 100 µL RPMI 1640 medium with 10% heat-
inactivated FBS) were seeded into wells of a 96-well plate. After 24 h, 100 µL of 2 x 105 
amastigote Leishmania donovani were added. The amastigotes were taken from an axenic 
amastigote culture grown at pH 5.4. The medium containing free amastigote forms was 
removed after 24 h and replaced with fresh medium. The washing step was repeated and 
afterwards the serial drug dilution was prepared with at least 6 dilution steps. Compound 
was dissolved in DMSO at 10 mg/mL and further diluted in medium. After incubation for 96 
hours at 37 °C under a 5 % CO2 atmosphere, the medium was removed and cells were fixed 
by adding 50µl 4% formaldehyde solution followed by a staining with a 5 µM DRAQ5 
solution. Plates were imaged in ImageXpress XLS (MD) microscope using a 20x air objective 
(635 nm excitation: 690/50 emission). 9 images were collected per well. Automated image 
analysis was performed with a script developed on Meta Xpress Software (MD). Three 
outputs were provided for each well: i) number of host cell nuclei; ii) numbers of infected 
and non-infected host cells; iii) number of parasite nuclei per infected host cell. The IC50 
values were calculated based on the infection rate and the numbers of intracellular 
amastigotes. Miltefosine was used as control. Assays were performed in two independent 
replicates at least. 
 
Activity against Plasmodium falciparum 
In vitro activity against the erythrocytic stages of P. falciparum was determined using a 3H-
hypoxanthine incorporation assay [63], using the drug-sensitive NF54 strain [64]. 
Compounds were dissolved in DMSO at 10 mg/mL and further diluted in medium before 
addition to parasite cultures incubated in RPMI 1640 medium without hypoxanthine, 
supplemented with HEPES (5.94 g/L), NaHCO3 (2.1 g/L), neomycin (100 U/mL), Albumax
R (5 
g/L) and washed human red cells A+ at 2.5% haematocrit (0.3% parasitaemia). Serial drug 
dilutions of eleven 3-fold dilution steps covering a range from 100 to 0.002 μg/mL were 
prepared. The 96-well plates were incubated in a humidified atmosphere at 37 °C; 4% CO2, 
3% O2, 93% N2. After 48 h 50 μl of 
3H-hypoxanthine (=0.5 μCi) was added to each well of the 
plate. The plates were incubated for a further 24 h under the same conditions. The plates 
were then harvested with a Betaplate™ cell harvester (Wallac, Zurich, Switzerland), and the 
red blood cells transferred onto a glass fibre filter then lysed with distilled water. The dried 
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filters were inserted into a plastic foil with 10 mL of scintillation fluid, and counted in a 
Betaplate™ liquid scintillation counter (Wallac, Zurich, Switzerland). IC50 values were 
calculated from sigmoidal inhibition curves by linear regression using Microsoft Excel. 
Chloroquine (Sigma C6628) was used as positive control. Assays were performed in two 
independent replicates at least. 
 
Activity against Trypanosoma brucei rhodesiense 
The stock was originally isolated from a Tanzanian patient and adapted to axenic culture 
conditions after several mouse passages and cloned. Minimum Essential Medium (50 µL) 
supplemented with 25 mM HEPES, 1g/L additional glucose, 1% MEM non-essential amino 
acids (100x), 0.2 mM 2-mercaptoethanol, 1mM Na-pyruvate [65] and 15% heat inactivated 
horse serum was added to each well of a 96-well microtiter plate. Serial drug dilutions of 
eleven 3-fold dilution steps covering a range from 100 to 0.002 μg/mL were prepared. Then 
4x103 bloodstream forms of T. b. rhodesiense STIB 900 in 50 µL were added to each well and 
the plate incubated at 37 °C under a 5 % CO2 atmosphere for 70 h. 10 µL resazurin solution 
(resazurin, 12.5 mg in 100 mL double-distilled water) was then added to each well and 
incubation continued for a further 2–4 h [66]. Then the plates were read with a Spectramax 
Gemini XS microplate fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA) 
using an excitation wavelength of 536 nm and an emission wavelength of 588 nm. Data were 
analyzed with the graphic programme Softmax Pro (Molecular Devices Cooperation, 
Sunnyvale, CA, USA), which calculated IC50 values by linear regression [67], and 4-parameter 
logistic regression from the sigmoidal dose inhibition curves. Melarsoprol (Arsobal Sanofi-
Aventis, received from WHO) was used as control. Assays were performed in two 
independent replicates at least. 
 
In vitro cytotoxicity with L-6 cells 
 Assays were performed in 96-well microtiter plates, each well containing 100 L of RPMI 
1640 medium supplemented with 1% L-glutamine (200mM) and 10% fetal bovine serum, and 
4000 L-6 cells (a primary cell line derived from rat skeletal myoblasts) [68]. Serial drug 
dilutions of eleven 3-fold dilution steps covering a range from 100 to 0.002 μg/mL were 
prepared 24 h post seeding L-6 cells. After 70 hours of incubation the plates were inspected 
under an inverted microscope to assure growth of the controls and sterile conditions. 10 L 
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of resazurin was then added to each well and the plates incubated for another 2 hours. Then 
the plates were read with a Spectramax Gemini XS microplate fluorometer (Molecular 
Devices Cooperation, Sunnyvale, CA, USA) using an excitation wavelength of 536 nm and an 
emission wavelength of 588 nm. The IC50 values were calculated by linear regression and 4-
parameter logistic regression from the sigmoidal dose inhibition curves using SoftmaxPro 
software (Molecular Devices Cooperation, Sunnyvale, CA, USA). Podophyllotoxin (Sigma 
P4405) was used as control. All assays were performed in two independent replicates at 
least. 
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C NMR Spectroscopic Data for Compound 1 and 2 (DMSO-d6; 500.13 
MHz for 
1
H and 125.77 for 
13
C NMR; δ in ppm)  






  1  2 
Position  δC
a
 δH (mult J in Hz)  δC
a
 δH (mult J in Hz) 
2  81.9, CH 4.98, d (6.4)  86.5, CH 4.34, d (5.8) 
3  40.7, CH 2.62, m  43.8, CH 2.20, m 
4  40.7, CH 2.62, m  43.8, CH 2.20, m 
5  81.9, CH 4.98, d (6.4)  86.5, CH 4.34, d (5.8) 
 1', 1''  131.4, C   133.1, C  
 2', 2''  110.7, CH 6.94, s  110.8, CH 6.95, s 
3', 3'' 
 
147.2, C   147.5, C  
4', 4'' 
 
145.3, C   146.1, C  
5', 5'' 
 
115.1, CH 6.79 b  115.3, CH 6.78b 
 6', 6'' 
 
118.7, CH 6.79 b  118.8, CH 6.81b 
3-Me 
 
11.5, CH3 0.51, d (6.4)  12.6, CH3 0.94, d (6.1) 
4-Me 
 
11.5, CH3 0.51, d (6.4)  12.6, CH3 0.94, d (6.1) 
3'-OMe, 3''-OMe 
 
55.6, CH3 3.76, s  55.6, CH3 3.75, s 






C NMR Spectroscopic Data for Compounds 5-8 (DMSO-d6; 500.13 MHz for 
1
H and 125.77 for 
13




































a 13C NMR data extracted from HSQC and HMBC spectra, b Overlapping signals, c Signal not visible due to low amount of compound. 





 δH (mult J in Hz) δC
a
 










δH (mult J in 
Hz) 
1 132.2, C  126.8, C  c  c  
2 112.7, CH 6.76, d (1.5) 111.3, CH 7.14, br s 112.0, CH 7.01, d (1.5) 111.0, CH 7.11, br s 
3 147.4, C  148.1, C  c  c  
4 144.8, C  148.6, C  c  c  
5 115.2, CH 6.70 b 116.1, CH 6.87, d (8.2) 114.8, CH 6.76, d (8.2) 115.9, CH 6.82, d (8.2) 
6 120.3, CH 6.59, dd (7.8, 1.4) 121.9, CH 7.03 b 124.5, CH 7.14, dd (8.2, 1.5) 121.5, CH 6.98, br d (8.2) 
7 30.8, CH2 2.72, t (7.6) 139.6, CH 7.46, d (15.6) 
c  138.8, CH 7.32, d (15.9) 
8 37.4, CH2 2.34, t (7.8) 119.3, CH 6.56, d (15.6) 
c  119.3, CH 6.46, d (15.9) 
9 171.6, C  166.2, C  16.9, CH3 2.03, s 
c  
10       38.3, CH2 3.20
  b 
11       26.9, CH2 1.50, m 
1' 132.2, C  129.8, C  c  c  
2' 129.3, CH 6.95, d (8.4) 129.7, CH 7.05 b 112.0, CH 7.01, d (1.5) 111.0, CH 7.11, br s 
3' 115.2, CH 6.70 b 115.5, CH 6.76, d (8.2) c  c  
4' 155.7, C  155.9, C  c  c  
5' 115.2, CH 6.70 b 115.5, CH 6.76, d (8.2) 114.8, CH 6.76, d (8.2) 115.9, CH 6.82, d (8.2) 
6' 129.3, CH 6.95, d (8.4) 129.7, CH 7.05 b 124.5, CH 7.14, dd (8.2, 1.5) 121.5, CH 6.98,  br d (8.2) 
7' 34.4, CH2 2.58, t (7.3) 34.7, CH2 2.73, t (7.0) 
c  138.8, CH 7.32, d (15.9) 
8' 40.5, CH2 3.22, dt (5.2, 6.7) 40.9, CH2 3.45, dt (5.5, 5.5) 
c  119.3, CH 6.46, d (15.9) 
9'     16.9, CH3 2.03, s 
c  
10'       38.3, CH2 3.20
  b 
11'       26.9, CH2 1.50, m 
3-OMe 55.7, CH3 3.75, s 55.9, CH3 3.81, s     
3'-OMe     55.5, CH3 3.70, s 55.5, CH3 3.81, s 
NH  7.77, t (5.2)  7.97, t (5.5)    7.93, t (4.9) 







C NMR Spectroscopic Data for Compounds 9-10 (DMSO-d6; 500.13 
MHz for 
1
H and 125.77 for 
13
C NMR; δ in ppm)  
  9  10  
Position  δC
a
 δH (mult J in Hz)  δC
a
 δH (mult J in Hz)  
1  126.3, C   132.3, C   
2  111.1, CH 7.11 b  113.1, CH 6.68 b  
3 
 
147.8, C   147.2, C   
4 
 
147.6, C   144.2, C   
5 
 
115.7, CH 6.82, d (7.9)  115.0, CH 6.70 b  
6 
 
121.7, CH 6.97, dd (7.9, 1.5)  121.0, CH 6.57, dt (7.8, 2.5)  
7 
 
139.1, CH 7.31, d (15.6)  32.0, CH2 





119.0, CH 6.52, d (15.9)  45.7, CH 1.67, m  
9 
 
165.5, C   61.0, CH2 3.34, dd (12.5, 7.0)  
1'  130.5, C   132.3, C   
2'  127.7, CH 7.11 b  113.1, CH 6.68 b  
3' 
 
115.1, CH 6.77, d (8.2)  147.2, C   
4' 
 
157.2, C   144.2, C   
5' 
 
115.1, CH 6.77, d (8.2)  115.0, CH 6.70 b  
6' 
 
127.7, CH 7.11 b  121.0, CH 6.57, dt (7.8, 2.5, 2.5)  
7' 
 
79.5, CH 4.28, dd (7.5, 5.0)  39.1, CH2 





45.3, CH2 3.34, d  33.6, CH 2.04, m  
9' 
 
   15.1, CH3 0.82, d (6.7)   
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a 13C NMR data extracted from HSQC and HMBC spectra, b Overlapping signals.
1'' 
 
63.3, CH2 3.31, q (7.0)     
2'' 
 
15.1, CH3 1.10, t (6.9)     
3-OMe 
 
55.7, CH3 3.81, s  55.4, CH3 3.73, s  
3'-OMe 
 
   55.4, CH3 3.73, s  
NH 
 
 7.86, t (5.5)     






C NMR Spectroscopic Data for Compounds 11-13 (DMSO-d6; 600.18 Hz 
for 
1
H and 150.92 for 
13
C NMR; δ in ppm)  
  11  12  13 
Position  δC
a
 δH (mult J in Hz)  δC
a
 δH (mult J in Hz)  δC
a
 δH (mult J in Hz) 
1  37.2, CH2 
1.78 b 
0.96 b 
 37.2, CH2 
1.78 b 
0.96 b 
 37.1, CH2 
1.76 b 
0.96 b 
2  29.4, CH2 
1.77 b 
1.44 b 
 29.4, CH2 
1.77 b 
1.44 b 









2.39, br d (11.4) 
2.15, dd (11.4, 11.4) 
 38.1, CH2 
2.39, br d (11.4) 
2.15, dd (11.4, 11.4) 





140.7, C   140.7, C   140.6, C  
6 
 






 31.9, CH2 
1.91 b 
1.49 b 





31.4, CH 1.54 b  31.4, CH 1.54 b  31.3, CH 1.53 b 
9 
 
50.0, CH 0.88 b  50.0, CH 0.88 b  50.0, CH 0.87 b 
10 
 






 20.8, CH2 
1.47 b 
1.38 b 








 39.5, CH2 
1.67 b 
1.12 b 





40.2, C   40.2, C   39.8, C  
14 
 






 31.8, CH2 
1.88 b 
1.17 b 





80.7, CH 4.27 b  80.7, CH 4.27 b  80.5, CH 4.26 b 
17 
 
62.0, CH 1.65 b  62.0, CH 1.65 b  61.8, CH 1.64 b 
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a 13




 broad signal due to concentrated sample.  
18 
 




19.4, CH3 0.94, s  19.4, CH3 0.94, s  19.2, CH3 0.93, s 
20 
 
42.0, CH 1.75 b  42.0, CH 1.75 b  41.4, CH 1.78 b 
21 
 










 25.9, CH2 
1.80 b 
1.26 b 








 25.8, CH2 
1.87 b 
1.33 b 









3.78, br d (10.0) 
3.21 b 
 64.7, CH2 
3.78, br d (10.0) 
3.21 b 









98.4, CH 4.43, d (7.5)  98.4, CH 4.43, d (7.5)  98.4, CH 4.41 b 
2- Glc1 
 
76.4, CH 3.22 b  76.4, CH 3.22 b  76.0, CH 3.23 b 
3- Glc1 
 
76.4, CH 3.50 b  76.4, CH 3.50 b  76.3, CH 3.51 b 
4- Glc1 
 
81.1, CH 3.32 b  81.1, CH 3.32 b  81.0, CH 3.34 b 
5- Glc1 
 






 60.5, CH2 
3.69 b 
3.58 b 
 60.5, CH2 
3.70 b 
3.59 b 
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Table S4. (continued) 
 
 




a δH (mult J in Hz)  δC
a δH (mult J in Hz)  δC
a δH (mult J in Hz) 
1- Rha1 
 
100.4, CH 5.04, br s  100.4, CH 5.04, br s    
2- Rha1 
 
70.8, CH 3.63 b  70.8, CH 3.63 b  70.7, CH 3.64 b 
3- Rha1 
 
71.0, CH 3.40 b  71.0, CH 3.40 b  70.9, CH 3.40 b 
4- Rha1 
 
72.3, CH 3.18 b  72.3, CH 3.18 b  72.2, CH 3.19 b 
5- Rha1 
 




 b  18.2, CH3 1.07




103.0, CH 4.34, d (7.5)  103.2, CH 4.28 b  102.9, CH 4.34 b 
2- Glc2 
 
73.1, CH 3.18 b  74.4, CH 3.09 b  72.9, CH 3.20 b 
3- Glc2 
 
86.4, CH 3.40 b  81.3, CH 3.38 b  86.2, CH 3.41 b 
4- Glc2 
 
68.4, CH 3.16 b  68.7, CH 3.11 b  68.3, CH 3.16 b 
5- Glc2 
 






 61.1, CH2 
3.66 b 
3.42 b 





105.0, CH 4.38, d (7.1)  - -  104.7, CH 4.38 b 
2- Xyl 
 
74.1, CH 3.05 b  - -  73.9, CH 3.06 b 
3- Xyl 
 
76.6, CH 3.13 b  - -  76.1, CH 3.14 b 
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- -  101.0, CH 5.01, br s    
2- Rha2 
 
- -  70.9, CH 3.69 b    
3- Rha2 
 
- -  70.9, CH 3.47 b    
4- Rha2 
 
- -  72.4, CH 3.17 b    
5- Rha2 
 
- -  68.5, CH 3.87, m    
6- Rha2 
 
- -  18.2, CH3  1.07
 b    
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Eumycetoma is a chronic, debilitating, inflammatory fungal infection caused mainly by 
Madurella mycetomatis and recently enlisted by the WHO among the neglected tropical 
diseases (NTDs). Current therapies include long-term treatment with itraconazole and 
surgical intervention in most of the cases. Given the limited efficacy, frequent side 
effects, and unaffordable price of treatment, there is an urgent need for new 
antimycetomal drugs. The chloroform and the water fractions of the ethanolic extract of 
Haplophyllum tuberculatum roots (Forssk.) A. Juss. (Rutaceae) were selected from a 
subset of extracts from a repository of Sudanese medicinal plants traditionally used as 
anti-infectives.  Isolated compounds 1-13, obtained by HPLC-activity profiling, were 
screened for in vitro activity against M. mycetomatis employing a resazurin-based 
viability assay. Additional natural compounds isolated from other plant species, and 
which had been reported for their antifungal and anti-infective activities, were also 
screened for their antimycetomal activity. Of these compounds; eudesmane 
sesquiterpenes from Verbesina lanata B. L. Rob. & Greenm. (Asteraceae) (14-27), the 
neolignans honokiol (28) and magnolol (29), as well as the diterpenes serratol (30), and 
1S,3E,7R,8R,11E-7,8-epoxy-cembra-3,11-dien-1-ol (31), isolated from Boswellia serrata 
(Burseraceae). The MICs against one or more M. mycetomatis strains, along with the 
cytotoxicity against L-6 rat skeletal cells, were determined. The eudesmane 
sesquiterpenes (14, 15, and 22) possessed MIC values within a range of 20 to 40 µM. Of 
them, 6β-Cinnamoyloxy-1β,2α-dihydroxyeudesm-4(15)-ene (22) exhibited the highest 
antifungal activity (MIC of 20.8 µM), and selectivity (SI 1.3) against M. mycetomatis. The 
lignans, honokiol (28) and magnolol (29), showed similar activity profiles against the SO1 
strain (MIC value 30.1 µM). However, magnolol exhibited 2-fold higher selectivity 
indices compared to honokiol. Moreover, magnolol (29) possessed the highest activity 
(MIC 15 µM) and selectivity (SI 4.9) against the CBS131320 strain among all tested 
compounds. 
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5.2  Introduction 
 
Mycetoma is a chronic, progressively destructive, morbid inflammatory disease acquired 
by traumatic inoculation of certain fungi (Eumycetoma) or ‎bacteria (Actinomycetoma) 
into the subcutaneous tissue [1]. Usually the foot is the most affected part but any part 
of the body can be involved [2]. It is one of the most neglected diseases at all levels and 
was recently included in the WHO list of neglected tropical diseases (NTDs) [3]. The 
disease is geographically distributed through what is called “the Mycetoma belt”, which 
includes India, Yemen, Somalia, Sudan, Senegal, Mexico, Venezuela, Colombia, and 
Argentina [4]. Sudan is among the most affected countries with more than 6000 cases, 
of which 64% are under the age of 30 [5]. The bacterial type of mycetoma, 
actinomycetoma, is readily cured by antibiotic combination therapy [6]. In contrast, 
management of the fungal type (Eumycetoma), which accounts for 70% of the cases in 
Sudan [5], is much more challenging. Treatment usually involves surgical excision 
combined with prolonged antifungal therapy, which has limited efficacy, toxic adverse 
effects, is expensive, and has high percentage of treatment failures [7]. Late chronic 
stages of the disease result in destruction, deformity, loss of function, and may often 
lead to amputation. Hence, there is a dire need to find new therapeutic agents for 
eumycetoma that are efficient, affordable, safe, and reduce the treatment period and 
surgical interventions [8]. 
Fungi are important plant pathogens. Many natural products derived from plant 
secondary metabolites with a wide variety of scaffolds, namely alkaloids, terpenoids, 
saponins, and phenolic compounds have antifungal activity and could serve as potential 
hits also against human pathogenic fungi [9,10]. However, very limited reports [11-14] 
are available on the antimycetomal activity of natural products. 
In an ongoing search for promising hits against eumycetoma, several Sudanese 
medicinal plant extracts were screened for their in vitro activity against Madurella 
mycetomatis using the resazurin viability assay [15]. Of these extracts, the chloroform 
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and the water fractions of the ethanolic extract of Haplophyllum tuberculatum roots 
(Forssk.) A. Juss. (Rutaceae) revealed inhibitory activity towards eumycetoma (MIC 
˃80% at 10 µg/mL). Compounds isolated from these fractions by HPLC- activity profiling 
approach were screened for their antimycetomal activity. 
Moreover, we persued an “educated-guess” approach to find additional antimycetomal 
hits of natural origin. A set of natural compounds of different classes, belonging to 
different plant species, that have been previously reported for their antifungal and anti-
infective activities were also screened for their activity against M. mycetomatis. 
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5.3 Results and Discussion 
 
In a screening of Sudanese medicinal plant extracts for antimycetomal activity, the 
ethanolic extract of Haplophyllum tuberculatum roots (Forssk.) A. Juss. (Rutaceae), was 
found active (MIC ˃80% at 10 µg/mL).  HPLC-based activity profiling allocated the 
activity to the chloroform and the water fractions. Combination of preparative and 
semi-preparative chromatography yielded compounds 1-10 from the chloroform 
fraction (Figure 1). The water fraction yielded subfractions J (containing a mixture of 
compounds 11 and 12) and subfraction K (containing a mixture of compounds 11 and 













Figure 1. Structures of compounds 1-10 from Haplophyllum tuberculatum. 













Figure 2. Structures of saponins 11-13 from Haplophyllum tuberculatum. 
These compounds were screened in a 96-well microtitre plates for in vitro activity 
against M. mycetomatis employing resazurin viability assay [15] (Table 1).  The Minimal 
inhibitory concentration (MIC) was defined as the lowest concentration of the 
compound that exhibited ≥ 80% growth inhibition. The MICs against one or more of M. 
mycetomatis strains, along with the cytotoxicity against L-6 rat skeletal cells, were 
determined.  
The compounds isolated from Haplophyllum tuberculatum 1-10 as well as the J and K 
fractions (mixtures of compounds 11-13), were found inactive below 100 µM (MIC ˃256 
µg/mL for fractions J and K) against CBS131320. Therefore, an educated-guess approach 
for further selection of natural products was followed.  
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Table 1: In vitro minimal inhibitory concentrations (MIC80) and selectivity (SI) of Compounds 
1−10, isolated from the chloroform and water fractions of the ethanolic extracts of the roots of 
Haplophyllum tuberculatum against Madurella mycetomatis (CBS131320 strain) and Cytotoxicity 
in L6 Cells. 
a 
The MICs are mean values from at least two independent replicates. 
b 





n.d: Not determined 
 
A set of natural compounds of different chemical classes and obtained from different 
plant species, and that had been reported for their antifungal and anti-infective 
activities, were screened for their activity against M. mycetomatis. Of these compounds 
(Figure 3); eudesmane sesquiterpenes from Verbesina lanata B. L. Rob. & Greenm. 
(Asteraceae) (14-27) [17], the neolignans honokiol (28) and magnolol (29), as well as the 
diterpenes serratol (30), and 1S,3E,7R,8R,11E-7,8-epoxy-cembra-3,11-dien-1-ol (31), 
previously isolated from Boswellia serrata (Burseraceae) [18]. The antimycetomal 
activity displayed by these compounds was followed up by testing against an additional 
M. mycetomatis strain (SO1) (Table 2). The eudesmane sesquiterpenes from V. lanata 
(14, 15, and 22) possessed MIC values within a range of 20 to 40 µM. Compound 22 
exhibited the highest antifungal activity (MIC of 20.8 µM), and selectivity (SI 1.3) against 
the two tested strains of M. mycetomatis, consistently. Copmound 21 was inactive. 
Since compounds 22 and 21 are positional isomers, this indicates that isomerism has 
Compound Name M. mycetomatis (CBS131320) L6 cells 
No.  MICa  (µM) SI b  
1 Tetrahydrofuroguaiacin B 743.3 0.1 95.2 ± 9.3 
2 Nectandrin B 1486.6 0.1 115.0 ± 2.6 
3 Fragransin B2 1266.7 0.1 170.5 ± 40.1 
4 Fragransin B1 1266.7 0.1 138.9 ± 3.8 
5 Dihydroferuloyltyramine 158.7 n.d ˃317.5 
6 feruloyltyramine 319.5 0.8 246.8 ± 3.7 
7 furoguaiaoxidin 280.9 n.d ˃280.9 
8 diferuloylputrescine 227.3 0.6 146.5 ± 18.8 




289.0 0.4 127.6 ± 3.9 
Positive control  0.4 c  0.03 d 
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considerable impact on both the activity and selectivity of these compounds. Compound 
14 showed consistent activity and selectivity against the two strains (MIC 20.7 µM, SI 
1.5). The vast majority of the eudesmane sesquiterpenes showed low selectivity indices 
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Table 2: In vitro minimal inhibitory concentrations (MIC) and selectivity (SI) of compounds 14−31 
against different strains of M. Mycetomatis. 
  MIC (µM) 
NO. Compound CBS131320  SO1 
L6 
Cytotox  












































20.8 (1.3) 20.8 (1.3) 27.7 























28 Honokiol 30.0 (1.3) 30.0 (1.3) 38.5 
29 Magnolol 15.0 (4.9) 30.0 (2.4) 73.3 
















The MICs are mean values from at least two independent replicates. 
b 
Selectivity index (SI): IC50 in L6 cells divided by MIC in the titled parasitic strain, given in parentheses. 
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Eudesmane sesquiterpenes had been isolated from other plants, mostly Asteraceae, and 
have shown activity against different fungal species [19,20]. However, this is the first 
report on their antimycetomal activity.  
The lignans honokiol (28) and magnolol (29) showed similar activity profiles against SO1 
with MIC 30 µM. However, magnolol exhibited a 2-fold higher selectivity index 
compared to honokiol. Moreover, magnolol (29) possessed the highest activity (MIC 15 
µM) and selectivity (SI 4.9) against the CBS131320 strain among all tested compounds.  
Honokiol (28) and magnolol (29), previously isolated from Magnolia obovata, have been 
reported for their activity against various human pathogenic fungi [21]. Honkiol has 
been reported to increase the antioxidant enzymatic activity of Candida albicans by 
inducing reactive oxygen species-mediated apoptosis through mitochondrial 
dysfunction [22]. This is the first report on the activity of the aforementioned 
compounds against M. mycetomatis. 
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4.4 Materials and Methods 
 
Preparation of plant extracts  
Dried plant material of Haplphyllum tuberculatum was milled to coarse powder in a 
hammer mill. 100-500 g of powdered material was extracted for 4 h with 500 ml of 70% 
ethanol in water bath. Extracts were filtered through Whatman no. 1 filter paper and 
concentrated by solvent removal in a rotary vacuum evaporator. The crude extract were 
was suspended in water and partitioned consecutively with petroleum ether, 
chloroform, ethyl acetate, and n-butanol. Crude extract and the respective fractions 
were allowed to dry at room temperature, weighed, and reconstituted in DMSO (10 
mg/mL) to serve as stock solutions for antiparasitic testing. 
HPLC- analyses and Microfractionation  
HPLC analyses were performed on a Shimadzu HPLC system equipped with photo diode 
array detector (PDA) (SPD-M20A, Shimadzu), evaporative light scattering detector 
(ELSD) (3300, Alltech), and an electrospray ionisation mass spectrometer (ESIMS) (LCMS-
8030, Shimadzu). LabSolutions software was used for data acquisition and processing. 
The separation was performed on a C18 SunFire column (3.0 × 150 mm; 3.5 μm; 
Waters).  
Microfractionation was carried out by analytical RP-HPLC on the same instrument (LC-
MS 8030 system, Shimadzu), connected with an FC204 fraction collector (Gilson). For 
each fraction, a solution of 10 mg/mL was prepared in DMSO. A total of three injections 
were performed: 2 × 35 μL with only UV detection (254 nm) for collection (0.7 mg of 
fraction in total) and 1 × 35 μL with UV-ELSD-ESIMS detection without collection. 
The mobile phase consisted of water with 0.1% formic acid (A) and acetonitrile with 
0.1% formic acid (B). The gradient was 5% to 100% B in 30 min, followed by washing 
with 100% B for 10 min. The flow rate was 0.4 ml/min. Fractions of 1 min each were 
collected from minute 1 to minute 40, resulting in 40 microfractions in total. 
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Microfractions of two successive injections of sample were collected into the 
corresponding wells of a 96-deepwell plate. Plates were then dried in a Genevac EZ-2 
evaporator prior testing [23,24]. 
Exrtaction and isolation of compounds  
Extraction, isolation and structure elucidation of the compounds 1-13 from the 
chloroform and water fractions of the ethanolic extract of Haplophyllum tuberculatum 
roots (Forsskal) A. Juss. (Rutaceae) was achieved by HPLC- based activity profiling 
approach. Detailed preprative and semipreparative procedures, along with NMR data 
were as previously described [16]. 
The eudesmane sesquiterpenes 14-27 were isolated as described in a previous project 
of Verbesina lanata B. L. Rob. & Greenm. (Asteraceae) for their inhibitory activity against 
grapevine downy mildew caused by Plasmopara viticola (Berk. & M. A. Curtis) Berl. & de 
Toni [17].  
The lignans, honokiol (28) and magnolol (29), were purchased from Sigma-Aldrich. 
Serratol (30) and 1S,3E,7R,8R,11E-7,8-epoxy-cembra-3,11-dien-1-ol (31) has been 
previously isolated from Boswellia serrata (Burseraceae) [18]. 
In vitro susceptibility assay against Madurella Mycetomatis 
Clinical isolates of M. mycetomatis strains (CBS131320 and SO1) from different 
geographical origins identified to the species level by sequencing the rRNA ITS region 
were used for susceptibility assays. Each strain was independently inoculated in RPMI 
1640 medium supplemented with 0.35 g/L L-glutamine and 1.98 mM 4-
morpholinepropane sulfonic acid. The mixture was sonicated for 10 sec at 28 um 
(QSONICA Q55), and incubated for 7 days at 37°C. The mycelia were harvested by 
another sonication step and 5-min centrifugation (Andres Hettich GMBH, EBA20). The 
pellets were washed and resuspended in fresh RPMI 1640 medium to obtain a fungal 
suspension of 68-72% transmission range (JENWAY 6305 UV/Vis Spectrophotometer). A 
1:2 serial drug dilution covering a range from 256 to 0.063 μg/mL was prepared. 100 µL 
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of adjusted fungal suspension was added to each well of a 96-well microtiter plate. 20 
µL resazurin solution (at final concentration of 0.15 mg/mL) was then added to each 
well. The plates were incubated for 7 days at 37°C and afterwards, plates were 
inspected for visual and spectrometrical endpoints. Absorbance was measured at 570 
nm using a microplate reader (Themo Scientific Multiskan Spectrum, Thermo Fisher 
Scientific, Finland). The minimal inhibitory concentration (MIC) was defined as the 
lowest concentration of the compound with ≥ 80% growth inhibition. Itraconazole was 
used as control. Assays were performed in two independent replicates at least [15]. 
 
In vitro cytotoxicity with L-6 cells 
 Assays were performed in 96-well microtiter plates, each well containing 100 L of 
RPMI 1640 medium supplemented with 1% L-glutamine (200 mM) and 10% fetal bovine 
serum, and 4000 L-6 cells (a primary cell line derived from rat skeletal myoblasts) [25]. 
Serial drug dilutions of eleven 3-fold dilution steps covering a range from 100 to 0.002 
μg/mL were prepared. The plates were incubated for 70 h and inspected under an 
inverted microscope to assure growth of the controls and sterile conditions. 10 L of 
resazurin was then added to each well and the plates incubated for another 2 hours. 
Then the plates were read with a Spectramax Gemini XS microplate fluorometer 
(Molecular Devices Cooperation, Sunnyvale, CA, USA) using an excitation wavelength of 
536 nm and an emission wavelength of 588 nm. The IC50 values were calculated by 
linear regression and 4-parameter logistic regression from the sigmoidal dose-inhibition 
curves using SoftmaxPro (Molecular Devices Cooperation, Sunnyvale, CA, USA). 
Podophyllotoxin (Sigma P4405) was used as control. Assays were performed in two 
independent replicates at least. 
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I have performed compounds preliminary antimycetomal activity testing. Compounds 
were selected by Marcel Kaiser. Shereen Abd Algaffar performed further confirmative 
tests and the testing for the salicylanilides. 
 
  




Redox-active prodrugs are the mainstay of parasite chemotherapy. To assess their 
repurposing potential for eumycetoma, we have tested a set of nitroheterocycles and 
peroxides against Madurella mycetomatis. All the compounds were inactive except for 
niclosamide. The analog MMV665807 and niclosamide ethanolamine were active as 
well. The three compounds also exhibited good activity against Actinomadura spp., 
causative agents of actinomycetoma. We therefore propose to further evaluate 
salicylanilides, in particular niclosamide, as repurposing candidates for mycetoma. 
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Madurella mycetomatis, Actinomadura, Mycetoma, Drug repurposing, 
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Eumycetoma is endemic from India over the Middle East and across the Sahel, with the 
highest prevalence in Sudan [1,2] . It is a chronic subcutaneous mycosis that slowly 
spreads, starting from an initial lesion at the site of inoculation, into the skin and deeper 
tissues, ultimately destroying muscles, tendons, and bones. The leg and foot are most 
often affected, likely due to inoculation via thorn pricks. While eumycetoma can be 
caused by various fungi [3], the majority of cases in Sudan are due to Madurella 
mycetomatis [2]. Eumycetoma is a debilitating, disfiguring, and stigmatizing disease. It is 
also an enigmatic disease in the light of the many open questions regarding its 
epidemiology, pathogenesis, and the biology of the causative agents [2,4]. 
There is no satisfactory treatment for eumycetoma. The current therapy consists of a 
combination of surgery and long-term chemotherapy with antifungal azoles such as 
itraconazole [2]. However, the cure rates are low and amputation of the affected limb 
may be the only measure to stop the flesh-eating fungus [5]. Given the urgent need for 
better drugs and the fact that eumycetoma is a neglected disease affecting neglected 
patients, drug repurposing suggests itself as a fast and cost-effective way towards new 
antimycetomal agents [6,7]. Here we pursue this strategy by testing a small set of redox-
active parasiticides and antibiotics for their in vitro activity against M. mycetomatis. 
Redox-active molecules are the mainstay of current parasite chemotherapy [8, 9]. Since 
saprophytic fungi can dwell in hypoxic environments and may possess reducing agents 
of low redox potential, we speculated that Madurella, too, might be susceptible to 
prodrugs that are activated by electron transfer. A selection of nitroheterocycles and 
peroxides was evaluated for their in vitro activity against two isolates of M. 
mycetomatis, SO1 and CBS131320 (mycetoma collection of the Erasmus Medical Centre, 
Rotterdam, the Netherlands). The mycelia were grown at 37 °C in RPMI 1640 medium 
supplemented with 0.35 g/L L-glutamine and 1.98 mM 4-morpholinepropane sulfonic 
acid in 96-well microtiter plates in serial dilution of test compounds; resazurin was 
added (0.15 mg/mL) for spectrometric read-out (absorbance at 570 nm) [10]. The 
minimal inhibitory concentration (MIC) was defined as the lowest concentration of test 
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compound that, after 7 days of incubation, had inhibited the growth by at least 80% 
compared to untreated cultures. 
The tested peroxides were inactive, which is in agreement with the reported lack of 
activity of artemisinin [11]. The nitroimidazoles and nitrofurans were all inactive as well. 
The one notable exception was niclosamide, which had a MIC around 1 µg/ml (Table 1). 
This interesting finding was followed up by testing niclosamide and two related 
compounds also against Actinomadura spp., causative agents of actinomycetoma. A. 
madurae SAK-A05 and A. syzygii SAK-A08 were originally isolated from Sudanese 
patients and cultured in the pharmaceutical research laboratory, University of Science 
and Technology repository (Omdurman, Sudan). The bacteria were grown for 5 days at 
35 °C in Mueller Hinton II broth (CAMHB) medium in 96-well microtiter plates with serial 
dilution of test compounds and 0.15 mg/mL resazurin. 
Niclosamide, niclosamide ethanolamine, and MMV665807 exhibited good activity 
against Madurella as well as Actinomadura, with MIC values somewhat higher than the 
reference drug itraconazole for M. mycetomatis and considerably lower than the 
reference drug cotrimoxazole for Actinomadura (Table 2). MMV665807 is a salicylanilide 
from the Medicines for Malaria Venture's malaria box [12] that has shown antibacterial 
[13], antiprotozoal [14,15], and anticestodal [16,17] activity. Niclosamide ethanolamine 
(NEN, also called niclosamide olamine or clonitralide) has a better water-solubility and 
bioavailability than niclosamide [18,19], and it is being considered for different 
(re)purposes [20-24]. 
Niclosamide itself is an old drug of many uses [25,26]. It was developed by Bayer in the 
1950s as a molluscicide for schistosomiasis control. Since 1982, when it was approved 
by the FDA for human use, its primary indication has been as a broad-spectrum 
anthelmintic for tapeworms (Taenia spp., Diphyllobothrium latum) and intestinal fluke 
(Fasciolopsis buski) [27]. Niclosamide was shown to have promising antibacterial [28,29]  
as well as antifungal [30] activity. What restricted its use to intestinal pathogens was the 
poor oral bioavailability, i.e. the fact that niclosamide is not significantly absorbed from 
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the gastrointestinal tract [19,31] . Different carriers or formulations have been 
employed to overcome this issue; see e.g. [32-34]. 
In conclusion, we have found a promising hit even though our hypothesis that the 
metabolism of the fungus would activate redox-active prodrugs turned out to be wrong. 
Given the lack of activity of the tested nitrofurans and nitroimidazoles, the observed 
activity of niclosamide is likely not due to its nitro group but due to the salicylanilide 
moiety. This is supported by the good activity of MMV665807 a salicylanilide that lacks a 
nitro group (Figure 1). The finding that a drug like niclosamide, which is on the WHO's 
list of Essential Medicines, exhibits in vitro activity against both Madurella mycetomatis 
and Actinomadura spp. warrants the testing of further salicylanilides against these 
pathogens and the consideration of niclosamide or its ethanolamine salt as repurposing 
candidates for mycetoma.  
Chapter 6: In vitro activity of niclosamide against causative agents of mycetoma 
175 
 
Table 1. Selected redox-active agents and their in vitro activity against the two M. mycetomatis 
isolates SO1 and CBS131320. For the experimental compounds Ro 15-6547 [35], RJ-55, RJ-164 
[36], and OZ78 [37,38], the envisaged indication is in parentheses (HAT, human African 
trypanosomiasis). All assays were performed in at least two independent replicates. 
 
Compound Class Primary indication MIC [µg/ml] 
   SO1  CBS131320 
Niclosamide Salicylanilide Tapeworms 0.78 1.6  
Secnidazole Nitroimidazole Bacterial vaginosis >256 >256 
Metronidazole Nitroimidazole Broad spectrum antimicrobial >256 >256 
Fexinidazole Nitroimidazole HAT >256 >256 
RJ-164 Nitroimidazole (HAT) >256 >256 
RJ-55 Nitroimidazole (HAT) >256 >256 
Ro 15-6547 Nitroimidazole (HAT) >256 >256 
Nifurtimox Nitrofuran Chagas' disease, HAT >256 >256 
Nifuroxazide Nitrofuran Colitis and diarrhea >256 >256 
Nitrofurantoine Nitrofuran Urinary tract infections >256 >256 
OZ 78 Peroxide (Malaria, trematodes) >256 >256 
Artemisinin Peroxide Malaria 16 16 
Dihydroartemisinin Peroxide Malaria >256 >256 
Artesunate Peroxide Malaria >256 >256 
Artemether Peroxide Malaria 64 64 
Itraconazole Triazole Antifungal 0.13 0.25 
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Table 2. Niclosamide and related compounds tested against two M. mycetomatis isolates (SO1 
and CBS131320) and two Actinomadura species, A. madurae (SAK-A05) and A. syzygii (SAK-A08); 
EN, ethanolamine. All assays were performed in at least two independent replicates. 
 
 MIC [µg/ml]  
 SO1 CBS131320 SAK-A05 SAK-A08 
Niclosamide 0.78 1.6 0.39 0.39 
Niclosamide-EN 0.78 1.6 0.19 0.39 
MMV665807 1.6 1. 6 0.39 0.39 
Itraconazole  0.13 0.25 n.d. n.d. 
Cotrimoxazole n.d. n.d. 20 10 
  















Figure 1. Chemical structures of niclosamide and MMV665807. 
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7.1 Overview of the research outcomes 
Tropical plants of the arid zones are a treasure chest for the discovery of bioactive 
secondary metabolites. Sudan has a highly diverse flora, coupled with a very rich 
ethnomedical heritage that remains a promising untapped reservoir for the discovery of 
diverse bioactive natural products (NPs). Subjecting Sudanese medical practice to the 
currently available modern scientific tools can be considered as the first step in the 
direction to validate its scientific merits. In this study, we compiled a review of plants 
that are used in Sudanese traditional medicine, with a focus on malaria and neglected 
tropical diseases caused by protozoa. On the basis of this survey, a total of 62 plant 
species belonging to 35 different families were assembled. The plant materials were 
extracted in 70% ethanol and further fractionated consecutively by liquid-liquid 
partitioning using solvents of increasing polarity. This resulted in a library of 235 
fractions. Phenotypic screening was pursued. The library was tested in vitro against 
panel of protozoan parasites: Plasmodium falciparum (proliferative erythrocytic stages), 
Trypanosoma brucei rhodesiense (bloodstream forms), Trypanosoma cruzi (intracellular 
amastigotes), and Leishmania donovani (axenic amastigotes). Extracts with antiparasitic 
activity were also tested for cytotoxicity. This was done against rat L6 skeletal myoblast 
cells. The most susceptible parasite was P. falciparum, followed by T. b. rhodesiense, L. 
donovani; the least susceptible was T. cruzi (Chapter 2). 
A dereplication approach was performed for active extracts to enable prioritization for 
follow-up selection. This was achieved by HPLC activity profiling in combination with on-
line spectroscopy, which enabled a rapid identification of known active compounds, i.e. 
guieranone A from Guiera senegalensis J.F.Gmel., pseudosemiglabrin from Tephrosia 
apollinea (Delile) DC, in addition to other ubiquitous plant secondary metabolites. Plants 
that displayed interesting activities, namely Croton gratissimus, Cuscuta hyalina, and 
Haplophyllum tuberculatum were further pursued for a follow-up HPLC-activity profiling. 
Preparative isolation of active compounds to perform structure elucidation and in vitro 
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testing was achieved. Nine compounds were isolated from the chloroform fraction of 
the ethanolic extract of Croton gratissimus (Chapter 3). Of these, six flavonoids were 
identified as quercetin-3,3’,4’-trimethylether (1), ayanin (2), retusin (3), naringenin (4), 
quercetin-3,4’-dimethyl ether (5), quercetin-3,7-dimethylether (6) , along with 3-
methoxy-4-hydroxybehzoic acid (7), and two benzyltetrahydroisoquinoline alkaloids; 
laudanine (8) and laudanosine (9). All of them are being described for the first time from 
C. gratissimus. Quercetin-3,7-dimethylether (6) was the most active against the 
trypanosomatids (50% inhibitory concentration (IC50) ˂5 µM; selectivity index (SI) ˃10) 
followed by ayanin (2). The antiprotozoal activities of (2) and (6) are being described for 
the first time. The structure-activity relationships (SAR) among the bioactive compounds 
were discussed in relation to the three parasites. The chloroform fraction of the 
ethanolic extract of Cuscuta hyalina yielded four secondary metabolites, including the 
furofuran lignan, pinoresinol (10), and the flavonoids, isorhamnetin (11), (-)-
pseudosemiglabrin (12), and kaempferol (13). Pseudosemiglabrin (12) is being described 
for the first time from Cuscuta species (Chapter 3).  
In addition, the chloroform and water fractions of Haplophyllum tuberculatum were 
investigated (Chapter 4). In total, 13 compounds were identified. HPLC-based activity 
profiling led to the isolation of eight compounds from the chloroform fraction, including 
four lignans; tetrahydrofuroguaiacin B (1), nectandrin B (2), furoguaiaoxidin (7) and 3,3′-
dimethoxy-4,4′-dihydroxylignan-9-ol (10), in addition to four cinnamoylphenethyl 
amides; dihydro-feruloyltyramine (5), N-trans-feruloyltyramine (6), N,N′-
diferuloylputrescine (8), and (E)-7′-ethoxy-feruloyltyramine (9). The water fraction 




-(1→2)]-β-ᴅ-glucopyranoside (12), and (3S,20S,22R,25R)-spirost-5-en-3-yl-(β-ᴅ-
xylopyranosyl-(1→3)-β-ᴅ-glucopyranosyl-(1→4)[α-ʟ-rhamnopyranosyl-(1→2)]-β-ᴅ-
glucopyranoside (13). The isolation of compounds 1, 2, and 5-13 is being reported for 
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the first time from Haplophyllum species and the family Rutaceae. Nectandrin B (2) 
exhibited the highest activity against L. donovani (IC50 4.5 µM) with a promising 
selectivity index (SI) of 25.5. The lignan 3,3′-dimethoxy-4,4′-dihydroxylignan-9-ol (10) 
was the most active against P. falciparum (IC50 9.3 µM; SI 13.7), while the steroidal 
saponins were the least selective. 
Regarding the fungal disease mycetoma, two drug discovery approaches were tackled: a 
natural products approach and a drug repurposing (repositioning) approach. For the 
natural products (Chapter 5), Haplophyllum tuberculatum was found active during 
preliminary screening, hence the previously isolated compounds were screened for their 
in vitro antimycetomal activity. However, the compounds were not active. Therefore, 
we proposed the educated guess strategy. Pure natural compounds of different classes 
from different plant species, that had been previously reported for their antifungal and 
anti-infective activities, were screened for their in vitro activity against Madurella 
mycetomatis, the main causative agent of fungal mycetoma. These compounds were 
eudesmane sesquiterpenes from Verbesina lanata B. L. Rob. & Greenm. (Asteraceae) 
(14-27), the neolignans honokiol (28) and magnolol (29), in addition to the diterpenes 
serratol (30), and 1S,3E,7R,8R,11E-7,8-epoxy-cembra-3,11-dien-1-ol (31), previously 
isolated from Boswellia serrata (Burseraceae). The Minimal inhibitory concentration 
(MIC) was set as the lowest concentration of antifungal activity producing ≥ 80% growth 
inhibition. The MICs against one or more of M. mycetomatis strains, along with the 
cytotoxicity against L-6 rat skeletal cells, were determined. The eudesmane 
sesquiterpenes (14, 15, and 22), isolated from V. lanata has possessed MIC80 values 
within a range of 20 to 40 µM. Of them, 6β-Cinnamoyloxy-1β,2α-dihydroxyeudesm-
4(15)-ene (22) exhibited the highest activity (MIC of 20.8 µM), and selectivity (SI 1.3) 
across the three tested strains of M. mycetomatis. The lignans, honokiol (28) and 
magnolol (29), showed similar activity profiles against SO1 strain with MIC (30.1 µM). 
However, magnolol exhibited 2-fold higher selectivity indices compared to honokiol 
against the aforementioned strains. Moreover, magnolol (29) possessed the highest 
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activity (MIC 15 µM) and selectivity (SI 4.9) against CBS131320 strain among all tested 
compounds. 
Since the natural products approach did not yield very promising candidates, we 
pursued a repurposing approach for eumycetoma in parallel. A series of nitroimidazole 
compounds were screened in vitro against M. mycetomatis. From this screening, 
niclosamide showed interesting activity at ˂5 µM.  Furthermore, additional niclosamide 
analogues were tested for the proof of concept. The tested compounds showed similar 
activity against both fungal and bacterial mycetoma compared to niclosamide.    
Overall, it can be concluded that, this assessment provides a comprehensive overview of 
Sudanese medicinal plants and supports the notion that they are a potential source of 
bioactive molecules against parasitic infections. Moreover, it also emphasizes the 
potentialities of the repurposing approach for the fungal disease eumycetoma. In the 
following, I shall briefly discuss the approaches and methodology used in this research 
and highlight provisions of improvements in the context of this work.  
7.2 Why phenotypic screening?  
The advent of modern molecular biology methods and the knowledge of the human 
genome have dramatically changed the drug discovery strategy in the pharmaceutical 
industry into a hypothesis-driven target-based approach [1]. Yet the contribution of the 
classical phenotypic approach remains of great value for drug discovery, in particular for 
diseases of poverty.  This arises from the fact that it does not require a prior knowledge 
of validated molecular target or specific mechanism of action, which is the case for most 
of the antiparasitic drugs that are available today [2,3]. For many years, drug discovery 
has been driven by chemocentric approaches, i.e., approaches based on a specific 
compound or compound class which served as starting point for further optimization. 
These chemotypes were either discovered through ethnobotanical knowledge or 
derived from natural ligands and substances. The unique case of the discovery of the 
antimalarial quinine represented a milestone in the history of drug discovery where the 
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drug (quinine) was discovered before the differentiation and elaboration of the disease 
itself [4]. Furthermore, phenotypic screening has given other non-systematic 
approaches, e.g. serendipity, the consideration of being a source of successful molecules 
of unexpected bioactivity. Well-known examples are the anticancer compounds 
vinblastine and taxol [5]. 
7.3 Why an ethnobotanical approach? 
Ethnomedicine represents one of the primary sources of health care in Africa and many 
developing countries [6]. This widespread use is justified by the limited availability 
and/or accessibility of conventional medicine-based health services. In contrary, 
traditional medicine is being present on the ground and readily affordable. Since 
medicinal plants are the ‘backbone’ of traditional medicine, this reflects the 
considerable utilization of medicinal plants by the vast majority of the population in the 
less developed countries, including Sudan. Through the ethnobotanical knowledge, the 
African continent has made considerable contribution to the field of drug discovery. For 
example, the cardiac glycosides strophanthin and ouabin from the Mozambican seeds 
Strophanthus gratus, and the parasympathomimetic alkaloid, physostigmine, from the 
West African Calabar bean (Physostigma venenosum) [4]. Thus, plants must not be 
ignored also in rational drug development.  
Data analyzed from drug discovery screening campaigns have shown that molecules 
from ethnomedically used plants have a higher hit rate of bioactivity than randomly 
selected molecules [7]. In our antiprotozoal drug discovery screening we have confirmed 
a high hit rate: 125 extracts out of 235 (53%) showed growth inhibitory activity >80% at 
10 μg/ml, and >50% at 2 μg/ml against at least one of the tested protozoan parasites. 
Moreover, regarding the antiplasmodial activity, the plants that were documented as 
antimalarial remedies (n=17) were slightly more active against P. falciparum in vitro 
than the other plants, both at 2 µg/ml (mean inhibition of 43% vs. 39%) and at 10 µg/ml 
(mean inhibition of 89% vs. 75%). However, these differences were not statistically 
significant (p=0.70, two-tailed Mann-Whitney test). 




Unlike the traditional Chinese medicine or Ayurvedic medicine, which involves a high 
degree of authenticated medical practice and well written documented history, the 
African traditional medicine is usually of no formal educational component. In such a 
system, whereby information is passed on from person to person, father to son, guru to 
disciple, the information is considered highly secretive and is not in manuscript format 
[8]. Sudan is not an exception. There is a lack of well documented and scientifically 
sound ethnomedical surveys that could serve as platforms for further phytochemical 
investigations. Thus, qualitative analyses of the local remedies and practices and their 
rationalization (i.e. valorization) is desperately needed. A key factor to achieve this is 
through a multidisciplinary integrative approach that includes traditional plant 
specialists, anthropologists, pharmacologists, medical doctors, and phytochemists. 
Concurrently, issues of accessibility, fair and equitable sharing of the benefits arising 
from the usage of these resources [9] should be adequately addressed. 
Though the aforementioned points are beyond the context of this thesis, yet, in this 
regard, Chapter 2 in this work could set a starting point of a collective approach for 
further in-depth pre-clinical assessment and clinical evaluation of the efficacy and safety 
of Sudanese medicinal plants used as antiparasitics.  
7.5 Extraction procedures 
Extraction is the first step in the drug discovery process from plants. Several general 
procedures like solid-liquid extraction techniques and water maceration and/or 
decoction represent the first choice, since traditional healers commonly use water as 
solvent [10]. Further sequential extraction with liquid-liquid partitioning using solvents 
of increasing polarity, such as petroleum ether, chloroform, and ethyl acetate, are 
necessary for a preliminary separation based on the hydro-/lipophilic properties of the 
biologically active compounds as well as to maximize the chances of discovering new 
bioactive NPs from complex mixtures [11]. Such enrichment procedures may improve 
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biological and chemical profiling screening steps. A vivid example from the preliminary 
screening performed (Chapter 2; Supplementary table 1) is given by Cassia occidentalis 
L. (Leguminosae). The crude ethanolic extract of this plant showed only weak 
antiplasmodial inhibition (˂ 30% at 10 µg/mL). However, the petroleum ether fraction of 
the crude extract showed strong inhibition of the same parasite (91.6% at 10 µg/mL). 
This indicates that the displayed activity is a result of the enrichment procedure for the 
bioactive compounds in the apolar fraction. In addition, the fractionation of extracts 
prior to bioassays can mask potential synergistic or antagonistic effects observed within 
crude extracts. This step also offers an indisputable advantage by increasing the 
constituent concentration in each fraction. It is also common that chemical 
transformation occurs during the extraction procedures leading to artifacts. For 
example, ethyl gallate detected in Acacia nilotica could be possibly formed from gallate 
due to extraction with ethanol. Therefore, this issue should be considered during 
extraction process. Moreover, variations between extraction methods used in 
traditional medicine and those exhaustive ones used for phytochemical investigations 
and their potential effects on the overall quality of extract should not be overlooked. 
7.6 Bioassays and screening procedures 
A number of pivotal quality standards need to be set at the level of primary evaluation 
in bioassay screening models to guarantee sound selection of extracts or molecules with 
relevant pharmacological action and worthy of follow-up. Some special considerations 
to limit the number of leads for follow-up evaluation include a high selectivity, a high 
sensitivity (to detect low concentrations of active compounds) as well as adaptability to 
poorly soluble compounds and chemically complex materials [12]. A review by Cos et al 
has discussed a number of considerations and provided recommendations that enable 
to define a more sound ‘proof-of-concept’ for antiparasitic potential in natural products 
[13]. On the light of this review, the major following points will be addressed: 
I. In vitro models using the whole target organism should be used whenever 
possible. In addition, activity should be discriminated from unspecific cell 
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toxicity, thus compelling the inclusion of a parallel evaluation in host cell lines 
(cytotoxicity evaluation): On this regard, the bioassays performed in this work for 
antiparasitic screening were based on in vitro whole organism. In parallel, 
extracts with interesting activity were pursued further for cytotoxicity testing 
against rat L6 skeletal myoblast cells. Concentration-response curves allowed the 
calculation of both 50% and 90% inhibitory concentrations (IC50 and IC90; Table 3, 
Chapter 2). The cytotoxicity data of the tested fractions cannot directly be 
compared to their antiparasitic activity because the antiparasitic and cytotoxic 
activity of a given fraction can be due to different molecules. Nevertheless, the 
aim was to identify non-toxic fractions for the following HPLC-based activity 
profiling and identification of active compounds.  
II. Use of sensitive endpoint reading techniques: Bioassay interference with natural 
products cannot be excluded in fluorescence and UV/visible read-out assays [14]. 
These include two counteractant phenomena; i) binding to proteins in the 
aqueous media that are predominantly used in bioassays (such as bovine serum 
albumine) or precipitation as major cause for false negatives, and ii) light 
scattering in UV/visible read-out assays, and membrane disruption leading to 
false positives. The latter can be excluded in our case since we have employed 
viability assays with fluorescence read-out for activity determination. However, a 
compound could inhibit reduction of resazurin (false positive hit) or be 
fluorescent itself (false negative). As these noisy effects cannot be omitted at the 
level of extracts, they should be considered at compound level. Assay-interfering 
compounds were designated as pan-assay interference compounds (PAINS) 
[15]. Some of these compounds that had manifold ascribed bioactivities were 
listed by occurrence, activity, and distinct activity, and were labelled 
as invalid metabolic panaceas (IMPs) [16]. Luckily, some of these compounds 
were rapidly dereplicated at the preliminary screening level, as will be discussed 
in more detail in the next section (Section 1.6). 
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III. Determination of optimal criteria for efficacy: the biological activity levels as 
inclusion criteria of extracts or purified compounds should be clearly defined. 
Many articles on natural products claim so-called “exciting” anti-infective 
activities, despite major flaws in the used methodologies [17]; among these is 
the lack of sound criteria for activity. In this regard, activity criteria were set from 
the preliminary screening performed. Extracts that exhibited >80% growth 
inhibition at 10 μg/ml, or >50% growth inhibition at 2 μg/ml, against at least one 
of the tested parasites were considered active. Of the 235 extracts in our library, 
125 (53%) fulfilled these activity criteria. However, concerns regarding 
concentration of crude extracts to be tested and cut-off values for activity 
criteria are still argumentative in regards to validation of herbal medicines [18].  
Therefore, there is a dire need for establishing standard criteria for the 
evaluation of plant extract activities to enable the comparison of different 
studies [19]. One way to make different assays comparable is the inclusion of 
reference drugs as was done herein: chloroquine for P. falciparum, melarsoprol 
for T. brucei, miltefosine for L. donovani, and podophyllotoxin for L6 cells. This 
provides a point of reference to which to compare the recorded activities of 
extracts, fractions, and purified molecules. 
IV. Whenever possible, activities discovered at one particular screening level should 
be confirmed using a model in the next higher evaluation level: We have 
considered this particularly for plant extracts of antileishmanial activity. Extracts 
that have displayed potent and selective activity against L. donovani axenic 
amastigotes in the preliminary screening were further investigated for their 
activity in intramacrophage amastigotes. Based on the latter high content image 
screening, the chloroform fractions of the ethanolic extracts of Croton 
gratissimus and Cuscuta hyalina were selected for further HPLC-activity profiling 
(Chapter 3). Compounds isolated from these two plants were tested for their 
activity in both axenic and intracellular activity models. Some compounds like 
quercetin-3,7-dimethylether and ayanin have shown IC50s of ˂10 µM and 
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selectivity indices ˃10 in the axenic amastigotes screening, these compounds 
showed considerably higher IC50s against intracellular parasites. This 
discrepancies could be justified by different factors; I) the compound is not 
reaching the parasite, either because it has to cross several membranes or due 
to protein binding in the host cell cytosol; II) the compound is exposed to 
hydrolysis or metabolism in the host cell phagolysosome [20]. Nevertheless, 
compounds that were not active in the axenic assays were also inactive 
intracellularly. Compounds that are active against axenic amastigotes but not 
against intracellular amastigotes do not fulfill lead criteria for further 
development. However, if their selectivity for axenic amastigotes over 
mammalian cells is high, such compounds are still of interest to identify novel, 
parasite-specific drug targets. 
7.7 Dereplication 
Developing advanced analytical procedures for the rapid identification of known natural 
products (NPs) in crude plant extracts (dereplication) is indispensable to avoid their 
unnecessary re-isolation when their bioactivity has already been described. 
Dereplication strategies for the early identification of NPs in complex mixtures have 
evolved considerably over the last decade [16]. Hyphenated techniques incorporating 
online (e.g. MS and UV) and offline (NMR) spectroscopic data linked to bioactivity 
results acquired in screening campaigns, along with previously reported 
pharmacological data, allows interpretation of screening results from a novel and 
holistic perspective. It also allows for the prioritization of NPs and for the targeted 
isolation of new bioactive molecules of interest. 
Dereplication is particularly useful to detect “frequent hitters”, or the so called pan-
assay interference compounds (PAINS) [17]. These are compounds exhibiting multiple 
behaviors that could interfere in assay readouts, such as metal chelation, redox cycling, 
and protein reactivity and hence, falsely reported as actives in bioassays.  
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In this regard, a relevant example for the successful use of HPLC-activity profiling 
approach in prioritization of extracts for further follow-up from preliminary screening 
results is the rapid dereplication of the ubiquitous compounds (also PAIN); ellagic acid 
and quercetin from Anogeissus leiocarpus (DC.) Guill. & Perr., and catechin, ethyl 
gallate, and epicatechin gallate from Acacia nilotica (L.) Delile. Extracts containing such 
compounds, though active, were excluded from further investigations, since the activity 
was most likely due to presence of the tannins. Hence, their follow up isolation was 
prevented in first place.  
However, incorporation of comprehensive natural product databases with relevant 
spectroscopic data and linking it to the setting format would have further improved the 
high performance dereplication workflows and the prioritization process consequently. 
7.8 HPLC-based activity profiling 
The efficient tracking of bioactive molecules remains a major challenge in the search for 
new lead compounds in plant extracts. The classical bioactivity-guided isolation strategy 
involving several iterative steps of purification and biological testing is time consuming 
and requires large amounts of plant starting material. It frequently leads to the isolation 
of ubiquitous metabolites and may ultimately lead to loss of the originally observed 
activity [21]. A number of more efficient alternatives and innovative approaches 
involving the recent advances in chromatography and spectroscopy have been 
described for tracking bioactivity in complex matrices; among them is the HPLC-based 
activity profiling approach [22]. 
HPLC-based activity profiling in combination with on-line and off-line spectroscopic data 
allowed complete characterization of bioactive compounds and chemical structure 
determination from a minimal amount of starting material as well as performing target 
preparative isolation of the active principles present in the active fraction, enabling 
rapid dereplication of known compounds [23,24]. This platform has been successfully 
applied to the prioritization and subsequent characterization of hits using different 
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bioassay formats such as whole organism assays, cell-based functional assays, and 
target-based screens. These include parasitic diseases where HPLC-based activity 
profiling protocols have been validated and applied for the follow-up of extracts with 
antiprotozoal activities [25]. This approach has enabled the identification of some 
compound classes that had not been previously reported from the plant species or the 
family. The isolation of the steroid saponins from Haplophyllum tuberculatum (Chapter 
4) is a relevant example. Moreover, many compounds of different classes have been 
reported from the respected plant species for the first time (Chapters 3 and 4).    
7.8.1 Considerations in the HPLC-activity profiling approach 
Efficient isolation of pure compounds directly from crude extracts at the preparative 
chromatographic scale while maintaining similar analytical scale chromatographic 
selectivity and resolution levels is still challenging. Solving this issue would prevent 
tedious multiple chromatographic steps applied on large-scale extraction. Moreover, 
efficient chromatographic gradient transfers from analytical to semi-preparative HPLC 
(i.e. method optimization) is another critical step that should be optimized. Fractions are 
often diluted and injected in large volumes of organic solvents when introduced to semi-
preparative HPLC, hence solubility issues, notably with reverse-phase separation, could 
significantly compromise the resolution. Also, extrapolation of pure compound yield 
from early separation steps is rather difficult. This is important especially in case of 
minor compounds, whose low yield may not permit to perform successive chemical 
measurements and biological testing procedures. 
Innovative approaches are emerging for the rapid identification of NPs in mixtures and 
prioritization for target isolation based on novelty and/or bioactivity [26]. An example is 
the bioactivity-based, multi-informative molecular network approach which involves 
spectra annotations through interrogation of public and private databases, combined 
with bioactivity and taxonomy which can be mapped on the molecular network for 
extract prioritization and targeted isolation [27]. Nevertheless, a limiting factor could be 
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the quality and completeness of MS/MS databases that are still incomplete compared to 
the total number of NPs described to date. 
7.9 The empirical antiparasitic drug discovery approach applying 
biological screening and activity-oriented separation of medicinal 
plants: Could it be improved? 
Optimal screening strategies, assay standardization, data analyses, and optimization of 
hit selection criteria are subjects of continuing discussions. There are certain gaps or 
bottlenecks that are encountered in the classical drug discovery strategies of natural 
products used in traditional medicine (Figure 1). These bottlenecks can be summarized 
in two major points: 
(a) The approach itself that restricts the activity/cytotoxicity of a whole plant to one or 
a few active compounds. This is rather reductionistic and disregards the potential 
synergistic / antagonistic interactions of other, “inactive” phytoconstituents which 
could be lost during fractionation. This is illustrated by the case of berberine, whose 
antimicrobial activity was enhanced by more than 100-fold in combination with an 
inactive component, 5′-methoxyhydnocarpin, isolated from the same plant [28]. 
This will lead to a further challenging question, how to identify and prove synergism 
or antagonism? Which compounds should be tested? Answering these questions is 
particularly challenging if other compounds from the investigated plant are still 
unknown! However, combining activity and metabolomics data can reveal some 
answers. In parallel, screening efforts should be carried out using a multiple 
screening approach on different mammalian cells and potential target systems.  
(b) In vitro / in vivo correlation (IVIVC): While in vitro antiparasitic activity does not 
necessarily indicate clinical efficacy, clinical efficacy vice versa is not always 
detectable in in vitro systems.  Prodrugs, i.e. compounds which have to be 
metabolized in order to exhibit activity, cannot be detectable in in vitro systems 
where no host metabolism is present [29]. Neither are compounds that have 
indirect activity by stimulating the immune system, or by alleviation or reduction of 
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clinical symptoms (palliative properties). The latter point might not be applicable for 
fatal parasitic diseases, especially in trypanosomiasis since the parasite has to be 
killed; however, this could be more relevant to other infections (i.e. bacterial, viral, 




Figure 1: Empirical drug discovery approach from medicinal plants and considerations for 
improvements 
7.10 Other options for exploring traditional medicine: lessons from 
history 
Considering all these challenging and critical aspects, the paradigm of “single compound 
– single target” will not help much to understand the potentially complex bioactivity of 
mixtures. Other approaches could be revitalized. For instance, pharmacological 
evaluation of extracts from medicinal plants may lead to the establishment of 
standardized extracts that serve as a good starting point [12]. Other option is the 
“bedside–bench–bedside” approach, also known as “Reverse pharmacology [30]“, which 
relies on evidence-based traditional medicine. This has been very successful in 
traditional Chinese medicine [31]. Development of artemisinin-based 
antimalarials represents one of the great victories in drug discovery, combining a holistic 
traditional approach with a modern, evidence-based approach [32]. Crucial 
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prerequisites for the aforementioned approaches are the quality control and quality 
assessment as well as safety and efficacy of botanical extracts for drug development.  
7.11 Mycetoma Drug Discovery 
Despite the advances made in the research of mycetoma and advocacy, thanks to the 
recent recognition of the disease by WHO as an NTD, many gaps and challenges are still 
present. In particular, finding effective medicines and, consequentially, optimizing 
therapeutic approaches [33]. The treatment of mycetoma depends mainly on its 
etiological agent and the extent of the disease. Knowing the mycetoma type 
(actinomycetoma or eumycetoma) is vital for the correct medical management [34]. 
Actinomycetoma is curable by different antibiotic combination therapies depending on 
the severity, dissemination, and location of the granulomas [35]. In contrast, the 
management of Madurella mycetomatis, the most common fugal type of eumycetoma, 
is more complicated. Current treatment usually implicates surgical excision combined 
with the long-term use of azole antifungals. However, late chronic stages of the disease 
result in destruction, deformity, and loss of function and may often lead to amputation 
[36].  
There have been several studies regarding the in vitro susceptibility of M. mycetomatis 
against known antifungals [37,38]. Nevertheless, there is relatively few information on 
their clinical efficacy. The poor response to antifungal therapy observed in clinical 
practice may be due to the fact that M. mycetomatis produces melanin, which is 
thought to protect the fungus from the host immune system and from antifungal agents 
[39]. Local administration of antifungals showed inconsistent results with a high rate of 
failure and complications [40]. The first randomized clinical trial for eumycetoma has 
started early 2017, supported by DNDi, to assess the clinical efficacy and safety of 
fosravuconazole, which had been found to be active in a previous in vitro screen [41]. 
However, fosravuconazole has the same mechanism of action as other azole antifungals, 
which rises the threat of cross-resistance. Hence, there is a pressing need for novel 
therapeutic alternatives based on new chemotypes. 
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7.11.1 Natural products against Eumycetoma 
Although traditional remedies have been investigated in various infectious diseases, 
very limited studies have been conducted on the activity of medicinal plants against 
eumycetoma. Furthermore, it was reported that 42.2% of the Sudanese myctoma 
patients at the Mycetoma Center had used herbal medicine at some stage of their 
illness, with a complication rate of 29.3% [42]. Tea tree oil was shown to inhibit the 
growth of M. mycetomatis at concentrations below 0.25% (v/v) [43]. Another study 
tested the in vitro antimycetomal activity of some Sudanese medicinal plants, and has 
shown that stigmatriene from Boswellia papyrifera was active (MIC50 of 32 μg/ml) [44]. 
However, these reports lacked a full characterization of the active compounds and 
cytotoxicity profiling.  
We used the so called “educated guess” for the search of an antimycetomal lead. 
Natural compounds of known antifungal and anti-infective activities were tested in vitro 
against M. mycetomatis employing viability assays with a resazurin read-out (Chapter 5). 
The cytotoxicity of these compounds against L-6 rat skeletal cells was also determined. 
Of all tested natural compounds, magnolol possessed the highest activity (MIC of 15 
µM) and selectivity (SI of 4.9). It is recommended that confirmatory tests should be 
performed with a larger set of Madurella strains or with eumycetoma causative agents 
other than Madurella spp. Moreover, the effect of melanin on the MIC should be 
considered in secondary assays.  
7.11.2 Repurposing approach 
“The most fruitful basis for the discovery of a new drug is to start with an old one”, a 
quote from the pharmacologist and Nobel laureate 1988 James Black, seems quite 
relevant specially in the area of neglected tropical diseases, where an enormous unmet 
need for therapies still remains [45]. This strategy has the benefits of lowering the costs 
and timeline for drug development, as well as profiting from the availability of clinical 
data from pre-existing programs [46]. 
Chapter 7:  General Discussion 
201 
 
Drug repurposing has been considered in eumycteoma drug screening campaigns. 
Indeed, the frontrunner clinical candidate fosravuconazole was repurposed from Chagas 
disease [41]. Drug-like molecules from The Pathogen and Stasis boxes were screened for 
in vitro and in vivo activity against eumycetoma, and fenarimols were identified as 
potential hits [47]. Fenarimols are fungicides that act by inhibiting ergosterol 
biosynthesis of fungi [48]. However, these compounds are known for their endocrinal 
[49] and neurological toxicities [50], rendering them rather less favorable options, 
particularly, for long-term use which is the case for eumycetoma. Niclosamide, which 
was identified as a potential antimycetomal candidate in Chapter 6, could be a safer 
option. While niclosamide by itself is not absorbed from the gastrointestinal tract, the 
ethanolamine salt of niclosamide (NEN) has a better solubility in water and is 
systemically absorbed. NEN is presently being studied for different diseases [51–57] and 
might be repurposable for eumycetoma, too. Yet, further investigations concerning the 
accessibility of the drug into the fungal grain and its in vivo activity will need to be 
performed to evaluate the potential of niclosamide-ethanolamide as an antimycetomal 
agent. 
7.12 Final conclusion 
This work afforded a comprehensive overview of Sudanese medicinal plants, and it 
demonstrated that these plants are a promising source of bioactive molecules against 
protozoan parasites. Systematic evaluation of their antiparasitic and cytotoxicity profiles 
was achieved. A dereplication strategy was accomplished for a number of active extracts 
and allowed prioritization for follow-up selection. Three plants, namely Croton 
gratissimus, Cuscuta hyalina, and Haplophyllum tuberculatum, were pursued for HPLC-
based activity profiling. Preparative isolation of active compounds to perform structure 
elucidation and in vitro test was performed. Thanks to HPLC-hyphenated techniques, 
the isolation of some of these compounds from the investigated plants as well as their 
antiprotozoal activities have been reported for the first time. The neglected disease 
mycetoma has received special consideration, and different approaches were tackled to 
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ultimately identify potential hits. With regard to antimycetomal natural products, 
several compounds were selected based on an educated-guess and were assessed 
accordingly. Furthermore, this work explored the potential of drug repurposing as a 
promising strategy for mycetoma drug development.  
All in all, this thesis is a contribution to the scientific validation of Sudanese medicinal 
plants and to the discovery of new molecules against protozoa and mycetoma. The 
encouraging outcomes of this research have clearly demonstrated that natural products 
represent an unparalleled reservoir of molecular diversity for drug discovery and 
development, and contribute to a better understanding of the natural products–based 
drug discovery approach. 
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